---
document_datetime: 2025-01-21 15:31:48
document_pages: 82
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/darzalex-h-c-004077-ii-0072-epar-assessment-report-variation_en.pdf
document_name: darzalex-h-c-004077-ii-0072-epar-assessment-report-variation_en.pdf
version: success
processing_time: 84.1639778
conversion_datetime: 2025-12-26 18:27:59.222134
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 September 2024 EMA/CHMP/494023/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Darzalex

International non-proprietary name: Daratumumab

EMEA/H/C/004077/II/0072

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                 | ..............................................7                                                           |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                     | ..................................................................................................7       |
| 1.2. Steps taken for the assessment of the product.........................................................8               |                                                                                                           |
| 2. Scientific discussion                                                                                                   | ................................................................................9                         |
| 2.1. Problem statement                                                                                                     | ...............................................................................................9          |
| 2.1.1. About the product............................................................................................11     |                                                                                                           |
| 2.1.2. The development programme, compliance with scientific advice                                                        | ............................11                                                                            |
| 2.2. Non-clinical aspects                                                                                                  | ............................................................................................12            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                           | .........................................................12                                               |
| 2.3. Clinical aspects                                                                                                      | ..................................................................................................12      |
| 2.3.1. Introduction....................................................................................................12  |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................14     |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................17        |                                                                                                           |
| 2.3.4. PK modelling...................................................................................................20   |                                                                                                           |
| 2.3.5. Discussion on clinical pharmacology...................................................................22            |                                                                                                           |
| 2.3.6. Conclusions on clinical pharmacology.................................................................24             |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                     | ..................................................................................................24      |
| 2.4.1. Main study......................................................................................................24  |                                                                                                           |
| 2.4.2. Discussion on clinical efficacy............................................................................53       |                                                                                                           |
| 2.4.3. Conclusions on the clinical efficacy.....................................................................56         |                                                                                                           |
| 2.5. Clinical safety                                                                                                       | ....................................................................................................57    |
| 2.5.1. Discussion on clinical safety                                                                                       | ..............................................................................74                          |
| 2.5.2. Conclusions on clinical safety                                                                                      | ............................................................................75                            |
| 2.5.3. PSUR cycle                                                                                                          | .....................................................................................................75   |
| 2.6. Risk management plan........................................................................................76        |                                                                                                           |
| 2.7. Update of the Product information ........................................................................78          |                                                                                                           |
| 2.7.1. User consultation.............................................................................................78    |                                                                                                           |
| 3. Benefit-Risk Balance..............................................................................78                    |                                                                                                           |
| 3.1. Therapeutic Context                                                                                                   | ...........................................................................................78             |
| 3.1.1. Disease or condition.........................................................................................78     |                                                                                                           |
| 3.1.2. Available therapies and unmet medical need.......................................................78                 |                                                                                                           |
| 3.1.3. Main clinical studies                                                                                               | .........................................................................................79               |
| 3.2. Favourable effects                                                                                                    | ..............................................................................................79          |
| 3.3. Uncertainties and limitations about favourable effects.............................................79                 |                                                                                                           |
| 3.4. Unfavourable effects...........................................................................................79     |                                                                                                           |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | .........................................80                                                               |
| 3.6. Effects Table......................................................................................................80 |                                                                                                           |
| 3.7. Benefit-risk assessment and discussion.................................................................81             |                                                                                                           |
| 3.7.1. Importance of favourable and unfavourable effects..............................................81                   |                                                                                                           |
| 3.7.2. Balance of benefits and risks.............................................................................81        |                                                                                                           |
| 3.8. Conclusions                                                                                                           | .......................................................................................................81 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations .................................................................................  81

5. EPAR changes  ........................................................................................  82

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

antidrug antibody

ADR

adverse drug reaction

AE

adverse event

AL amyloidosis

amyloid light chain or primary amyloidosis

ALT

alanine aminotransferase

ASCT

autologous stem cell transplant

AST

aspartate aminotransferase

CCDS

Company Core Data Sheet

CCO

clinical cutoff

CI

confidence interval

Cmax

maximum plasma drug concentration

CMH

Cochran-Mantel-Haenszel

COVID-19

coronavirus disease caused by severe acute respiratory syndrome coronavirus 2

CR

complete response

CrCl

creatinine clearance

CRF

case report form

CSR

clinical study report

Ctrough

trough plasma concentration (taken directly before next administration)

D Kd

daratumumab, carfilzomib, and dexamethasone

DoR

duration of response

D Pd

daratumumab, pomalidomide, and dexamethasone

D-R

daratumumab and lenalidomide

D Rd

daratumumab, lenalidomide, and dexamethasone

DT

drug tolerant

D-VMP

daratumumab, bortezomib, melphalan, and prednisone

D-VRd

daratumumab, bortezomib, lenalidomide, and dexamethasone

ECG

electrocardiogram

ECOG

Eastern Cooperative Oncology Group Scale of Performance Status

EMA

European Medicines Agency

EMN

European Melanoma Network

E-R

exposure-response

ESMO

European Society for Medical Oncology

<div style=\"page-break-after: always\"></div>

| EU        | European Union                                                           |
|-----------|--------------------------------------------------------------------------|
| FDA       | Food and Drug Administration                                             |
| FISH      | fluorescence in situ hybridization                                       |
| FOIA      | Freedom of Information Act                                               |
| GCP       | Good Clinical Practice                                                   |
| G-CSF     | granulocyte colony-stimulating factor                                    |
| GHS       | Global Health Score                                                      |
| GOF       | Goodness of fit                                                          |
| HBV       | hepatitis B virus                                                        |
| HLT       | high level term                                                          |
| HR        | hazard ratio                                                             |
| ICH       | International Council for Harmonisation                                  |
| IDMC      | Independent Data Monitoring Committee                                    |
| IDSMB     | Independent Data Safety Monitoring Board                                 |
| IgG       | Immunoglobulin G                                                         |
| IMiD      | immunomodulatory imide drug                                              |
| IMWG      | International Myeloma Working Group                                      |
| IRR       | infusion-related reaction                                                |
| ISS       | International Staging System                                             |
| ITT       | intent-to-treat                                                          |
| IV        | intravenous                                                              |
| KRd       | carfilzomib, lenalidomide, and dexamethasone                             |
| LS        | least squares                                                            |
| mAb       | monoclonal antibody                                                      |
| MedDRA    | Medical Dictionary for Regulatory Activities                             |
| MM        | Multiple myeloma                                                         |
| MRD       | minimal residual disease                                                 |
| NCCN      | National Comprehensive Cancer Network                                    |
| NCI CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| NDMM      | newly diagnosed multiple myeloma                                         |
| NE        | not evaluable                                                            |
| NGS       | next generation sequencing                                               |
| NK        | natural killer                                                           |

<div style=\"page-break-after: always\"></div>

| NONMEM   | Non-linear Mixed Effects Modelling                          |
|----------|-------------------------------------------------------------|
| OR       | odds ratio                                                  |
| ORR      | overall response rate                                       |
| OS       | overall survival                                            |
| PABAK    | prevalence-adjusted bias-adjusted kappa                     |
| Pd       | pomalidomide and dexamethasone                              |
| PD       | progressive disease/disease progression                     |
| PFS      | progression-free survival                                   |
| PFS2     | progression free survival on/after the next line of therapy |
| PI       | proteasome inhibitor                                        |
| PR       | partial response                                            |
| PRO      | patient reported outcomes                                   |
| PT       | preferred term                                              |
| R        | lenalidomide alone                                          |
| Rd       | lenalidomide and dexamethasone                              |
| rHuPH20  | recombinant human hyaluronidase PH20                        |
| RRMM     | relapsed or refractory multiple myeloma                     |
| SAE      | serious adverse event                                       |
| sARR     | systemic administration-related reaction                    |
| SC       | subcutaneous                                                |
| sCR      | stringent complete response                                 |
| SD       | standard deviation                                          |
| SOC      | system organ class                                          |
| SPM      | second primary malignancy                                   |
| TEAE     | treatment-emergent adverse event                            |
| US       | United States                                               |
| VCd      | bortezomib, cyclophosphamide, and dexamethasone             |
| VGPR     | very good partial response                                  |
| VRd      | bortezomib, lenalidomide, and dexamethasone                 |
| VTd      | bortezomib, thalidomide, and dexamethasone                  |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International N.V. submitted to the European Medicines Agency on 6 March 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include, in combination with bortezomib, lenalidomide and dexamethasone, the treatment of adult patients with newly diagnosed multiple myeloma, who are eligible for autologous stem cell transplant for Darzalex, based on the primary analysis results from the pivotal study 54767414MMY3014 (PERSEUS) and the results from study 54767414MMY2004 (GRIFFIN) and the D-VRd cohort of study 54767414MMY2040 (PLEIADES).

MMY3014 (PERSEUS) is a randomised, open-label, active-controlled, multicentre phase 3 study in adult subjects with newly diagnosed multiple myeloma, who are eligible for high dose therapy (as required for autologous stem cell transplant). The primary objective is to compare the efficacy of (subcutaneous) daratumumab in combination with bortezomib, lenalidomide and dexamethasone (DVRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in terms of progression free survival (PFS).

MMY2004 (GRIFFIN) is a randomised, open-label, active controlled, multicentre phase 2 study in adult subjects with newly diagnosed multiple myeloma, who are eligible for high dose therapy and autologous stem cell transplant. The primary objective is to compare the efficacy of daratumumab in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) versus bortezomib, lenalidomide and dexamethasone (VRd), in terms of stringent complete response (sCR) rate. MMY2040 (PLEIADES) is a randomised, open-label, multicentre phase 2 study to evaluate subcutaneous daratumumab in combination with standard multiple myeloma treatment regimens. The D-VRd cohort included adult subjects with newly diagnosed multiple myeloma, who were evaluated for clinical benefit in terms of very good partial response or better (VGPR) rate.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

## Information relating to orphan designation

Darzalex, was designated as an orphan medicinal EU/3/13/1153 on 17 July 2013. Darzalex was designated as an orphan medicinal product in the following indication:

- Treatment of plasma cell myeloma

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0264/2017 on the granting of a product-specific waiver.

<div style=\"page-break-after: always\"></div>

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Protocol assistance

The MAH did not seek Protocol Assistance at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Aaron Sosa Mejia

Co-Rapporteur:

N/A

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 6 March 2024      |
| Start of procedure:                                  | 30 March 2024     |
| CHMP Rapporteur Assessment Report                    | 6 June 2024       |
| PRAC members comments                                | 5 June 2024       |
| Updated PRAC Rapporteur Assessment Report            | 6 June 2024       |
| PRAC Outcome                                         | 13 June 2024      |
| CHMP members comments                                | 17 June 2024      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 21 June 2024      |
| Request for supplementary information (RSI)          | 27 June 2024      |
| CHMP Rapporteur Assessment Report                    | 19 August 2024    |
| PRAC Rapporteur Assessment Report                    | 20 August 2024    |
| PRAC members comments                                | 28 August 2024    |
| Updated PRAC Rapporteur Assessment Report            | Not applicable    |
| PRAC Outcome                                         | 5 September 2024  |
| CHMP members comments                                | 9 September 2024  |
| Updated CHMP Rapporteur Assessment Report            | 13 September 2024 |
| Opinion                                              | 19 September 2024 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## Disease or condition

Daratumumab is approved as monotherapy in subjects with relapsed and refractory multiple myeloma and in combination with standard of care regimens for transplant-ineligible and transplant-eligible newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma.

The MAH submitted a variation application to extend the indication of daratumumab for the treatment of  adult  patients  with  newly  diagnosed  multiple  myeloma  who  are  eligible  for  autologous  stem  cell transplant in combination with bortezomib, lenalidomide and dexamethasone.

The proposed new indication is only for the subcutaneous use of daratumumab.

## Epidemiology

Multiple  myeloma,  a  malignant  disorder  of  the  plasma  cells,  is  characterised  by  uncontrolled  and progressive proliferation of a plasma cell clone and is estimated to represent 1.0% to 1.8% of all new cancer cases worldwide and approximately 10% of hematologic malignancies (Sung 2021; SEER 2022). In 2020, an estimated 176,404 patients were diagnosed with multiple myeloma globally, with a crude incidence rate of 2.3 cases per 100,000 persons and a world population age-standardized incidence rate of 1.8 cases per 100,000 persons (Ferlay 2020). In the EU-27 countries, the 2022 crude incidence rate was 7.9 cases per 100,000 persons, and the European population age-standardized incidence rate was 7.3 cases per 100,000 persons. The estimated number of new cases for the EU overall was 35,333 cases in  2022.  In  general,  Western  Europe  had  the  highest  incidence  rates  of  multiple  myeloma.  Crude incidence  rates  ranged  from  3.0 per  100,000  persons  in  Bulgaria  to  11.3  per  100,000  persons  in Denmark (European Cancer Information System 2023).

Despite  the  significant  improvement  in  patients'  survival  in  the  recent  decades,  only  10%-15%  of patients  achieve  expected  survival  compared  with  the  matched  general  population  (Usmani,  Blood Cancer J. 2018)

The median age at diagnosis of MM is approximately 70 years (Palumbo 2011).

## Biologic features and Clinical presentation

The proliferation of the malignant clonal plasma cells leads to subsequent replacement of normal bone marrow  hematopoietic  precursors  and  overproduction  of  monoclonal  proteins.  Multiple  myeloma  is characterized by osteolytic lesions, usually in the pelvis, spine, ribs, and skull. Lesions are caused by expanding  plasmacytomas  or  by  cytokines  secreted  by  myeloma  cells  that  activate  osteoclasts  and suppress  osteoblasts.  Increased  bone  loss  may  also  lead  to  hypercalcemia.  Solitary  extraosseous plasmacytomas are unusual but may occur in any tissue. In many patients, renal failure is present at diagnosis or develops during the course of the disorder and is caused by the deposition of light chains in the distal tubules or by hypercalcemia. Patients also often develop anaemia due to kidney disease or suppression of erythropoiesis by cancer cells. These signs and symptoms are commonly denoted by the mnemonic acronym CRAB: Calcemia, Renal damage, Anaemia, and Bone lesions (Palumbo 2011).

## Management

Treatment choices for multiple myeloma vary with age, performance status, comorbidity, aggressiveness of the disease, and related prognostic factors (Palumbo 2011). Patients with newly diagnosed multiple

<div style=\"page-break-after: always\"></div>

myeloma  (NDMM)  are  typically  categorized  into  2  subpopulations:  Eligible  for  autologous  stem  cell transplant (ASCT) or transplant ineligible. Eligibility is usually defined by age and suitability for intensive treatment. Patients will typically receive an induction regimen followed by treatment with ASCT, followed by consolidation therapy and maintenance treatment. For those not considered eligible for ASCT, longerterm  treatment  with  multiagent  combinations,  including  alkylators  (e.g.,  cyclophosphamide  (C))  , steroids  (e.g.,  dexamethasone  (d))  and  newer  agents  such  as  proteasome  inhibitors  (PIs)  (e.g., bortezomib  (V))  and  immunomodulatory  imide  drug  (IMiDs)  (e.g.,  lenalidomide  (R))  are  currently considered standards of care.

Over the past decade, the introduction of new classes of drugs, such as PIs and IMiDs, have changed the management of frontline treatment in both transplant and nontransplant candidates (Kumar 2023 [NCCN  Guidelines];  Durie  2017;  Dimopoulos  2021  [ESMO  Guidelines];  Cavo 2011;  Palumbo 2014). Studies have indicated that multidrug combinations are superior to single- or double-agent combinations in treating multiple myeloma (Cavo 2012; van der Veer 2011).

## Patients with NDMM who are eligible for ASCT

While multiple myeloma is primarily a disease of the elderly, approximately 37% of patients are &lt;65 years (Palumbo 2011; Kyle 2003). For the majority of these younger patients, as well as selected, fit patients over the age of 65 years, an intensive treatment approach, including ASCT, is considered the standard of care according to both US (NCCN; Kumar 2023) and European guidelines (ESMO; Dimopoulos 2021; Gay 2018).

ASCT-eligible patients with NDMM generally receive an induction therapy and ASCT, sometimes followed by consolidation treatment and commonly followed by lenalidomide maintenance therapy.

## Induction therapy in transplant-eligible patients.

VRd,  along  other  triplet  regimens  such  as  VTd  and  VCd,  is  one  of  the  preferred  frontline  regimens recommended by NCCN and ESMO treatment guidelines for the primary therapy of patients with NDMM who are transplant-candidates (Kumar 2023; Dimopoulos 2021). The recommendation is based upon randomized  studies,  including  the  IFM2009  and  DETERMINATION  studies,  which  demonstrated  the benefit of ASCT and VRd compared with VRd alone in this patient population (Attal 2017; Richardson 2022). The randomized Phase 3 IFM2009 study established that three 21-day cycles of induction therapy with VRd, ASCT, 2 cycles of consolidation therapy, and 1 year of maintenance therapy with lenalidomide resulted  in  superior  median  PFS  compared  with  8  cycles  of  VRd  and  1 year  of  maintenance  with lenalidomide (47.3 vs 35.0 months). The subsequent DETERMINATION study, which had a similar study design  but  administered  maintenance  lenalidomide  until  PD,  confirmed  the  benefit  of  ASCT  with prolongation of median PFS (67.5 vs 46.2 months).

Daratumumab is approved in combination with VTd for the treatment of patients with NDMM who are eligible for ASCT (Moreau 2019). This regimen is listed as one of the options in the ESMO treatment guidelines for the treatment of patients who are transplant eligible.

## High-dose chemotherapy and stem cell rescue

High-dose chemotherapy followed by ASCT is the standard approach for eligible patients, and recent Phase 3 trials have shown the benefit in the area of 'novel agents' (Kumar 2018; Gay 2018; Attal 2017; Cavo 2016). After attaining an optimal response from induction therapy, blood stem cells are mobilized in peripheral blood with the use of G-CSF alone or with plerixafor in combination with G-CSF (Giralt 2009). Cyclophosphamide with G-CSF may be used in patients who are unable to mobilize with G-CSF alone.  Stem  cells  are  then  harvested  by  apheresis/leukapheresis.  High-dose  chemotherapy  typically consists  of  melphalan  140  to  200 mg/m2  followed  2 days  later  by  infusion  of  previously  collected autologous stem cells.

The  autologous  stem  cells  themselves  have  no  therapeutic  effect  but  decrease  the  duration  of neutropenia and thrombocytopenia after high-dose chemotherapy reducing the risk of infectious and bleeding complications. The infusion of stem cells thus allows to increase the dose of chemotherapy administered with the hope to achieve a deeper remission and longer disease control.

<div style=\"page-break-after: always\"></div>

## Consolidation therapy in transplant-eligible patients

After  transplant,  some patients are given a further short intense period of treatment to deepen the response obtained with induction therapy, commonly referred to as consolidation therapy. Consolidation therapy administered after transplant generally has a short duration and aims to increase the depth of response after ASCT. Studies have demonstrated that consolidation therapy can enhance the depth of response  achieved  during  previous  treatment  phases  (Lee 2016).  The  VTd  consolidation  (2  cycles) improved response rates and PFS (Cavo 2012; Leleu 2013). Consolidation therapy with VTd yielded molecular remissions in up to 60% of patients (Ladetto 2010; Terragna 2010). Recently, a Phase 3 study (EMN02/HOVON95 MM TRIAL) showed an improvement of PFS with 2 cycles of a triplet consolidation therapy after ASCT (Sonneveld 2016; Sonneveld 2018). In general, the same triplet therapy that was used in induction is given as 2 cycles of treatment consolidation post transplantation.

Additionally, Study 54767414MMY3006 (CASSIOPEIA), a Phase 3 study, was the basis for the marketing authorization approval of daratumumab in combination with VTd in the first-line treatment of transplanteligible patients with NDMM (Moreau 2019). In the first part of Study 54767414MMY3006, patients were randomized to receive induction and consolidation treatment with daratumumab in combination with VTd vs VTd alone. The data from Study 54767414MMY3006 demonstrated that D-VTd resulted in a clinical benefit  that  is  both  statistically  significant  and  clinically  meaningful  compared  with  VTd  alone.  The improvement  in  depth  of  response  achieved  with  D-VTd  in  this  study  was  further  supported  by  a statistically significant and clinically meaningful improvement in PFS, confirming deeper responses and superior long-term outcomes for participants who received D-VTd.

## Maintenance therapy

Maintenance therapy is generally administered for a long duration and aims to improve PFS with minimal toxicity and without impacting quality of life. Lenalidomide was approved in the US and Europe in 2017 as monotherapy for maintenance therapy and is currently the standard of care. Lenalidomide is currently the only preferred maintenance therapy recommended by NCCN and ESMO guidelines.

## 2.1.1. About the product

Daratumumab is a human mAb that binds with high affinity to CD38, a transmembrane glycoprotein expressed on tumour cells, and induces tumour-cell death through multiple mechanisms of action. These mechanisms of  action  include  several  immune-mediated  activities,  including  complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and direct cytotoxicity by induction of apoptosis by Fc γ receptor-mediated crosslinking of tumour-bound mAbs (Overdijk 2016).

## 2.1.2. The development programme, compliance with scientific advice

The  MAH  submitted  a  request  for  Scientific  Advice  for  daratumumab  on  01  September  2017.  The objective of this Scientific Advice procedure was to seek CHMP input on the planned studies, MMY3014 and MMY3016  to evaluate daratumumab in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of subjects with newly diagnosed multiple myeloma who are not receiving ASCT as part of initial therapy (MMY3016) and subjects with newly diagnosed multiple myeloma  who  are  eligible  for  ASCT  (MMY3014).  The  main  discussion  points  with  regards  to Study MMY3014 were:

<div style=\"page-break-after: always\"></div>

- Since the correlation between MRD and PFS has not yet been demonstrated the CHMP advised that it would be preferable for the MAH to seek regulatory approval with PFS as the primary endpoint, whilst MRD could be considered an intermediate endpoint.
- A re-randomisation strategy or alternatively a single maintenance treatment was suggested due to concerns on whether the study design ( Figure 4) would allow evaluation of the correlation between MRD and PFS.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

No environmental risk assessment for daratumumab was submitted, as daratumumab is a monoclonal antibody and is consequently classified as a protein. According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00), amino acids, peptides and proteins are exempted because they are unlikely to result in significant risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

This application for an extension of the indication is mainly based upon the primary analysis results from the  pivotal  phase  3  study  54767414MMY3014  (PERSEUS,  also  referred  to  in  this  report  as  study MMY3014) further supported by the results from study 54767414MMY2004 (GRIFFIN, also referred to in this  report  as  study  MMY2004)  and  the  D-VRd  cohort  of  study  54767414MMY2040  (PLEIADES,  also referred  to  in  this  report  as  study  MMY2040).  Clinical  pharmacology  objectives  and  endpoints  were incorporated into the 3 clinical studies assessing daratumumab in combination with VRd.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Study Number   | Phase   | Study Description/Design Participant Population   | Study Drugs/Dose Regimen Number of Treated Participants   |
|----------------|---------|---------------------------------------------------|-----------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Study Number   |   Phase | Study Description/Design Participant Population                          | Study Drugs/Dose Regimen Number of Treated Participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------|---------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MMY3014        |       3 | Randomized, open-label Participants with NDMM who are eligible for ASCT  | Daratumumab (D-VRd arm only): SC 1800 mg QW for Cycles 1 to 2, Q2W for Cycles 3 to 6, and Q4W for Cycles 7+. Bortezomib: SC 1.3 mg/m 2 twice a week for Cycles 1 to 6. Lenalidomide: PO 25 mg daily on Days 1 to 21 for Cycles 1 to 6 and 10 mg daily on Days 1 to 28 for Cycles 7+ (15 mg starting at Cycle 10 unless there was a tolerability concern). Dexamethasone: PO 40 mg on Days 1 to 4 and 9 to 12 during Cycles 1 to 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| GRIFFIN        |       2 | Randomized, open-label Participants with NDMM who were eligible for ASCT | VRd treated = 347 Daratumumab (D-VRd arm only): IV 16 mg/kg QW for Cycles 1 to 4, Q3W for Cycles 5 and 6, and IV 16 mg/kg or SC 1800 mg Q4W or Q8W for Cycles 7+ for 24 months. Bortezomib: SC 1.3 mg/m 2 twice a week for 6 cycles or until end of Cycle 4, then for Cycles 5 and 6 at the same dose that was tolerated at the end of Cycle 4. Lenalidomide: PO 25 mg daily on Days 1 to 14 for Cycles 1 to 6 or until end of Cycle 4, then for Cycles 5 and 6 at the same dose that was tolerated at the end of Cycle 4., and 10 mg daily on Days 1 to 21 for Cycles 7+ (15 mg starting at Cycle 10 unless there was a tolerability concern). Dexamethasone: PO 40 mg QW for Cycles 1 to 6 or until end of Cycle 4, then for Cycles 5 and 6 at the same dose that was tolerated at the end of Cycle 4. For the D-VRd group, 20 mg administered as a pre- infusion medication replaced the oral dexamethasone dose for that day and 20 mg was administered as a pre-infusion medication for maintenance. D-VRd treated = 116 (16 in the safety run-in phase and 100 in the main study) VRd treated = 101 |

<div style=\"page-break-after: always\"></div>

| Study Number            |   Phase | Study Description/Design Participant Population              | Study Drugs/Dose Regimen Number of Treated Participants                                                                                                                                                                                                                                   |
|-------------------------|---------|--------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PLEIADES (D-VRd cohort) |       2 | Open-label Participants with NDMM who were eligible for ASCT | Daratumumab: SC 1800 mg on Days 1, 8, 15 for Cycles 1 to 3 and on Day 1 for Cycle 4. Bortezomib: SC 1.3 mg/m 2 on Days 1, 4, 8, and 11 for Cycles 1 to 4. Lenalidomide: PO 25 mg on Days 1 to 14 for Cycles 1 to 4. Dexamethasone: PO 20 mg on Days 1, 2, 8, 9, 15, 16 for Cycles 1 to 4. |

## 2.3.2. Pharmacokinetics

## Phase 3 Study MMY3014

## Study Design

The  randomised,  open-label,  multicentre,  Phase  3  Study  MMY3014  compared  D-VRd  to  VRd  in participants with NDMM who were eligible for ASCT. The treatment phase consisted of 28-day cycles, including 4 cycles of induction, followed by ASCT, then 2 cycles of consolidation, followed by maintenance therapy. Daratumumab SC 1800 mg was administered weekly on Days 1, 8, 15, and 22 for Cycles 1 to 2, then every 2 weeks on Days 1 and 15 for Cycles 3 to 6. For maintenance cycles 7 and over, participants received  daratumumab  SC  every  4  weeks  on  Day  1  until  documented  disease  progression  or unacceptable toxicity.

For the D-VRd arm, serum samples were used to evaluate the pharmacokinetics of daratumumab and were collected predose on Day 1 of Cycles 1, 3, 5, 7, 9, and 12; predose on Day 15 of Cycle 4; on Day 4 of Cycles 1, 3, and 5; and at 8 weeks (±1 week) post-treatment.

## Demographic and Baseline Characteristics

At the time of clinical cut-off (CCO) (01 August 2023), 351 participants in the D-VRd arm and 347 participants in the VRd arm received study treatment. Demographic and baseline disease characteristics were generally balanced between the 2 treatment arms. The median age was 60 years (range, 31-70 years).  The  median  baseline  body  weight  was  74.5  kg  (range,  37.0-167.6  kg).  The  majority  of  the participants were white (92.1%), male (58.7%), and had an ECOG performance status of 0 (63.6%).

## Serum Daratumumab Concentrations Over Time

The pharmacokinetic results from the D-VRd combination were consistent with observations following 1800 mg daratumumab SC administration in previous monotherapy and combination studies.

In Study MMY3014, the observed mean (SD) Cmax of 115 (73.6) μ g/mL following the first daratumumab SC administration occurred at Cycle 1 Day 4 and mean (SD) maximum Cmax of 652 (244) μ g/mL occurred at Cycle 3 Day 4 following weekly daratumumab SC administrations during induction treatment.

In Study MMY3014, mean maximum Cmax at Cycle 3 Day 4 was 5.67-fold that of the Cmax at Cycle 1 Day 4, indicating extensive systemic accumulation of serum daratumumab concentration following weekly daratumumab SC administrations during induction treatment.

The mean maximum Ctrough of daratumumab, which occurred immediately prior to dose administration at Cycle 3 Day 1 predose, was similar across studies between participants treated with D-VRd (Study

<div style=\"page-break-after: always\"></div>

MMY3014), daratumumab SC monotherapy, D-Pd, D-Rd, and D-Kd (526, 581, 537, 526, and 744 μ g/mL, respectively).

The proportion of treated participants who proceeded to stem cell transplantation was similar between the treatment arms (D-VRd: 89.7%, VRd: 87.0%).

## Phase 2 study GRIFFIN

## Study Design

The  randomised,  multicentre,  open-label,  active-controlled  Phase  2  Study  GRIFFIN  (MMY2004) compared D-VRd to VRd in participants with NDMM eligible for ASCT. A total of 116 participants were treated with D-VRd (16 in the safety run-in phase and 100 in the main study) and 101 participants were treated with VRd. Daratumumab IV 16 mg/kg was administered weekly during induction treatment (Days 1, 8, and 15 of Cycles 1-4), every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), and every 4 weeks or every 8 weeks during maintenance treatment (on Day 1 of Cycles 7 and over for 24 months). All induction and consolidation cycles were 21 days and maintenance treatment cycles were 28  days.  After  the  implementation  of  protocol  amendment  4,  there  was  an  option  to  administer daratumumab SC 1800 mg as maintenance treatment every 4 weeks or every 8 weeks (on Day 1 of Cycles  7  and  over).  Nineteen  participants  received  at  least  1  daratumumab  SC  injection,  all  during maintenance therapy.

Serum samples were used to evaluate the pharmacokinetic of daratumumab and were collected pre- and pos-tinfusion on Day 1 of Cycles 1, 4, 5, and 6, and at 4 weeks and 8 weeks post-treatment. Serum samples for evaluation of anti-daratumumab antibodies were collected pre-dose on Day 1 of Cycles 1, 4 and 5, and at 4 weeks and 8 weeks post-treatment.

## Demographic and Baseline Characteristics

At the time of CCO (25 January 2019), all 16 participants in the safety run-in group received DVRd. In the main study, 201 participants received treatment (D-VRd: 100 participants; VRd: 101 participants). Additionally,  19  participants  received  at  least  1  daratumumab  SC  injection,  all  during  maintenance therapy.

Overall, demographics and baseline characteristics were balanced between the 2 randomized treatment groups. The majority of participants were male (118 [57.0%] participants) and white (161 [78.2%] participants). The median age was 60 years (range, 29-70 years) and the median baseline body weight was 82.0 kg (range, 37.4-158.6 kg). Approximately half of the participants (103 [50.7%]) had an ECOG score of 1 at baseline.

## Serum Daratumumab Concentrations Over Time

The pharmacokinetic results from participants in the randomized D-VRd treatment group and participants in the safety run-in group were similar and consistent with observations from previous monotherapy and combination  therapy  following  administration  of  daratumumab  IV  at  the  same  dose  regimen  and schedule. The Cmax of daratumumab increased following weekly doses of daratumumab in Cycles 1 to 4. At Cycle 4 Day 1 post-infusion, the mean (SD) Cmax was 890 (236) μ g/mL in participants in the randomized D-VRd treatment group, which was a 3.27-fold increase as compared with the value at Cycle 1 Day 1 post-infusion. Following less frequent dose administration of daratumumab (every 3 weeks) in Cycle 5, the Ctrough at Cycle 6 Day 1 pre-infusion and Cmax at Cycle 6 Day 1 post-infusion decreased to 129 (77.4) μ g/mL and 461 (125) μ g/mL, respectively, in the randomized D-VRd treatment group, compared with the values at Cycle 4 Day 1 post-weekly doses. Due to the long half-life of daratumumab, concentrations  were  quantifiable  at  4  weeks  and  8  weeks  after  the  last  dose  of  daratumumab. Intersubject variability for daratumumab exposure in the randomized D-VRd treatment group ranged from 26.6% to 31.8% CV in Cycles 1 to 6 for post-infusion concentrations and was 50.5% and 60.7% CV at 4 weeks and 8 weeks, respectively, after the last dose of daratumumab.

<div style=\"page-break-after: always\"></div>

## Phase 2 study PLEIADES (D-VRd cohort)

## Study design

The randomised, multicenter, open-label Phase 2 Study PLEIADES (MMY2040) evaluated daratumumab SC  in  combination  with  VRd  in  participants  with  NDMM  who  were  eligible  for  ASCT.  A  total  of  67 participants were treated with D-VRd. In the D-VRd cohort, daratumumab SC 1800 mg was administered for Cycles 1 to 3 (on Days 1, 8, and 15) and for Cycle 4 (on Day 1).

Serum samples were collected predose on Day 1 of Cycles 1 and 3; postdose on Day 4 of Cycles 1 and 4; at EOT; and 8 weeks post-treatment and used to evaluate the pharmacokinetics of daratumumab. Serum samples for evaluation of anti-daratumumab antibodies and plasma samples for evaluation of anti-rHuPH20 antibodies were collected predose on Day 1 of Cycles 1 and 4, at EOT, and 8 weeks posttreatment.

## Demographic and Baseline Characteristics

At the time of CCO (04 March 2019), 67 participants in the D-VRd cohort received study treatment. The median age of participants in the D-VRd cohort was 59 years. The majority of participants were male (71.6%). Most participants  were  white  (56.7%)  and  the  median  baseline  body  weight  was  77.0  kg (range, 43.0-147.6 kg). The majority of participants had an ECOG performance status of 0 to 1 (59.7% had an ECOG status of 0).

## Serum Daratumumab Concentrations Over Time (D-VRd cohort)

The mean (SD) value for D-VRd Cmax after the first dose was 100 (48.5) μ g/mL at Cycle 1 Day 4. The pharmacokinetic profile of daratumumab was consistent with previous data for the respective treatments (except  for  Cmax,  which  was  lower  with  daratumumab  SC  administration  compared  with  IV administration, as expected), and with daratumumab SC 1800 mg administration in other studies. The highest mean (SD) Ctrough of 635 (253) μ g/mL was observed at the end of weekly dosage (after 9 weekly doses at Cycle 4 Day 1). At EOT, the mean (SD) serum daratumumab concentration was 414 (215) μ g/mL. Due to the long half-life, concentrations of daratumumab were still detectable at 8 weeks after the last dose. The intersubject variability (%CV) for serum daratumumab concentrations ranged from 36.9% to 72.5% across all pharmacokinetic sampling timepoints.

## Special populations

## Weight

In the pharmacokinetic-evaluable population of Study MMY3014, the baseline body weight range was 44.5  to  125.0  kg,  which  was  similar  to  that  in  other  daratumumab  SC  studies.  The  body  weight percentiles  for  Study  MMY3014  (≤25%,  &gt;25%  to  ≤75%,  and  &gt;75%)  correspond  to  body  weight categories of ≤66 kg, &gt;66 to ≤86 kg, and &gt;86 kg, respectively, which are similar to baseline body weight cutoffs used in this analysis.

In  the  study  MMY3014,  there  was  considerable  overlap  in  serum  daratumumab  concentrations  at pharmacokinetic sampling timepoints across body weight subgroups. However, consistent with a mAb administered SC by flat dose, higher serum daratumumab concentrations were observed in participants with lower body weight ( ≤ 65 and ≤ 50 kg) and lower serum daratumumab concentrations were observed in participants with higher body weight (&gt;85 kg) at all pharmacokinetic sampling timepoints. For the lowest body weight subgroups ( ≤ 65 and ≤ 50 kg), mean Ctrough of daratumumab at Cycle 3 Day 1 predose was 17.5% and 63.1% higher, respectively, compared with that of the total pharmacokineticevaluable analysis set. For the highest body weight subgroup (&gt;85 kg), mean Ctrough of daratumumab at Cycle 3 Day 1 predose was 11.6% lower compared with that of the total pharmacokinetic-evaluable analysis  set.  For  the  middle  body  weight  subgroup  (&gt;65  to ≤ 85 kg and &gt;50 to ≤ 85 kg), the mean concentration  of  daratumumab  at  Cycle  3  Day  1  predose  was  comparable  to  that  of  the  total pharmacokinetic-evaluable analysis set. Five participants in the pharmacokinetic-evaluable analysis set had a body weight ≤ 50 kg and had mean (SD) daratumumab Cmax at Cycle 3 Day 4 of 1056 (223) µg/mL, which was within the range of Cmax (Cycle 3 Day 4) for participants in the total pharmacokinetic-

<div style=\"page-break-after: always\"></div>

evaluable analysis set (0.957-1479 µg/mL). The flat-dose administration of daratumumab SC achieved adequate  systemic  exposure  for  all  body  weight  subgroups  in  the  D-VRd  treatment  arm  (i.e.,  the systemic  exposure  in  the  majority  of  participants  exceeded  the  236  µg/mL  threshold  previously established to be necessary for 99% target saturation).

## Race

In the MMY3014 study, the observed mean (SD) Ctrough,max of daratumumab at Cycle 3 Day 1 predose in black/African American participants (N=4) was 415 (154) μ g/mL, approximately 21% lower than in white participants (526 [211] μ g/mL, N=275). The observed mean (SD) Ctrough,max at Cycle 3 Day 1 predose  in  Asian  participants  (495  [90.3] μ g/mL,  N=4)  appeared  to  be  similar  to  that  of  white participants.

## Pharmacokinetic interaction studies

Since  there  is  no  overlapping  pathway  of  elimination,  no  interactions  are  expected  between daratumumab and small-molecule drugs including VRd.

## 2.3.3. Pharmacodynamics

Pharmacodynamic/biomarker  assessments  were  not  conducted  in  Studies  MMY3014,  GRIFFIN,  and PLEIADES, but the mechanism of action of daratumumab has been previously characterised.

## Mechanism of action

Daratumumab is an IgG1 κ human monoclonal antibody (mAb) that binds to the CD38 protein expressed on  the  surface  of  cells  in  a  variety  of  haematological  malignancies,  including  clonal  plasma  cells  in multiple myeloma and AL amyloidosis, as well as other cell types and tissues. CD38 protein has multiple functions such as receptor mediated adhesion, signalling, and enzymatic activity.

Daratumumab has been shown to potently inhibit the in vivo growth of CD38-expressing tumour cells. Based on in vitro studies, daratumumab may utilise multiple effector functions, resulting in immune mediated tumour cell  death.  These  studies  suggest  that  daratumumab  can  induce  tumour  cell  lysis through  complement-dependent  cytotoxicity,  antibody-dependent  cell-mediated  cytotoxicity,  and antibody-dependent cellular phagocytosis in malignancies expressing CD38. A subset of myeloid derived suppressor  cells  (CD38+MDSCs),  regulatory  T  cells  (CD38+Tregs)  and  B  cells  (CD38+Bregs)  are decreased by daratumumab mediated cell lysis. T cells (CD3+, CD4+, and CD8+) are also known to express CD38 depending on the stage of development and the level of activation. Significant increases in  CD4+  and  CD8+  T  cell  absolute  counts,  and  percentages  of  lymphocytes,  were  observed  with daratumumab treatment in peripheral whole blood and bone marrow. In addition, T-cell receptor DNA sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immune modulatory effects that may contribute to clinical response.

## Immunogenicity

The immune response-evaluable analysis set included participants who received at least 1 administration of  daratumumab  SC  and  had  1  or  more  ADA  samples  obtained  after  their  first  daratumumab  SC administration.  In  the  D-VRd  treatment  arm,  339  participants  were  included  in  the  daratumumab immune response-evaluable analysis set and 338 participants were included in the rHuPH20 immune response-evaluable analysis set.

## Incidence of Anti-daratumumab Antibodies

<div style=\"page-break-after: always\"></div>

Two (0.6%) of the 339 participants in the daratumumab SC immune response-evaluable analysis set had treatment-emergent anti-daratumumab antibodies with peak titers of 1:48 and 1:192, respectively, indicating  a  low  risk  of  immune  response  to  daratumumab  in  combination  with  VRd.  One  of  the  2 participants who tested positive for treatment-emergent anti-daratumumab antibodies was also positive for NAbs. In 1 of the 2 participants who was positive for anti-daratumumab antibodies, there was no apparent effect on the pharmacokinetics of daratumumab. Serum concentrations of daratumumab were lower in the other participant who was positive for treatment-emergent antibodies to daratumumab compared to participants who were negative for anti-daratumumab antibodies. However, these findings should  be  interpreted  with  caution  given  the  small  number  of  participants  who  tested  positive  for antibodies to daratumumab. Neither anti-daratumumab antibody-positive sample was associated with a systemic administration-related reaction (sARR).

Of note, 5 (1.5%) of the 339 participants in the daratumumab immune response-evaluable analysis set tested  positive  for  anti-daratumumab  antibodies  at  baseline  (prior  to  receiving  daratumumab  SC treatment) with titers of 1:384 or lower. None of these participants were positive for treatment-emergent anti-daratumumab antibodies.

## Incidence of Anti-rHuPH20 Antibodies

Twenty-one (6.2%) of the 338 participants in the recombinant human hyaluronidase PH20 (rHuPH20) immune response-evaluable analysis set tested positive for anti-rHuPH20 antibodies at baseline (prior to receiving daratumumab SC) with generally low titers data not shown).

Thirty-seven (10.9%) of the 338 participants in the rHuPH20 immune response-evaluable analysis set had treatment-emergent anti-rHuPH20 antibodies after the first daratumumab SC administration. Peak titers  were  generally  low,  and  no  participants  had  NAbs  to  rHuPH20.  Daratumumab  exposure  was comparable between participants with and without treatment-emergent anti-rHuPH20 antibodies. These results were consistent with the reported incidence of treatment-emergent anti-rHuPH20 antibodies in previous daratumumab SC studies.

## Efficacy exposure-response analysis

All participants from study MMY3014 who received at least one dose of daratumumab with at least one evaluable pharmacokinetic sample postdose (for the D-VRd arm) were included in the exposure-efficacy analysis.

The purpose of this analysis was to explore the E-R relationship to confirm and supplement the evidence of efficacy and safety of the daratumumab SC 1800 mg dose regimen in patients with NDMM.

The relationship between exposure and the primary efficacy endpoint, PFS, was analysed graphically using Kaplan-Meier and Cox regression analysis. The effect of age, sex, body weight, race, renal and hepatic function, type of myeloma (IgG versus non-IgG), ISS, and ECOG status on efficacy was also evaluated.

## Results

The intent-to-treat population included a total of 709 participants who were randomly assigned to D-VRd (N=355) or VRd (N=354) in a 1:1 ratio. Of the 709 participants, 11 participants did not receive any protocol-defined treatment (D-VRd: 4, VRd: 7) and 698 participants received at least 1 dose of study treatment (D-VRd: 351, VRd: 347). From the 351 participants assigned to the D-VRd arm, there were 14 participants who had missing pharmacokinetic exposure metrics (i.e., Ctrough,max) for the exposureefficacy  analysis.  Therefore,  the  efficacy  dataset  for  the  E-R  analysis  contained  data  from  684 participants (D-VRd: 337, VRd: 347).

The relationship between exposure and the primary efficacy endpoint, PFS, was analysed graphically using Kaplan-Meier and Cox regression analysis (Figure 1 ).

<div style=\"page-break-after: always\"></div>

Figure 1. Kaplan-Meier Curves of Progression-free Survival by Daratumumab Exposure Subgroups in Combination with VRd in Study MMY3014

<!-- image -->

Most of the investigated covariates (i.e., age, sex, race, type of myeloma, renal and hepatic function) were well balanced between the VRd arm and the quartiles of exposure from the D-VRd arm.

Body weight and ISS showed imbalance across the quartiles of exposure in D-VRd. A slight trend for body weight (i.e., lower body weight in highest quartile Q4 and higher body weight in lowest quartile Q1) was observed among the quartiles of exposure The percentage of participants with ISS in stage 1 was lower in Q1 than the other 3 quartiles.

Because of the imbalanced covariates observed in the exposure quartiles, a covariate analysis for PFS was performed to determine the effect of demographic- and disease-related covariates on efficacy. As expected, the covariate that appeared to correlate with PFS was ISS ( Figure 2 ).

<div style=\"page-break-after: always\"></div>

Figure 2. Influence of the Covariates on Progression-free Survival: ISS

## h)InternationalStaging System

<!-- image -->

No differences in PFS were detected when the analysis was categorized into additional subgroups (i.e., sex or body weight tiers, age, ECOG status [0 versus 1 or above], type of myeloma [IgG versus nonIgG], hepatic function [normal versus impaired], renal function [≥90, 60 to 90, 30 to 60 mL/min], and race  [non-white  versus  white]).  Multivariate  Cox  regression  analysis  was  conducted  in  a  step-wise manner  aiming  to  adjust  the  covariate  effects  of  ISS  and  body  weight.  These  covariates  were  not statistically  significant  and  showed  no  exposure-effect  modification  when  incorporated  into  the  Cox regression model (data not shown).

## Safety exposure-response analysis

All participants who received at least one dose of study treatment with at least one evaluable sample postdose  were  included  in  the  exposure-safety  analysis.  The  key  safety  endpoints  of  interest  were included in the exposure-safety analysis.

The E-R relationship for safety was evaluated graphically by means of exploratory bar plots and direct comparison of TEAE rates across the exposure quartiles of daratumumab.

## Results

The exposure-safety analysis for all selected TEAEs, was the same as that for the exposure-efficacy analysis, except for sARRs, which included 691 participants (D-VRd: 344, VRd: 347), as the relationship of sARRs was evaluated with Cpeak,first, which was available from 344 participants who received D-VRd.

There was no apparent increase in TEAE rates with increasing exposure (Cpeak,first or Cpeak,max) for sARRs, thrombocytopenia, anaemia, neutropenia, lymphopenia, or infections/infestations (all grades and Grades ≥3) within the studied drug concentration range in MMY3014 ( data not shown).

## 2.3.4. PK modelling

## Population PK (PPK) modelling

The PPK analysis was based on a total of 3889 daratumumab pharmacokinetic samples (3028 SC samples and 861 IV samples) from a total of 526 pharmacokinetic evaluable participants from Study MMY3014 (N=344; pharmacokinetic data cutoff date: 01 August 2023), GRIFFIN (N=115; pharmacokinetic data

<div style=\"page-break-after: always\"></div>

cutoff date: 31 May 2022), and PLEIADES (N=67; pharmacokinetic data cutoff date: 07 December 2020). Pharmacokinetic evaluable participants were defined as participants who received at least 1 dose of daratumumab and had at least 1 measurable serum daratumumab concentration value above LLOQ after dose administration. The proportion of pharmacokinetic concentrations below the LLOQ of 0.2 μ g/mL was low (1.6%).

At baseline, participants included in the PPK analysis had a median age of 60 years and median body weight of 77 kg (range, 43.0 -158.6 kg). Of note, there were 7 participants with body weight &lt;50 kg and 15 participants  with  body  weight  ≥120 kg.  The  analysis  population  was  predominantly  white  race (65.6%) with normal renal function or mild renal impairment (73.2%), and normal hepatic function (71.3%). Disease characteristics included primarily low ECOG status (0 and 1: 93.4%), IgG myeloma (58.4%), and low ISS (49.6%). Statistics were generally similar across the different studies for most covariates, with no prominent differences in overall covariate distributions. Exceptions include a large proportion of participants from PLEIADES that were classified as 'Other' race, and a considerable amount of missing data in GRIFFIN participants for hepatic/renal function as well as unevaluable or missing data for ADA status.

An  external  model  evaluation  was  performed  to  verify  the  predictive  performance  of  a  previously developed PPK model with the current pooled clinical pharmacokinetic data which revealed a consistent underprediction of daratumumab concentrations relative to observed data. Based on the Goodness of Fir (GOF) plots and corresponding prediction-corrected visual predictive checks (pcVPC) results obtained from the external validation, the model parameters of the previously developed PPK model were reestimated using a pooled dataset in Non-Linear Mixed Effects Model (NONMEM).

The observed concentration-time data of daratumumab were adequately described by a 2 compartment PPK model with parallel linear and nonlinear elimination pathways. The absorption of the daratumumab SC formulation was modeled as a first-order absorption process. Bioavailability (F1) was estimated to be  0.591,  which  is  consistent  with  a  previously  developed  IV/SC  publication  (Luo  2021;  SC MM/Mod5.3.3.5/PPK Report) and other mAbs subcutaneously co-administered with rHuPH20 (Gibiansky 2021; Quartino 2016).

Daratumumab concentrations increased slowly after SC administration with a first-order absorption rate constant of 0.0176 1/h (0.422 1/day) and with Cmax typically reached approximately 5 to 7 days after first dose. Maximum Ctrough was reached at the end of the once-weekly dose schedule, ie, Cycle 3 Day 1,  and  maximum  Cmax  was  reached  at  Cycle  3  Day  4  after  the  once-weekly  dose  schedule.  The estimated linear CL (0.00429 L/h [0.103 L/day]) was somewhat lower than the reported CL of nonspecific endogenous IgG in the literature (Ryman 2017) and the V1 (6.71 L) was generally close to plasma volume; both parameters were related to body weight, as expected for mAbs. Linear CL, volumes of distribution,  and  absorption  rate  parameter  estimates  were  similar  to  those  previously  reported (differences &lt;30%) (Luo 2021; SC MM/Mod5.3.3.5/PPK Report).

A  forest  plot  was  created  ( Figure  3 )  for  the  comparison  of  daratumumab  exposures  in  different subpopulations  of  interest  including  age,  sex,  race,  body  weight,  albumin  concentration,  renal  and hepatic function, ECOG status, and type of myeloma.

<div style=\"page-break-after: always\"></div>

Figure 3. Forest Plot of Subgroup Analyses on Percent Change and 95% CI Relative to Reference Value for Ctrough,C3D1 per the Recommended Dose Schedule for D-VRd Combination Therapy

<!-- image -->

N=comparatornumberofsubjectsvs.thereferencenumberofsubjects.

Solid blue point represents percentage change of geometric mean and short horizontal bar represents 95% CI.

Dashed line represents reference value of zero.

Shaded area represents spans from -20 to +25 percentage change relative to reference.

Values represent percentage of change and the associated CI.

An additional evaluation was performed for weight groups ≤50 kg (N=5), &gt;50 to ≤85 kg (reference, N=247), and &gt;85 kg (N=92). The % change relative to reference (95% CI) was 62 (25, 109) for ≤50 kg vs &gt;50 to ≤85 kg and -17 (-23, 11) for &gt;85 kg vs &gt;50 to ≤85 kg.

In the PPK analysis, race did not have a clinically meaningful effect on daratumumab pharmacokinetics.

## 2.3.5. Discussion on clinical pharmacology

## Pharmacokinetics

The PPK analysis included a total of 3889 daratumumab pharmacokinetic samples (3028 SC samples and 861 IV samples) from 526 pharmacokinetic-evaluable participants across three studies: MMY3014 (N=344), GRIFFIN (N=115), and PLEIADES (N=67). An external model evaluation was performed to verify the predictive performance of previously developed PPK model with the current pooled clinical

<div style=\"page-break-after: always\"></div>

pharmacokinetic data. The previous PPK model was deemed unacceptable, and the parameters of the PPK model were re-estimated. After re-estimation of model parameters, the structure of the model remained the same as previously: daratumumab was described by a 2-compartment PPK model with parallel linear and nonlinear elimination pathways. Likewise, the covariate structure remained the same as previously with the effect of serum albumin concentration, body weight and type of myeloma (IgG versus  non-IgG)  on  linear  clearance;  body  weight  and  sex  on  volume  of  distribution  in  the  central compartment, which is considered typical for mAbs. No significant bias  was  observed in any of the goodness-of-fit plots. The precision of estimated PK parameters was proved based on 95% CIs derived from standard errors from the covariance matrix and bootstrap analysis (830/1000).  The shrinkage values suggested moderate to high shrinkage for most parameters, indicating potential challenges in estimating individual variability for CL, V1, Vmax, kdes, ka, and F1. The overall model performance was observed based on the study-stratified pcVPCs, suggesting no significant trends across the different percentiles.

The impact of covariates on the exposure metric Ctrough, C3D1 was evaluated using a forest plot. Forest plots  with  other  exposure  metrics  were  not  presented.  Immunogenicity  was  not  evaluated  in  this subgroup analysis due to the small number of ADA-positive participants. The forest plot suggested that none  of  the  investigated  covariates  (sex,  race,  body  weight,  albumin  concentration,  renal/hepatic function,  ECOG  status  and  type  of  myeloma)  had  clinically  relevant  effects  on  daratumumab pharmacokinetics, as expected from previous investigations. Based on these results, it seems that no additional dose recommendations are required for daratumumab.

Sparse PK-sampling was done in the 3 clinical studies which was conducted to support this application for use of daratumumab SC in combination with Lenalidomide, Bortezomib, and Dexamethasone (VRd) for treatment of NDMM in patients who are eligible for ASCT. The marketed drug product and SC dosing regimen of 1800 mg daratumumab was used in pivotal clinical study. In study MMY3014, daratumumab exposure was similar to that seen in monotherapy studies, with the maximum Ctrough (cycle 3 day 1 pre dose) mean ± SD of 526±209 µg/mL. Mean cycle 5 day 1 pre-dose concentration was considerably lower compared to study MMY3013. This difference was largely due to dosing interruption during the ASCT period. The pharmacokinetic profiles of daratumumab SC treatment of participants with NDMM who are eligible for ASCT were generally consistent with previous observations of daratumumab SC in combination and monotherapy studies.

The effect of covariates on PK, Ctrough at steady state, was evaluated from clinical PK-data in addition to the Pop-PK modelling.

The mean Cycle 3 Ctrough data showed as expected for a flat dosing regimen that the exposure was higher in the low BW groups, &lt;50 kg and &lt;65 kg, and that the exposure was lower in the high BW group, &gt;85 kg. A comparable weight effect was observed in the Po p-PK  analysis.  The  effect  of  weight  on exposure is comparable to what was previously reported for Darzalex in the SmPC.

## Pharmacodynamics

No exposure-response relationship for daratumumab has been demonstrated. A similar reduction in HR was found between exposure groups Q1 and Q3 and between Q2 and Q4. In all exposure quartiles a positive impact of adding daratumumab to VRd was demonstrated.

Body weight and ISS showed no exposure-effect modification on PFS in an adjusted model.

The  immunogenicity  results  following  daratumumab  SC  in  combination  with  VRd  treatment  in participants  with  NDMM  who  were  eligible  for  ASCT  were  consistent  with  observations  in  previous monotherapy and combination studies in multiple myeloma where development of anti-daratumumab antibodies was rare.

The exposure-safety relationship showed  no  apparent  increase in TEAE  rate with increasing daratumumab  exposure  for sARRs, thrombocytopenia, anaemia, neutropenia, lymphopenia, or infections.

<div style=\"page-break-after: always\"></div>

## 2.3.6. Conclusions on clinical pharmacology

The provided pharmacokinetics data from 3 clinical studies the exposure-efficacy and exposure-safety analyses support the use of 1800 mg daratumumab SC in combination with VRd in patients with NDMM who are eligible for ASCT.

## 2.4. Clinical efficacy

## 2.4.1. Main study

Study 54767414MMY3014 - PERSEUS: A phase 3 study comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in subjects with previously untreated multiple myeloma who are eligible for high-dose therapy.

## Methods

A diagrammatic representation of the study design is presented in Figure 4 .

Figure 4. Study 54767414 / MMY3014 schematic

<!-- image -->

## Study participants

Main inclusion criteria:

1. 18 to 70 years of age, inclusive.
2. Monoclonal plasma cells in the bone marrow ≥10% or presence of a biopsy proven plasmacytoma and documented multiple myeloma satisfying at least one of the calcium, renal, anemia, bone (CRAB) criteria or biomarkers of malignancy criteria (SLiM-CRAB):
- a. CRAB criteria:

<div style=\"page-break-after: always\"></div>

1. Hypercalcemia: serum calcium &gt;0.25 mmol/L (&gt;1 mg/dL) higher than upper limit of normal (ULN) or &gt;2.75 mmol/L (&gt;11 mg/dL)
2. Renal insufficiency: creatinine clearance &lt;40mL/min or serum creatinine &gt;177 μmol/L (&gt;2 mg/dL)
3. Anemia: hemoglobin &gt;2 g/dL below the lower limit of normal or hemoglobin &lt;10 g/dL
4. Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
- b. Biomarkers of Malignancy (SLiM-CRAB):
1. Clonal bone marrow plasma cell percentage ≥60%
2. Involved: uninvolved serum free light chain ratio ≥100
3. &gt;1 focal lesion on magnetic resonance imaging (MRI) studies
3. Measurable disease as defined by any of the following:
- a. Serum monoclonal paraprotein (Mprotein) level ≥1.0 g/dL or urine M -protein level ≥200 mg/24 hours; or
- b. Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin FLC ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio
4. Newly diagnosed subjects for whom high-dose therapy and autologous stem cell transplantation is part of the intended treatment plan.
5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
6. Female subjects of child-bearing age should not be pregnant and avoid pregnancy

## Main exclusion criteria:

1. Prior or current systemic therapy or SCT for any plasma cell dyscrasia, with the exception of emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment.
2. Peripheral neuropathy or neuropathic pain Grade 2 or higher.
3. Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years of date of randomization (exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).
4. Radiation therapy for treatment of plasmacytoma within 14 days of randomization (palliative radiation for pain control secondary to lytic lesion is allowed within 14 days of randomization).
5. Plasmapheresis within 28 days of randomization.
6. Clinical signs of meningeal involvement of multiple myeloma.
7. Pulmonary:
- a. Subjects &lt;65 years old with chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) &lt;50% of predicted normal.
- b. Subjects ≥65 years old with a FEV1 &lt;50% or diffusing capacity of the lungs for carbon monoxide [DLCO] &lt;50%.

<div style=\"page-break-after: always\"></div>

8. Moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification.  (subjects  who  currently  have  controlled intermittent  asthma  or controlled mild persistent asthma are allowed in the study).
9. Any of the following:
- a. Known to be seropositive for human immunodeficiency virus (HIV).
- b. Seropositive for hepatitis B. Subjects with resolved infection (ie, subjects who are HBsAg negative  but  positive  for  antibodies  to  hepatitis  B  core  antigen  [Anti-HBc]  and/or antibodies to hepatitis B surface antigen [Anti-HBs]) must be screened using real-time PCR measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.
- c. Known to be seropositive for hepatitis C, (except in the setting of a sustained virologic response  [SVR],  defined  as  aviremia  at  least  12  weeks  after  completion  of  antiviral therapy).

## Treatments

Treatment Arm A (VRd):

- Bortezomib SC injection (1.3 mg/m 2 ) - D1, D4, D8, D11 during C1 to C6; induction: 4, 28-day cycles (C1 to C4); consolidation: 2, 28-day cycles (C5 to C6).
- Lenalidomide  PO  (25  mg)  -  D1  to  D21  during  C1  to  C6;  induction:  C1-C4,  28-day  cycles; consolidation: C5-C6, 28-day cycles.
- o Maintenance: 10 mg daily PO on D1 to D28 (continuously) of each 28-day cycle until PD or unacceptable toxicity.
- Dexamethasone  PO  (40  mg)  on  D1  to  D4  and  D9  to  D12  of  each  28-day  cycle  during induction/consolidation (C1 to C6)
- ASCT after 4 cycles of induction: Within 6 weeks after the completion of induction therapy (cycle 4), stem-cell  mobilization  was  performed  with  the  use  of  the  local  standard  regimen,  such  as cyclophosphamide, granulocyte colony-stimulating factor, and plerixafor. A second round of stemcell mobilization or bone marrow harvest was permitted if the stem-cell yield was considered by the investigator to be inadequate. Patients underwent conditioning with melphalan (200 mg per square meter of body-surface area) over a period of 24 to 48 hours, followed by  autologous stem-cell transplantation. Consolidation therapy began 30 to 60 days after transplantation.

## Treatment Arm B (D-VRd):

- VRd, ASCT and lenalidomide maintenance as described above.
- Daratumumab SC (1800 mg) - once every week for C1 to C2, then every 2 weeks for C3 to C6. For maintenance C7+, once every 4 weeks until PD or unacceptable toxicity. Participants with CR or better and sustained MRD-negativity for 12 months will stop daratumumab after a minimum of 24 months of maintenance therapy and restart if loss of CR without PD or loss of MRD-negativity.

## Objectives

## Primary

- To determine if the addition of daratumumab to VRd prolongs PFS compared with VRd alone

## Secondary

- To determine if the addition of daratumumab to VRd will improve clinical outcome as measured by:
- -Overall rate of CR or better

<div style=\"page-break-after: always\"></div>

- -Overall MRD-negativity rate achieved at any time during the study
- -OS
- -MRD-negativity rate post-consolidation
- -ORR, rate of VGPR or better, rate of CR or better, and rate of sCR at post-induction, posttransplant, post-consolidation, and overall
- -PFS2
- -Time to response
- -Duration of response
- -To evaluate PROs and MRU
- -To evaluate time to engraftment post-ASCT

## Outcomes/endpoints

## Primary

- Time from the date of randomisation to the date of disease progression (assessed by the International Myeloma Working Group (IMWG) 2011 criteria)

## Secondary

- The percentage of ITT participants who achieved CR or sCR status anytime during the study per the 2011 IMWG criteria
- The proportion of ITT participants who achieved MRD-negativity (at or below the threshold of 10-5) by bone marrow aspirate and achieve CR or better response at any time after the date of randomization during the study (and prior to PD, subsequent therapy, or both).
- Measured from the date of randomization to the date the participant's death
- The proportion of ITT participants who achieve MRD-negativity (at or below the threshold of 10-5) at the end of consolidation and achieve CR or better response at any time of the study
- The proportions of ITT participants who achieved PR or better (VGPR or better, CR or better, or sCR) per 2011 IMWG criteria at post induction, post-transplant, post-consolidation, and overall
- The time from randomization to progression on next line of therapy or death, whichever comes first. PD on next line of treatment is based on investigator assessment.
- The time from randomization to date of initial PR or better response; time to CR/sCR defined as the time from randomization to date of initial CR/sCR
- The time from the date of first documentation of confirmed response (PR or better; CR or better) or first documentation of MRD negative status to the date of first documented evidence of PD, according to 2011 IMWG criteria, or death due to PD, whichever occurs first.
- Change in health-related quality of life, symptoms, and functioning using 2 EORTC questionnaires and the EQ-5D-5L
- ANC ≥0.5 x 10 9 / L and platelet count ≥20 x 10 9 /L

<div style=\"page-break-after: always\"></div>

## Sample size

The planned total sample size was approximately 690 participants. This was based on the assumptions that the median PFS for the VRd group would be 63 months and that the addition of daratumumab would decrease the risk of progression or death by 31% (HR=0.69; estimated median PFS of 91 months for DVRd group). In order to achieve 85% power with a two-sided alpha of 0.05, 285 PFS events would be required.  Assuming  a  12-month  accrual  and  64-month  of  additional  follow-up,  approximately  690 subjects (345/arm) would be needed.

Long-term follow-up for survival will continue until approximately 310 deaths have been observed or 9 years have elapsed after the last subject is randomized, whichever occurs earlier. Per the protocol, this will provide approximately 70% power to detect a 25% reduction in the risk of death (HR=0.75) with a log-rank test at a 2-sided alpha of 0.05. However, a hazard ratio of 0.71 or less will provide at least 80% power. A large Phase 3 trial (CASSIOPEIA, MMY3006) comparing D-VTd versus VTd in a similar study population (N=1085), observed a HR of 0.66 from first randomization censoring the events from the crossover VTd subjects after Part 1 of the study with median follow-up of 18.8 months, such a HR would provide approximately 93.5% power for this study with 310 deaths.

## Randomisation

This is a multi-centre randomised study. Participants are stratified by ISS Stage I, II, or III disease ( β -2 microglobulin and albumin) and cytogenetics (standard-risk or high-risk as defined by presence of del17p, t[4;14] or t[14;16]) and then randomised in a 1:1 ratio.

## Blinding (masking)

This is an open-label study.

## Statistical methods

## Analysis methods

For PFS, the primary analysis will consist of a stratified log-rank test for the comparison of the PFS distribution between the 2 treatment groups. The p-value from a stratified log-rank test will be reported. The Kaplan-Meier method will be used to estimate the distribution of overall PFS for each treatment. The treatment  effect,  measured  by  hazard  ratio  (Arm  B  vs.  Arm  A),  and  its  two-sided  95%  confidence intervals  are  to  be  estimated  using  a  stratified  Cox  regression  model  with  treatment  as  the  sole explanatory  variable.  Stratification  factors  used  in  the  analyses  include  ISS  staging  (I,  II,  III),  and cytogenetic risk (standard, high). The median PFS with 95% CI will be provided. The Kaplan-Meier PFS curve will also be plotted by treatment group.

In addition, PFS rates with 95% CI will be estimated by Kaplan-Meier method at landmarks (e.g., at 12month, and 18-month, etc.) and reported for each treatment group. The number and percentage of subjects who had a PFS event or were censored will be reported. Reasons for PFS censoring will be summarized for ITT.

## Sensitivity Analysis

The following sensitivity analyses will be conducted to evaluate the robustness of the primary analysis of PFS as appropriate.

Progressive  Disease  Based  on  Investigator  Assessment: A  sensitivity  analysis  of  PFS,  in  which progressive disease is based on investigator assessment according to the IMWG response criteria. The PFS  definition  used  in  the  sensitivity  analysis  is  similar  to  that  defined  above,  except  for  date  of progressive disease and date of censoring. The date of progressive disease is the date of initial disease progression recorded in the Disease Progression CRF page or earliest date of confirmed progressive disease recorded in the Evaluation of Response CRF page, based on investigator assessment. Similarly,

<div style=\"page-break-after: always\"></div>

the censoring date is the latest date of disease response recorded in the Evaluation of Response CRF page,  based  on  investigator  assessment.  In  addition,  reasons  for  PFS  and  censoring  based  on investigator assessment will be summarized for ITT population.

Unstratified  Analysis  of  PFS: A  sensitivity  analysis  of  PFS  by  using  unstratified  log-rank  test  and unstratified Cox's regression model will be performed in a similar manner as described for the primary analysis.

Not censored for Death/PD after Missing More Than One Disease Evaluation: A sensitivity analysis of PFS derived  from  the  algorithm  by  not  censoring  for  death  or progression  after  missing  consecutive evaluations will be performed in a similar manner as described for the primary analysis.  For any PFS (death or progression) event identified by the computer algorithm, if there is more than one scheduled disease evaluation missed between the event date and the latest date of scheduled disease evaluation (includes serum M-protein, urine M-protein, and serum FLC only) immediately preceding the event, then this event will be considered as a PFS event in the analysis.

## Key secondary Endpoint(s)

## Overall CR or Better Rate

Overall CR or better rate is defined as the percentage of ITT subjects who achieved CR or sCR status anytime during the study per the IMWG criteria. In addition, the specific response must be achieved prior to start of subsequent therapies.

## Overall MRD Negativity Rate

Overall MRD negativity rate is defined as the proportion of ITT subjects who achieve MRD negativity (at or below the threshold of 10-5) by bone marrow aspirate and achieve CR or better response at any time after the date of randomization during the study (and prior to progressive disease, subsequent therapy, or both). Subjects whose tested samples were found to be MRD positive or ambiguous, and subjects who were not tested will be considered as not achieving MRD negativity.

## Overall Survival (OS)

OS is measured from the date of randomization to the date of death due to any cause. Subjects who are lost  to  follow-up  will  be  censored  at  the  time  of  lost  to  follow-up.  Subjects  who  died  after  consent withdrawal will be considered as having an OS event. Subjects who are still alive at the clinical cut-off date for the analysis will be censored at the last known alive date. The date of last known alive will be determined by the maximum collection/assessment date from among selected data domains within the clinical database.

Secondary time-to-event efficacy endpoints, including PFS2 and OS, will be analyzed using the same method as for PFS. For OS, the final analysis will occur after approximately 310 deaths have been observed. Earlier analyses, in which OS is analyzed, will be considered as interim analyses. Even if the significance of PFS has already been established, testing of OS will continue as planned until a definitive conclusion on OS is reached.

Comparison between the 2 treatment groups of response-related endpoints at different timepoints and other binary endpoints will be conducted using the stratified Cochran Mantel-Haenszel test. The Mantel-Haenszel odds ratio will be provided along with its two-sided 95% confidence interval, and will be provided as the measure of treatment effect. Time to and Duration of response (PR or better), CR/sCR, MRD  negative  status  will  be  summarized  descriptively  without  formal  statistical  comparison.  A hierarchical testing will be used for the secondary efficacy endpoints to achieve strong control of the overall familywise Type I error rate at a two-sided significance level of 0.05.

## Interim Analyses

The study design includes 2 interim analyses and a final analysis for PFS, the first interim analysis will be performed when approximately 143 PFS events have occurred (corresponds to 50% of the total planned PFS events), the second interim analysis for PFS will be performed when approximately 185 PFS events have occurred (corresponds to 65% of the total planned PFS). If the superiority of D-VRd over

<div style=\"page-break-after: always\"></div>

VRd alone with respect to PFS could be established at the first or second interim analysis, the interim PFS analysis would serve as the primary PFS analysis, which otherwise is to occur when approximately 285 PFS events had been observed.

Only if  the  primary endpoint of PFS is statistically significant, the following key secondary endpoints would be sequentially tested, each with an overall two-sided alpha of 0.05, by utilizing the hierarchical testing approach that strongly controls Type I error rate. The key secondary endpoints will be tested in the following order:

- 1.Overall CR or better rate
2. Overall MRD negativity rate (threshold of 10-5)
3. Overall Survival
- -For Overall CR or better rate and MRD negativity rate (10-5) will only be tested at the interim or final PFS analysis when PFS is statistically significant.
- -For OS, descriptive analysis will be performed at the time of the first PFS interim analyses, expecting few OS events. In case PFS significance is established prior to the second interim or final PFS analysis, OS analysis will continue to be performed at approximately same time as if the second interim and final PFS analysis would occur (185, 285 PFS events). Expecting a long gap between the final  PFS  and  final  OS  analysis,  additional  looks  may  be  added  to  provide periodically OS updates until a definitive conclusion on OS is reached.

## Futility Analysis of OS

All subjects in the ITT population were randomized between 19 January 2019 and 03 January 2020. Given that the study was fully enrolled and ongoing at the peak of the COVID-19 pandemic prior to the availability of vaccine and/or treatment, and multiple myeloma subjects with advance aged are at high risk of developing serious COVID-19 infection and resulting in death, no formal OS futility analysis will be conducted for this trial since it would be difficult to accurately assess COVID-19 impact on the OS, especially if there is any imbalance between the two arms. Instead, sensitivity OS analyses such as censoring the COVID-19 death shall be conducted at the planned analyses, together with the routine IDMC's cumulative safety data review (especially for COVID-19 cases, and exposure impacted by the pandemic) every 6 months before the primary PFS analysis. In the event that the observed OS HR is greater than 1, it would be more appropriate to put it in the context of safety profile and benefit-risk assessment.

## Results

## Participant flow

Patient disposition in study 54767414MMY3014 is summarised in

Table 1. Summary of Treatment Disposition; Intent-to-treat Analysis Set (Study 54767414MMY3014)

<div style=\"page-break-after: always\"></div>

|                                         | VRd         | D-VRd       | Total       |
|-----------------------------------------|-------------|-------------|-------------|
| Analysis set: intent-to-treat           | 354         | 355         | 709         |
| Subjects randomized but not treated     | 7 (2.0%)    | 4 (1.1%)    | 11 (1.6%)   |
| Subjects treated*                       | 347 (98.0%) | 351 (98.9%) | 698 (98.4%) |
| Subjects who are still on treatmentb    | 159 (45.8%) | 260 (74.1%) | 419 (60.0%) |
| Subjects who discontinued treatmentb    | 188 (54.2%) | 91 (25.9%)  | 279 (40.0%) |
| Reason for discontinuationb             |             |             |             |
| Adverse event                           | 78 (22.5%)  | 32 (9.1%)   | 110 (15.8%) |
| COVID-19                                | 1 (0.3%)    | 1 (0.3%)    | 2 (0.3%)    |
| Progressive disease                     | 72 (20.7%)  | 29 (8.3%)   | 101 (14.5%) |
| Subject refused further study treatment | 14 (4.0%)   | 10 (2.8%)   | 24 (3.4%)   |
| Death                                   | 11 (3.2%)   | 9 (2.6%)    | 20 (2.9%)   |
| COVID-19                                | 0           | 3 (0.9%)    | 3 (0.4%)    |
| Physician decision                      | 9 (2.6%)    | 8 (2.3%)    | 17 (2.4%)   |
| Lost to follow-up                       | 2 (0.6%)    | 3 (0.9%)    | 5 (0.7%)    |
| Non-compliance with study drug          | 1 (0.3%)    | 0           | 1 (0.1%)    |
| Other                                   | 1 (0.3%)    | 0           | 1 (0.1%)    |
| COVID-19 related                        | 0           | 0           | 0           |

Key:VRd=bortezomib (VELCADE)+lenalidomide+dexamethasone;D-VRd=daratumumab +bortezomib (VELCADE) + lenalidomide + dexamethasone.

Percentages are caleulated based on the number of subjects randomized.

b Percentages are caleulated based on the number of subjects treated.

At the CCO, 260 patients in the D-VRd arm remained on maintenance treatment (D-R) but of these 207 have discontinued daratumumab per protocol due to sustained MRD negativity. 159 patients remain on lenalidomide maintenance in the VRd arm. Serum Daratumumab Concentrations Over

Time

## Recruitment

Study Initiation Date: 03 January 2019 (first participant was screened).

Data  Cutoff  Date:  01  August  2023  (Last  observation  recorded  as  part  of  the  database  for  interim analysis)

## Conduct of the study

Summary of main protocol amendments

Amendment 1 (04 Sept 2018):

To add language describing hepatitis testing, which is now required across daratumumab studies for subjects who are positive for anti-HBc or anti-HBs.

Amendment 2 (09 April 2019):

The overall reason for the amendment is in response to identification of a new important risk (hepatitis B virus [HBV] reactivation). Additionally, revisions and clarifications were made to considerations for lenalidomide use, secondary endpoints, dosing, as well as other measurement parameters throughout the Protocol.

Amendment 3 (20 March 2020)

<div style=\"page-break-after: always\"></div>

To remove language related to anticipated adverse events and align text with the daratumumab program standard language.

## Amendment 4 (27 June 2022)

The key reasons for this protocol amendment are to align study visits with disease evaluation visits for both study arms, to include protocol text with respect to COVID-19 vaccines and guidance during the COVID-19  pandemic  or  another  natural  disaster,  to  update  protocol  text  to  align  with  EU  CTR requirements including merging country-specific amendments into this Protocol Amendment 4, and to allow next-generation flow (NGF) in the Maintenance phase for determination of minimal residual disease (MRD) status to guide stopping/restarting of daratumumab.

## Protocol deviations

A total of 46 (6.5%) participants had major protocol deviations, 20 (5.6%) participants in the D-VRd and 26 (7.3%) participants in the VRd arm ( Table 2 ).

Table 2 . Summary of Subjects with Major Protocol Deviations; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                                 | VRd       | D-VRd     | Total     |
|-------------------------------------------------|-----------|-----------|-----------|
| Analysis set: intent-to-treat                   | 354       | 355       | 709       |
| Subjects with major protocol deviations         | 26 (7.3%) | 20 (5.6%) | 46 (6.5%) |
| Received a disallowed concomitant treatment     | 15 (4.2%) | 5 (1.4%)  | 20 (2.8%) |
| Entered but did not satisfy I/E criteria        | 4 (1.1%)  | 7 (2.0%)  | 11 (1.6%) |
| Received wrong treatment or incorrect dose      | 2 (0.6%)  | 8 (2.3%)  | 10 (1.4%) |
| Developed withdrawal criteria but not withdrawn | 2 (0.6%)  | 0         | 2 (0.3%)  |
| Other                                           | 4 (1.1%)  | 1 (0.3%)  | 5 (0.7%)  |

Key:  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  =  daratumumab  +  bortezomib (VELCADE) + lenalidomide + dexamethasone.

Note: Subjects may appear in more than one category.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Baseline data

Table 3. Summary of demographics and baseline characteristics; Intent-to-treat Analysis Set (Study 54767414MMY3014)

<div style=\"page-break-after: always\"></div>

|                                           | VRd                   | D-VRd                  | Total                 |
|-------------------------------------------|-----------------------|------------------------|-----------------------|
| Analysis set: intent-to-treat             | 354                   | 355                    | 709                   |
| Age, years                                |                       |                        |                       |
| N                                         | 354                   | 355                    | 709                   |
| Mean (SD)                                 | 58.1 (8.12)           | 58.7 (7.81)            | 58.4 (7.96)           |
| Median                                    | 59.0                  | 61.0                   | 60.0                  |
| Range                                     | (31; 70)              | (32; 70)               | (31; 70)              |
| Category, n (%)                           |                       |                        |                       |
| ≤50                                       | 54 (15.3%)            | 54 (15.2%)             | 108 (15.2%)           |
| 2 50 and < 65                             | 213 (60.2%)           | 207 (58.3%6)           | 420 (59.2%)           |
| ≥65                                       | 87 (24.6%)            | 94 (26.5%)             | 181 (25.5%)           |
| Sex, n (%)                                |                       |                        |                       |
| N                                         | 354                   | 355                    | 709                   |
| Female                                    | 149 (42.1%)           | 144 (40.6%6)           | 293 (41.3%)           |
| Male                                      | 205 (57.9%)           | 211 (59.4%)            | 416 (58.7%)           |
| Race, n (%)                               |                       |                        |                       |
| N                                         | 354                   | 355                    | 709                   |
| American Indian or Alaska Native          | 1 (0.3%)              | 2 (0.6%)               | 3 (0.4%)              |
| Asian                                     | 6 (1.7%)              | 4 (1.1%)               | 10 (1.4%)             |
| Black or African American                 | 4 (1.1%)              | 5 (1.4%)               | 9 (1.3%)              |
| Native Hawaiian or other Pacific Islander | 2 (0.6%)              | 2 (0.6%)               | 4 (0.6%)              |
| White Not Reported                        | 323 (91.2%) 18 (5.1%) | 330 (93.0%) 12 (3.4%%) | 653 (92.1%) 30 (4.2%) |
| Ethnicity, n (%)                          |                       |                        |                       |
| N                                         | 354                   | 355                    | 709                   |
| Hispanic or Latino                        | 20 (5.6%)             | 30 (8.5%6)             | 50 (7.1%)             |
| Not Hispanic or Latino                    | 254 (71.8%)           | 242 (68.2%)            | 496 (70.0%)           |
| Not Reported                              | 80 (22.6%)            | 83 (23.4%6)            | 163 (23.0%)           |
| Weighte, kg                               |                       |                        |                       |
| N                                         | 354                   | 354                    | 708                   |
| Mean (SD)                                 | 75.40 (17.314)        | 77.02 (14.932)         | 76.21 (16.176)        |
| Median                                    | 73.00                 | 75.40                  | 74.50                 |
| Range                                     | (37.0; 167.6)         | (44.5; 125.0)          | (37.0; 167.6)         |
| Category, n (%)                           |                       |                        |                       |
| 565                                       | 114 (32.2%)           | 82 (23.2%)             | 196 (27.7%)           |
| >65 - 85                                  | 149 (42.1%)           | 175 (49.4%6)           | 324 (45.8%)           |
| >85                                       | 91 (25.7%)            | 97 (27.4%)             | 188 (26.69%)          |
| Height, cm                                |                       |                        |                       |
| N                                         | 354                   | 355                    | 709                   |
| Mean (SD)                                 | 170.20 (10.416)       | 170.00 (9.525)         | 170.10 (9.973)        |
| Median                                    | 170.00                | 170.00                 | 170.00                |
| Range                                     | (145.0; 198.0)        | (142.0; 195.0)         | (142.0; 198.0)        |
| BSA', m²                                  |                       |                        |                       |
| N                                         | 354                   | 354                    | 708                   |
| Mean (SD)                                 | 1.879 (0.2516)        | 1.901 (0.2193)         | 1.890 (0.2361)        |
| Median                                    | 1.857                 | 1.888                  | 1.881                 |
| Range                                     | (1.26; 2.80)          | (1.37; 2.59)           | (1.26; 2.80)          |
| Baseline ECOG scoreb, n (%)               |                       |                        |                       |
| N                                         | 354                   | 355                    | 709                   |
| 0                                         | 230 (65.0%)           | 221 (62.3%)            | 451 (63.6%)           |
| 1                                         | 108 (30.5%)           | 114 (32.1%)            | 222 (31.3%)           |
|                                           | 16 (4.5%)             | 19 (5.4%6)             | 35 (4.9%)             |
| 3                                         | 0                     | 1 (0.3%)               | 1 (0.1%)              |

<div style=\"page-break-after: always\"></div>

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

ECOG = Eastern Cooperative Oncology Group; BSA = Body Surface Area.

a One subject did not have baseline weight or BSA. The subject is randomized but not treated.

b One subject had ECOG 0 at randomization and worsened to ECOG 3 at baseline.

Note: Percentages are calculated with the number of subjects in each group with available data as denominator.

Table 4. Summary of Baseline Disease Characteristics; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                                              | VRd         | D-VRd       | Total       |
|--------------------------------------------------------------|-------------|-------------|-------------|
| Analysis set: Intent-to-treat                                | 354         | 355         | 709         |
| Type of myeloma by immunofixation or sernum FLC assay, n (%) |             |             |             |
| N                                                            | 354         | 355         | 709         |
| IgG                                                          | 200 (56.5%) | 211 (59.4%) | 411 (58.0%) |
| IgA                                                          | 89 (25.1%)  | 76 (21.4%)  | 165 (23.3%) |
| IgM                                                          | 0           | 2 (0.6%)    | 2 (0.3%)    |
| IgD                                                          | 5 (1.4%)    | 4 (1.1%)    | 9 (1.3%)    |
| IgE                                                          | 0           | 0           | 0           |
| Light chain                                                  | 49 (13.8%)  | 47 (13.2%)  | 96 (13.5%)  |
| Kappa                                                        | 32 (9.0%)   | 26 (7.3%)   | 58 (8.2%)   |
| Lambda                                                       | 15 (4.2%)   | 15 (4.2%)   | 30 (4.2%)   |
| FLC-Kappa                                                    | 2 (0.6%)    | 5 (1.4%)    | 7 (1.0%)    |

<div style=\"page-break-after: always\"></div>

## Summary of Baseline Disease Characteristics; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                                             | VRd           | D-VRd        | Total        |
|-------------------------------------------------------------|---------------|--------------|--------------|
| FLC-Lambdab                                                 | 0             | 1 (0.3%)     | 1 (0.1%)     |
| Biclonal                                                    | 11 (3.1%)     | 15 (4.2%)    | 26 (3.7%)    |
| Type of measurable disease', n(%)                           |               |              |              |
| N                                                           | 354           | 355          | 709          |
| Serum                                                       | 281 (79.4%)   | 282 (79.4%)  | 563 (79.4%)  |
| IgG                                                         | 185 (52.3%)   | 204 (57.5%)  | 389 (54.9%)  |
| IgA                                                         | 85 (24.0%)    | 65 (18.3%)   | 150 (21.2%)  |
| Otherd                                                      | 11 (3.1%)     | 13 (3.7%)    | 24 (3.4%)    |
| Urine only                                                  | 46 (13.0%)    | 43 (12.1%)   | 89 (12.6%)   |
| Serum FLC only                                              | 27 (7.6%)     | 29 (8.2%)    | 56 (7.9%)    |
| NEe                                                         | 0             | 1 (0.3%)     | 1 (0.1%)     |
| Multiple myeloma diagnosis                                  |               |              |              |
| N                                                           | 352           | 354          | 706          |
| CRAB Criteria onlyf                                         | 113 (32.1%)   | 125 (35.3%)  | 238 (33.7%)  |
| Biomarkers of malignancy only                               | 65 (18.5%)    | 52 (14.7%)   | 117 (16.6%)  |
| CRAB criteria and Biomarkers of malignancy (both)           | 174 (49.4%)   | 177 (50.0%)  | 351 (49.7%)  |
| CRAB Criteria                                               |               |              |              |
| N                                                           | 287           | 302          | 589          |
| Hypercalcemia                                               | 31 (10.8%)    | 27 (8.9%)    | 58 (9.8%)    |
| Renal insufficiency                                         | 8 (2.8%)      | 11 (3.6%)    | 19 (3.2%)    |
| Anemia                                                      | 129 (44.9%)   | 127 (42.1%)  | 256 (43.5%)  |
| Bone lesions                                                | 237 (82.6%)   | 248 (82.1%)  | 485 (82.3%)  |
| Biomarkers of Malignancy                                    |               |              |              |
| N                                                           | 239           | 229          | 468          |
| Clonal bone marrow plasma cell percentage >60%              | 122 (51.0%)   | 106 (46.3%)  | 228 (48.7%)  |
| Involved: uninvolved serum FLC ratio >100                   | 136 (56.9%)   | 113 (49.3%)  | 249 (53.2%)  |
| >1 focal lesion on magnetic resonance imaging (MRI) studies | 48 (20.1%)    | 66 (28.8%)   | 114 (24.4%)  |
| ISS Staging, n(%)                                           |               |              |              |
| N                                                           | 353           | 355          | 708          |
| 1                                                           | 178 (50.4%)   | 186 (52.4%)  | 364 (51.4%)  |
| I1                                                          | 125 (35.4%)   | 114 (32.1%)  | 239 (33.8%)  |
| III                                                         | 50 (14.2%)    | 55 (15.5%)   | 105 (14.8%)  |
| IMWG Revised ISS staging', n(%)                             |               |              |              |
| N                                                           | 352           | 353          | 705          |
| I                                                           | 132 (37.5%)   | 132 (37.4%)  | 264 (37.4%)  |
|                                                             | 203 (57.7%)   | 197 (55.8%)  | 400 (56.7%)  |
| III                                                         | 17 (4.8%)     | 24 (6.8%)    | 41 (5.8%)    |
| Time from MM diagnosis to randomization (months)            |               |              |              |
| N                                                           | 354           | 355          | 709          |
| Mean (SD)                                                   | 3.00 (11.414) | 2.19 (4.459) | 2.59 (8.664) |
| Median                                                      | 1.12          | 1.18         | 1.15         |
| Range                                                       | (0.1; 184.6)  | (0.0; 46.5)  | (0.0; 184.6) |
| Number of lytic bone lesions, n (%)                         |               |              |              |
| N                                                           | 354           | 355          | 709          |
| None                                                        | 114 (32.2%)   | 102 (28.7%)  | 216 (30.5%)  |
| 1-3                                                         | 75 (21.2%)    | 84 (23.7%)   | 159 (22.4%)  |
| 4-10                                                        | 74 (20.9%)    | 87 (24.5%)   | 161 (22.7%)  |
| More than 10                                                | 91 (25.7%)    | 82 (23.1%)   | 173 (24.4%)  |
| Presence of diffuse myeloma-related osteopenia, n (%6)      |               |              |              |
| N                                                           | 349           | 354          | 703          |

<div style=\"page-break-after: always\"></div>

## Summary of Baseline Disease Characteristics; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                                    | VRd         | D-VRd       | Total       |
|----------------------------------------------------|-------------|-------------|-------------|
| Yes                                                | 76 (21.8%)  | 91 (25.7%)  | 167 (23.8%) |
| No                                                 | 273 (78.2%) | 263 (74.3%) | 536 (76.2%) |
| Number of extramedullary plasmacytomas, n (%)      |             |             |             |
| N                                                  | 354         | 355         | 709         |
| 0                                                  | 338 (95.5%) | 340 (95.8%) | 678 (95.6%) |
| ≥1                                                 | 16 (4.5%)   | 15 (4.2%)   | 31 (4.4%)   |
| % Plasma cells, bone marrow biopsy/aspirate, n (%) |             |             |             |
| N                                                  | 354         | 353         | 707         |
| <10                                                | 14 (4.0%)   | 14 (4.0%)   | 28 (4.0%)   |
| 10-30                                              | 132 (37.3%) | 138 (39.1%) | 270 (38.2%) |
| >30                                                | 208 (58.8%) | 201 (56.9%) | 409 (57.9%) |
| % Plasma cells, bone marrow biopsy, n (%)          |             |             |             |
| N                                                  | 159         | 158         | 317         |
| <10                                                | 4 (2.5%)    | 8 (5.1%)    | 12 (3.8%)   |
| 10-30                                              | 50 (31.4%)  | 48 (30.4%)  | 98 (30.9%)  |
| >30                                                | 105 (66.0%) | 102 (64.6%) | 207 (65.3%) |
| % Plasma cells, bone marrow aspirate, n (%)        |             |             |             |
| N                                                  | 322         | 333         | 655         |
| 10                                                 | 28 (8.7%)   | 32 (9.6%)   | 60 (9.2%)   |
| 10-30                                              | 144 (44.7%) | 148 (44.4%) | 292 (44.6%) |
| >30                                                | 150 (46.6%) | 153 (45.9%) | 303 (46.3%) |
| Cytogenetic risk', n (%)                           |             |             |             |
| N                                                  | 354         | 355         | 709         |
| Standard Risk                                      | 266 (75.1%) | 264 (74.4%) | 530 (74.8%) |
| High Riski                                         | 78 (22.0%)  | 76 (21.4%)  | 154 (21.7%) |
| del(17p)                                           | 34 (9.6%)   | 36 (10.1%)  | 70 (9.9%)   |
| t(4;14)                                            | 38 (10.7%)  | 33 (9.3%)   | 71 (10.0%)  |
| t(14;16)                                           | 14 (4.0%)   | 11 (3.1%)   | 25 (3.5%)   |
| Indeterminate                                      | 10 (2.8%)   | 15 (4.2%)   | 25 (3.5%)   |

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone; ECG = electrocardiogram; FLC = serum free light chain; ISS = International Staging System; MM = multiple myeloma; NE=not evaluable.

- a - Includes subjects without a positive immunofixation but with evidence of free light chain kappa by FLC testing.
- b - Includes subjects without a positive immunofixation but with evidence of free light chain lambda by FLC testing.
- c - Includes subjects without measurable disease in serum and urine.
- d - Includes subjects with IgD, IgM, IgE and biclonal.
- e - One subject with no evaluable measurable disease.
- f - At least one of the calcium, renal, anemia, bone (CRAB) criteria
- g - ISS staging is derived based on the combination of serum β2 -microglobulin and albumin.

h  -  Determination  is  based  on  three  factors:  International  Staging  System  (ISS);  presence  of  chromosomal abnormalities of t(4; 14), t(14; 16), or del17p by FISH/Karyotype testing and serum lactate dehydrogenase (LDH) at baseline.

- i - Cytogenetic risk is based on FISH.
- j - Subject may have more than one high-risk abnormality [del17p, t(4;14) or t(14;16)].

Note: Percentages are calculated with the number of subjects in each group with available data as denominator.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The number of participants included in each analysis set is provided

Table 5. Number of Subjects in Each Analysis Set; All Screened Subjects (Study 54767414MMY3014)

|                                          | VRd   | D-VRd   |   Total |
|------------------------------------------|-------|---------|---------|
| All screened subjects                    |       |         |     824 |
| Intent-to-treat analysis set             | 354   | 355     |     709 |
| Per-protocol analysis seta               | 350   | 348     |     698 |
| Safety analysis setb                     | 347   | 351     |     698 |
| Subject received maintenance treatmentc  | 300   | 322     |     622 |
| Pharmacokinetic analysis setd            |       | 349     |     349 |
| Daratumumab Immunogenicity analysis setd |       | 339     |     339 |
| rHuPH20 Immunogenicity analysis setd     |       | 338     |     338 |

Key: VRd =bortezomib (VELCADE) + 1enalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

* Includes subjects who are randomized and don't have major protocol deviation due to not meeting all entry criteria.

c Includes subjects who have received at least one dose of maintenance study treatment (partial or complete) in the maintenance phase.

b Includes subjects who have received at least one dose of study treatment (partial or complete) in the study.

d Includes subjects assigned to D-VRd group who have received at least 1 dose of daratumumab and have at least 1 sample value after the first administration of daratumumab.

## Outcomes and estimation

Primary endpoint: Progression-free Survival

Table 6 . Summary of Progression-free Survival Based on Computerized Algorithm; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                 | VRd                  | D-VRd             |
|---------------------------------|----------------------|-------------------|
| Analysis set: intent-to-treat   | 354                  | 355               |
| Progression-free survival (PFS) |                      |                   |
| Number of events (%)            | 103 (29.1%)          | 50 (14.1%)        |
| Number of censored (%)          | 251 (70.9%)          | 305 (85.9%)       |
| Kaplan-Meier estimate (months)  |                      |                   |
| 25% quantile (95% CI)           | 36.86 (30.85, 43.66) | NE (NE, NE)       |
| Median (95% CI)                 | NE (NE, NE)          | NE (NE, NE)       |
| 75% quantile (95% CI)           | NE (NE, NE)          | NE (NE, NE)       |
| P-valuea                        |                      | <0.0001           |
| Hazard ratio (95% CI)b          |                      | 0.42 (0.30, 0.59) |
| 6-month PFS rate % (95% CI)     | 94.5 (91.5, 96.4)    | 97.1 (94.7, 98.4) |
| 12-month PFS rate % (95% CI)    | 91.8 (88.3, 94.3)    | 95.1 (92.2, 96.9) |
| 24-month PFS rate % (95% CI)    | 85.4 (81.1, 88.8)    | 93.0 (89.8, 95.3) |
| 36-month PFS rate % (95% CI)    | 75.4 (70.3, 79.7)    | 89.7 (86.0, 92.5) |
| 48-month PFS rate % (95% CI)    | 67.7 (62.2, 72.6)    | 84.3 (79.5, 88.1) |
| 60-month PFS rate % (95% CI)    | NE (NE, NE)          | NE (NE, NE)       |

<div style=\"page-break-after: always\"></div>

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone; CI = confidence interval; NE = not evaluable.

- a - p-value is based on the log-rank test stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown).
- b - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown). A hazard ratio &lt;1 indicates an advantage for D-VRd.

Figure 5. Kaplan-Meier Plot for Progression-free Survival Based on Computerized Algorithm; Intent-to-treat Analysis Set (Study 54767414MMY3014)

<!-- image -->

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone

Data from 85.9% of participants in the D-VRd arm and 70.9% of participants in the VRd arm were censored at the time of this CCO. The majority of these participants were censored due to clinical cutoff (D-VRd: 286/355 [80.6%]; VRd: 215/354 [60.7%]).

## Secondary endpoint: Overall CR or better Rate

This endpoint was defined as ' the percentage of ITT participants who achieved CR or sCR status anytime during the study per the 2011 IMWG criteria'.

<div style=\"page-break-after: always\"></div>

Table 7. Summary of Overall Response Based on Computerized Algorithm; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                   | VRd         | VRd            | D-VRd       | D-VRd          | Odds Ratio (95% CI)a   | P-valueb   |
|-----------------------------------|-------------|----------------|-------------|----------------|------------------------|------------|
|                                   | n(%)        | 95% CI for %   | n(%)        | 95% CI for %   |                        |            |
| Analysis set: intent-to-treat     | 354         |                | 355         |                |                        |            |
| Response category                 |             |                |             |                |                        |            |
| Stringent complete response (sCR) | 158 (44.6%) | (39.4%, 50.0%) | 246 (69.3%) | (64.2%, 74.1%) | 2.83 (2.08, 3.86)      | <0.0001    |
| Complete response (CR)            | 90 (25.4%)  | (21.0%, 30.3%) | 66 (18.6%)  | (14.7% 23.0%)  |                        |            |
| Very good partial response (VGPR) | 68 (19.2%)  | (15.2%, 23.7%) | 26 (7.3%)   | (4.8% , 10.5%) |                        |            |
| Partial response (PR)             | 16 (4.5%)   | (2.6%, 7.2%)   | 5 (1.4%)    | (0.5%, 3.3%)   |                        |            |
| Stable disease (SD)               | 9 (2.5%)    | (1.2%, 4.8%)   | 4 (1.1%)    | (0.3%, 2.9%)   |                        |            |
| Progressive disease (PD)          | 1 (0.3%)    | (0.0%, 1.6%)   | 2 (0.6%)    | (0.1%, 2.0%)   |                        |            |
| Not evaluable (NE)                | 12 (3.4%)   | (1.8%, 5.8%)   | 6 (1.7%)    | (0.6%, 3.6%)   |                        |            |
| CR or better (sCR + CR)           | 248 (70.1%) | (65.0%, 74.8%) | 312 (87.9%) | (84.0%, 91.1%) | 3.13 (2.11, 4.65)      | <0.0001    |
| VGPR or better (sCR + CR + VGPR)  | 316 (89.3%) | (85.6%, 92.3%) | 338 (95.2%) | (92.4%, 97.2%) | 2.40 (1.33, 4.35)      | 0.0029     |
| Overall response (sCR+CR+VGPR+PR) | 332 (93.8%) | (90.7%, 96.1%) | 343 (96.6%) | (94.2%, 98.2%) | 1.89 (0.92, 3.87)      | 0.0762     |

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) +  lenalidomide  +  dexamethasone;  Dara  =  daratumumab;  Bor  =  bortezomib;  Len  =  lenalidomide,  Dex  = dexamethasone or equivalent;  CI = confidence interval.

a - Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are ISS staging (I, II, vs. III) and cytogenetic risk (high risk vs. standard risk).

b - P-value from the stratified Cochran Mantel-Haenszel Chi-Squared test.

Note:  Response  was  assessed  by  computerized  algorithm,  based  on  International  Uniform  Response  Criteria Consensus Recommendations. Percentages are calculated with the number of subjects in each group as denominator.

Improvements were observed in the D-VRd arm compared with the VRd arm for VGPR or better but not CR or better rates at the end of induction and at the end of ASCT, and for VGPR or better, CR or better, and  sCR  rates  at  the  end  of  consolidation  (data  not  shown).  Overall,  absolute  differences  between treatment arms increased through treatment phases for CR or better rates favouring the D-VRd arm.

## Secondary endpoint: Overall MRD-Negativity Rate

Overall MRD-negativity rate was defined as the proportion of participants in the ITT population who achieved both MRD-negativity by NGS per clonoSEQ test (at or below a sensitivity threshold of 10 -5 ) in bone marrow aspirate and a CR or better response at any time after the date of randomization (and prior to disease progression, receipt of subsequent therapy, or both).

Participants whose tested samples were found to be MRD-positive or ambiguous, and participants who were not tested were considered as not achieving MRD-negativity.

Table 8. Summary of Overall MRD Negativity Rate by NGS at or below 10 -5  in Participants with CR or Better; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                        | VRd            | D-VRd            |
|----------------------------------------|----------------|------------------|
| Analysis set: intent-to-treat          | 354            | 355              |
| MRD Negativity Rate (at or below 10-5) | 168 (47.5%)    | 267 (75.2%)      |
| 95% CI of MRD: negativity rate         | (42.2%, 52.8%) | (70.4%, 79.6%)   |
| Odds ratio with 95% CIb                |                | 3.40 (2.47,4.69) |
| P-valuec                               |                | <0.0001          |

<div style=\"page-break-after: always\"></div>

MRD  =  minimal  residual  disease.;  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

- a Exact 95% confidence interval.

b Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are ISS staging (I, II, vs. III) and cytogenetic risk (high risk vs. standard risk).

- c P-value from the stratified Cochran Mantel-Haenszel Chi-Squared test.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Other MRD-related Analyses

## Overall MRD-negativity Rate at 10 -6  Threshold

Table 9. Summary of Overall MRD Negativity Rate by NGS at 10 -6  in Participants with CR or Better; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                        | VRd            | D-VRd             |
|----------------------------------------|----------------|-------------------|
| Analysis set: intent-to-treat          | 354            | 355               |
| MRD Negativity Rate (at or below 10-0) | 114 (32.2%)    | 231 (65.1%)       |
| 95% CIP of MRD negativity rate         | (27.4%, 37.3%) | (59.9%, 70.0%)    |
| Odds ratio with 95% CI                 |                | 3.97 (2.90, 5.43) |
| P-valuec                               |                | <0.0001           |

MRD  =  minimal  residual  disease;  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

- a - Exact 95% confidence interval.
- b - Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are ISS staging (I, II, vs. III) and cytogenetic risk (high risk vs. standard risk).
- c - P-value from the stratified Cochran Mantel-Haenszel Chi-Squared test.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## MRD-Negativity Rate Post-consolidation

Table 10. Summary of Overall MRD Negativity Rate by NGS at or below 10 -5  in Participants with CR or Better by the End of Consolidation Phase; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                        | VRd            | D-VRd             |
|----------------------------------------|----------------|-------------------|
| Analysisset:intent-to-treat            | 354            | 355               |
| MRD Negativity Rate (at or below 10-5) | 115 (32.5%)    | 204 (57.5%)       |
| 95%CIaof MRDnegativityrate             | (27.6%, 37.6%) | (52.1%, 62.7%)    |
| Odds ratio with 95% CIb                |                | 2.79 (2.06, 3.78) |
| P-valuec                               |                | <0.0001           |

MRD  =  minimal  residual  disease;  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

- a Exact 95% confidence interval.

b Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are ISS staging (I, II, vs. III) and cytogenetic risk (high risk vs. standard risk).

- c P-value from the stratified Cochran Mantel-Haenszel Chi-Squared test.

Note: Percentages are calculated with the number of subjects in each group as denominator.

<div style=\"page-break-after: always\"></div>

## Sustained MRD-negativity Rate

Sustained MRD-negativity was defined as 2 consecutive MRD-negative results (at or below 10 -5 ) at least 12 months apart, without any MRD-positive (10 -4  or higher) results in between.

Table 11. Summary of Sustained MRD-Negativity Rate by NGS at or below 10 -5  in Participants with CR or Better; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                         | VRd            | D-VRd             |
|-----------------------------------------|----------------|-------------------|
| Analysis set:intent-to-treat            | 354            | 355               |
| Sustained MRD-negativity rate (10-5)a   | 105 (29.7%)    | 230 (64.8%)       |
| 95% CI of Sustained MRD-negativity rate | (24.9%, 34.7%) | (59.6%, 69.8%)    |
| Odds ratio with 95% CI°                 |                | 4.42 (3.22, 6.08) |
| P-valued                                |                | <0.0001           |

MRD = minimal residual disease; VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

a Sustained MRD-negativity is defined as MRD negative and confirmed by at least 1 year apart without MRD positive in between.

b Exact 95% confidence interval.

c Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are ISS staging (I, II, vs. III) and cytogenetic risk (high risk vs. standard risk).

d P-value from the stratified Cochran Mantel-Haenszel Chi-Squared test.

## Secondary endpoint: Overall survival

Table 12. Summary of Overall Survival; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                   | VRd               | D-VRd             |
|-----------------------------------|-------------------|-------------------|
| Analysis set: intent-to-treat     | 354               | 355               |
| Overall Survival                  |                   |                   |
| Number of events (%)              | 44 (12.4%)        | 34 (9.6%)         |
| Number of censored (%)            | 310 (87.6%)       | 321 (90.4%)       |
| Kaplan-Meier estimate (months)    |                   |                   |
| 25% quantile (95% CI)             | NE (NE, NE)       | NE (NE, NE)       |
| Median (95% CI)                   | NE (NE, NE)       | NE (NE, NE)       |
| 75% quantile (95% CI)             | NE (NE, NE)       | NE (NE, NE)       |
| Hazard ratio (95% CI) a           |                   | 0.73 (0.47, 1.14) |
| 12-month survival rate % (95% CI) | 95.1 (92.2, 96.9) | 97.7 (95.5, 98.8) |
| 24-month survival rate % (95% CI) | 92.5 (89.2, 94.8) | 96.3 (93.6, 97.8) |
| 36-month survival rate % (95% CI) | 89.0 (85.2, 91.9) | 94.2 (91.2,96.2)  |
| 48-month survival rate %(95% CI)  | 87.5 (83.5,90.6)  | 89.4 (85.4, 92.4) |
| 60-month survival rate %(95% CI)  | NE (NE, NE)       | NE (NE, NE)       |

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone; CI = confidence interval; NE = not evaluable.

a - Hazard ratio from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), and cytogenetic risk (high risk vs. standard risk or unknown). A hazard ratio &lt; 1 indicates an advantage for D-VRd.

<div style=\"page-break-after: always\"></div>

Figure 6 . Kaplan-Meier Plot for Overall Survival; Intent-to-treat Analysis Set (Study 54767414MMY3014)

<!-- image -->

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

## Progression-free Survival on Next Line of Therapy

At the time of the CCO, only 42 (11.8%) participants in the D-VRd arm and 58 (16.4%) in the VRd arm had had a PFS2 event. Analysis of PFS2 demonstrated a difference for participants treated with D-VRd with  a  HR=0.68  (95%  CI:  0.46,  1.01;  nominal  2-sided  p=0.0529)  compared  with  VRd  treatment suggesting a longer PFS2 for patients randomised to the D-VRd arm.

## Time to subsequent anti-myeloma therapy

Consistent with the improved PFS observed in the D-VRd arm, the time to subsequent antimyeloma therapy was longer for participants in the D-VRd arm compared with VRd arm (HR=0.31, 95% CI: 0.21, 0.46; nominal 2-sided p-value &lt;0.0001). The median time to subsequent anti-myeloma therapy was not reached in either treatment arm.

## Subsequent Therapies

Fewer participants in the D-VRd arm (33 [9.4%]) received subsequent anti-myeloma therapies compared with  the  VRd  arm  (93  [26.8%]).  Of  the  participants  receiving  subsequent  therapies  (D-VRd:  33 participants; VRd: 93 participants), the most common (≥10%) subsequent antineoplastic drugs were:

- carfilzomib (D-VRd: 69.7%; VRd: 46.2%)
- bortezomib (D-VRd: 27.3%; VRd: 30.1%)
- cisplatin (D-VRd: 12.1%; VRd: 4.3%)
- daratumumab (D-VRd: 18.2%; VRd: 66.7%)

<div style=\"page-break-after: always\"></div>

- isatuximab (D-VRd: 9.1%; VRd: 10.8%)
- belantamab mafodotin (D-VRd: 18.2%; VRd: 5.4%)
- teclistamab (D-VRd: 12.1%; VRd: 6.5%)
- cyclophosphamide (D-VRd: 36.4%; VRd: 23.7%)
- melphalan (D-VRd: 27.3%; VRd: 15.1%)
- doxorubicin (D-VRd: 18.2%; VRd: 7.5%)
- etoposide (D-VRd: 15.2%; VRd: 5.4%)
- dexamethasone (D-VRd: 84.8%; VRd: 83.9%)
- pomalidomide (D-VRd: 42.4%; VRd: 31.2%)
- lenalidomide (D-VRd: 24.2%; VRd: 25.8%)

Subsequent ASCT was reported for 10 (2.8%) participants in the D-VRd arm and 15 (4.3%) participants in the VRd arm.

## Stem cell-related procedures, transplant and time to engraftment

Only time to engraftment post-ASCT was a predefined secondary endpoint but other aspects related to stem-cell procedures such as mobilization, harvesting, and conditioning can also be considered part of both the efficacy and safety assessment of D-VRd vs. VRd.

The number of CD34+ stem cells collected was lower in the D-VRd arm (Median: D-VRd: 5.52x106/kg; VRd: 7.435 x106/kg) despite higher usage of plerixafor.

More participants undergoing mobilization in the D-VRd arm (40%, 134/351) received plerixafor than in the VRd arm (22.7%, 72/347).

A higher number of patients failed stem cell mobilization in the D-VRd arm (9 vs 3) suggesting that daratumumab can reduce the probability for a successful stem cell harvest. However, the frequency of patients who made it to successful engraftment post ASCT based on the ITT population was higher in the D-VRd arm compared to the VRd arm with 88.5% (314/355) vs 84.7% (300/354) respectively.

The proportion of participants proceeding to autologous stem cell transplant did not differ between study arms. 89.7% (315/351) of patients in the D-VRd arm proceeded to transplant. 87.0% (302/347) of patients in the VRd arm proceeded to transplant.

One participant in the VRd arm died after melphalan conditioning therapy due to an adverse event and as such did not receive stem cell infusion.

Despite increased use of plerixafor for stem cell mobilization and lower amount of collected CD34+ stem cells in the D-VRd arm, the following was observed: Similar rates of hematopoietic reconstitution were observed among transplanted participants for both treatment arms (D-VRd: 99.7% (314/315); VRd: 99.3% (300/302)). Median time to engraftment was similar between the two arms (D-VRd: 15.7 days ; VRd: 14.9  days).

Three participants died following stem cell infusion but before engraftment, 1 participant in the D-VRd arm (due to post procedural sepsis) and 2 participants in the VRd arm (1 due to sepsis and 1 due to pneumonia influenza).

## Patient reported outcomes

Patient  reported  outcomes  (PROs)  were  measured  by  EORTC  QLQ-C30  and  EORTC  QLQ-MY20  scale scores and EQ-5D-5L.  The compliance rate for PRO assessments was high and comparable between both treatment arms.

Across all inventories consistent and comparable improvements in both arms were observed.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup Analyses of Progression-free Survival

Table 13 . Forest Plot of Subgroup Analyses on Progression-free Survival Based on Computerized Algorithm; Intent-to-treat Analysis Set (Study 54767414MMY3014)

VRd

D-VRd

<!-- image -->

|                                 | Hazard Ratio and 95% Cl   |        |      |        | EVT/N Medlan EVT/N Medlan   | HR (95% CI)       |
|---------------------------------|---------------------------|--------|------|--------|-----------------------------|-------------------|
| Sex                             |                           |        |      |        |                             |                   |
| Male                            |                           | 61/205 | NE   | 36/211 | NE                          | 0.51 (0.34, 0.77) |
| Female                          |                           | 42/149 | NE   | 14/144 | NE                          | 0.29 (0.16, 0.53) |
| Age                             |                           |        |      |        |                             |                   |
| <65 years                       |                           | 84/267 | NE   | 30/261 | NE                          | 0.30 (0.20, 0.46) |
| sueaA 5gz                       |                           | 19/87  | NE   | 20/94  | NE                          | 0.97 (0.52, 1.81) |
| Race                            |                           |        |      |        |                             |                   |
| White                           |                           | E26/56 | NE   | 47/330 | NE                          | 0.42 (0.30, 0.60) |
| Other                           |                           | 8/31   | NE   | 3/25   | NE                          | 0.40 (0.11, 1.50) |
| ISS staging                     |                           |        |      |        |                             |                   |
|                                 |                           | 35/178 | NE   | 18/186 | NE                          | 0.46 (0.26, 0.81) |
| I1                              |                           | 43/125 | NE   | 19/114 | NE                          | 0.37 (0.22, 0.64) |
| III1I                           |                           | 25/50  | 41.9 | 13/55  | NE                          | 0.42 (0.22, 0.83) |
| Type of MM                      |                           |        |      |        |                             |                   |
| IgG                             |                           | 58/185 | NE   | 28/204 | NE                          | 0.36 (0.23, 0.57) |
| Non-lgG                         |                           | 96/TE  | NE   | 13/78  | NE                          | 0.46 (0.24, 0.88) |
| Cytogenetic risk *              |                           |        |      |        |                             |                   |
| Standard risk                   |                           | 62/266 | NE   | 25/264 | NE                          | 0.35 (0.22, 0.56) |
| High risk b                     |                           | 38/78  | 44.1 | 24/76  | NE                          | 0.59 (0.36, 0.99) |
| Indeterminate                   |                           | 3/10   | NE   | 1/15   | NE                          | 0.16 (0.02, 1.56) |
| Baseline ECOG performance score |                           |        |      |        |                             |                   |
| 0                               |                           | 60/230 | NE   | 28/221 | NE                          | 0.42 (0.27, 0.66) |
| ≥1                              |                           | 43/124 | NE   | 22/134 | NE                          | 0.41 (0.25, 0.69) |

+Favor D-VRd Favor VRd→

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) +  lenalidomide  +  dexamethasone;  CI  =  confidence  interval;  EVT  =  Number  of  subjects  with  an  event  in  each subgroup; N = Number of subjects in the intent-to-treat analysis set with data in each subgroup; HR = Hazard Ratio.

a - Cytogenetic risk is based on FISH.

b - Subject may have more than one high-risk abnormality [del17p, t(4;14) or t(14;16)].

Note:  Hazard  ratio  and  95%  CI  from  a  Cox  proportional  hazards  model  with  treatment  as  the  sole  explanatory variable. A hazard ratio &lt;1 indicates an advantage for D-VRd.

## Efficacy in the ≥65 years Subgroup

The subgroup of participants age ≥65 years represents approximately 25% of the study population in the primary analysis, 181 participants of 709 total (D-VRd: 94 participants; VRd: 87 participants).

<div style=\"page-break-after: always\"></div>

The primary analysis of PFS used the stratified analysis accounting for any differences in the 2 prognostic factors of cytogenetic risk and ISS stage. In contrast, the pre-planned subgroup analyses were based on the unstratified analysis to avoid inadequate number of participants in any given stratum within a specific subgroup. This analysis together with a number of post-hoc analysis stratified by various baseline disease characteristics are summarised in Table 14 .

Table 14. Progression-free Survival Analyses for the ≥65 years Subgroup

|                                                                                                                                                | Age ≥65 years                       | Age ≥65 years                       |
|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------|
| Progression-free survival (PFS)                                                                                                                | D-VRd (n=94)                        | VRd (n=87)                          |
|                                                                                                                                                | Hazard ratio (95% CI)               | Hazard ratio (95% CI)               |
| Univariate analysis a Primary censoring rules Not censored the events after 2 missing consecutive disease evaluation                           | 0.97 (0.52, 1.81)                   | 0.97 (0.52, 1.81)                   |
| Stratified by cytogenetic risk and ISS staging Primary censoring rules Not censored the events after 2 missing consecutive disease evaluations | 0.83 (0.45, 1.52)                   | 0.83 (0.45, 1.52)                   |
| Multivariate Analysis (cytogenetic risk, ISS staging. sex and baseline ECOG performance score) Primary censoring rules                         | 0.74 (0.39, 1.43) 0.67 (0.36, 1.26) | 0.74 (0.39, 1.43) 0.67 (0.36, 1.26) |
| Not censored the events after 2 missing consecutive disease evaluations                                                                        | 0.80 (0.41, 1.54) 0.72 (0.38, 1.36) | 0.80 (0.41, 1.54) 0.72 (0.38, 1.36) |

a - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable b - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown)

c - Hazard ratio and 95% CI from a Cox proportional hazards model with important baseline covariates identified by the stepwise model selection procedure, including treatment (D-VRd or VRd), cytogenetic risk (high risk vs. standard risk or unknown), ISS st aging (I, II, vs. III), sex (male or female), and ECOG (0, or ≥ 1) as the explanatory variables

## Key secondary efficacy endpoints CR and overall MRD-negativity

The results of the secondary endpoints of overall CR or better rate, overall MRD- negativity rate, and sustained MRD- negativity demonstrated a treatment effect of DVRd in the ≥65 years subgroup:

- A higher proportion of participants in the D-VRd arm achieved CR or better compared with the VRd arm (D-VRd 81.9%; VRd 71.3%; odd ratio 1.83).
- A higher proportion of participants achieved MRD-negativity in the D-VRd arm compared with the VRd arm (D-VRd: 67.0%; VRd: 49.4%; odds ratio 2.08).
- A higher proportion of participants achieved sustained MRDnegativity (≥12 months) in the D -VRd arm compared with the VRd arm (D-VRd: 53.2%; VRd: 31.0%; odds ratio 2.53)

## Progression-free Survival per Investigator Assessment and Agreement with Computerized Algorithm Analyses

<div style=\"page-break-after: always\"></div>

Table 15 . Summary of Progression-free Survival Based on Investigator Assessment; Intent-to-treat Analysis Set (Study 54767414MMY3014)

|                                 | VRd                  | D-VRd             |
|---------------------------------|----------------------|-------------------|
| Analysis set: intent-to-treat   | 354                  | 355               |
| Progression-free survival (PFS) |                      |                   |
| Number of events (%)            | 105 (29.7%)          | 51 (14.4%)        |
| Number of censored (%)          | 249 (70.3%)          | 304 (85.6%)       |
| Kaplan-Meier estimate (months)  |                      |                   |
| 25% quantile (95% CI)           | 35.94 (30.59, 43.17) | NE (NE, NE)       |
| Median (95% CI)                 | NE (NE, NE)          | NE (NE, NE)       |
| 75% quantile (95% CI)           | NE (NE, NE)          | NE (NE, NE)       |
| P-valuea                        |                      | 0.0001            |
| Hazard ratio (95% CI)b          |                      | 0.42 (0.30, 0.59) |
| 6-month PFS rate % (95% CI)     | 94.5 (91.5,96.4)     | 97.1 (94.7, 98.4) |
| 12-month PFS rate % (95% CI)    | 91.2 (87.6, 93.8)    | 95.1 (92.2, 96.9) |
| 24-month PFS rate % (95% CI)    | 85.1 (80.8, 88.5)    | 93.0 (89.8, 95.3) |
| 36-month PFS rate % (95% CI)    | 74.8 (69.8, 79.2)    | 89.4 (85.7, 92.3) |
| 48-month PFS rate % (95% CI)    | 67.2 (61.7, 72.1)    | 84.0 (79.1, 87.8) |
| 60-month PFS rate % (95% CI)    | NE (NE, NE)          | NE (NE, NE)       |

Key:  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  =  daratumumab  +  bortezomib (VELCADE) + lenalidomide + dexamethasone; CI = confidence interval; NE = not evaluable.

a - p-value is based on the log-rank test stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown).

b - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown). A hazard ratio &lt;1 indicates an advantage for D-VRd.

Table 16. Agreement on Disease Progression Assessment Between Algorithm and Investigator; Intentto-treat Analysis Set (Study 54767414MMY3014)

|                         | Computerized AlgorithmAssessment   | Computerized AlgorithmAssessment   | Computerized AlgorithmAssessment   |                                                     |                   |                                                            |
|-------------------------|------------------------------------|------------------------------------|------------------------------------|-----------------------------------------------------|-------------------|------------------------------------------------------------|
| Investigator Assessment | PD                                 | No PD                              | Total                              | Prevalence Adjusted andBias Adjusted Kappa (95% CI) | ObservedAgreement | Response Rate Difference (95% CI) (Investigator-Algorithm) |
| PD                      | 122 (96.8%)                        | 4 (3.2%)                           | 126                                |                                                     |                   |                                                            |
| No PD                   | 3 (0.5%)                           | 580 (99.5%)                        | 583                                |                                                     |                   |                                                            |
| Total                   | 125 (17.6%)                        | 584 (82.4%)                        | 709                                | 0.98 (0.97,0.99)                                    | 99.0%             | -0.001(-0.041,0.038)                                       |

VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone; CI = confidence interval; PD = progressive disease.

a Wald type confidence interval is provided.

Note: Percentages are calculated based on Total column.

Note: The higher the kappa coefficient, the higher the agreement between algorithm assessment and investigator assessment.

## Subgroup Analyses of MRD negativity

Figure 7. Forest Plot of Subgroup Analysis on Overall MRD Negativity Rate by NGS at or below 10 -5  in Participants with CR or Better; Intent-to-treat Analysis Set (Study 54767414MMY3014)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 17. Summary of Efficacy for study MMY3014 (PERSEUS)

| Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with   | Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                 | 54767414MMY3014 (PERSEUS) EMN17 EudraCT Number: 2018-002992-16 EU Trial Number: 2023-506125-10-00 Clinicaltrials.gov: NCT03710603                                                |

<div style=\"page-break-after: always\"></div>

| Design                    | Phase 3, randomized, open-label, multicenter study comparing D-VRd versus VRd in participants with newly diagnosed   | Phase 3, randomized, open-label, multicenter study comparing D-VRd versus VRd in participants with newly diagnosed   | Phase 3, randomized, open-label, multicenter study comparing D-VRd versus VRd in participants with newly diagnosed                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Study initiation: Screening Phase: Induction / ASCT / Consolidation / Maintenance Phase):                            | Phase (Treatment                                                                                                     | MM who are eligible for ASCT. 03 January 2019 (first participant screened) Starts up to 28 days before randomization Extends from C1D1 to discontinuation of all study treatment Starts when a participant experiences documented disease progression or unacceptable toxicity leading to all study                                                                                                                                                                                                                                                     |
| Design                    | Follow-up Phase:                                                                                                     | Follow-up Phase:                                                                                                     | treatment discontinuation or if they have not achieved a response of PR or better by C7D1.                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hypothesis                | Superiority of D-VRd over VRd                                                                                        | Superiority of D-VRd over VRd                                                                                        | Superiority of D-VRd over VRd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups         | VRd                                                                                                                  | VRd                                                                                                                  | Bortezomib SC injection (1.3 mg/m 2 ) - D1, D4, D8, D11 during C1 to C6; induction: 4, 28-day cycles (C1 to C4); consolidation: 2, 28-day cycles (C5 to C6). Lenalidomide PO (25 mg) - D1 to D21 during C1 to C6; induction: 4, 28-day cycles; consolidation: 2, 28-day cycles. Maintenance: 10 mg daily PO on D1 to D28 (continuously) of each 28-day cycle until PD or unacceptable toxicity. Dexamethasone PO (40 mg) on D1 to D4 and D9 to D12 of each 28-day cycle during induction/consolidation (C1 to C6) ASCT with high dose melphalan after 4 |
| Treatments groups         | D-VRD                                                                                                                | D-VRD                                                                                                                | VRd and ASCT as above Daratumumab SC (1800 mg) - once every week for C1 to C2, then every 2 weeks for C3 to C6. For maintenance C7+, once every 4 weeks until PD or unacceptable toxicity. Participants with CR or better and sustained MRD-negativity for 12 months will stop daratumumab after a minimum of 24 months of maintenance therapy and restart if loss of CR without PD or loss of MRD- negativity.                                                                                                                                         |
| Endpoints and definitions | Primary endpoint                                                                                                     | PFS by computerised algorithm                                                                                        | Time from the date of randomization to the date of PD (assessed by 2011 IMWG criteria) or death                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Endpoints and definitions | Key secondary                                                                                                        | Overall CR or better rate                                                                                            | The percentage of ITT participants who achieved CR or sCR status anytime during the study per the 2011 IMWG criteria                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                      | Key secondary        | Key secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | The proportion of ITT participants who achieved MRD-negativity (at or below the threshold of 10 -5 ) by bone marrow aspirate and achieve CR or better response at any time after the date of randomization during the study (and prior to PD, subsequent therapy, or both). Measured from the date of randomization to the                                                                                                                                                                                                                                                                                           | Overall MRD- negativity secondary Overall VRd   | Key survival                         |
|----------------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|--------------------------------------|
| 355                  | 355                  | 355                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 355                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 355                                             | 355                                  |
| 354                  | 354                  | PFS event by computerised algorithm,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS event by computerised algorithm,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS event by computerised algorithm,            | PFS event by computerised algorithm, |
| 50                   | 50                   | n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | n                                               | n                                    |
|                      |                      | %                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29.1% 248                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14.1%                                           | Overall CR or better                 |
|                      |                      | 312                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 70.1% (65.0%, 74.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | rate, n %(95% CI)                               | 87.9% (84.0%, 91.1%)                 |
|                      |                      | Overall MRD-negativity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 168 47.5% (42.2%, 52.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 267                                             | %(95% CI)                            |
| 75.2% (70.4%, 79.6%) | 75.2% (70.4%, 79.6%) | Overall survival, n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                 | % 9.6%                               |
|                      |                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | D-VRd vs VRd 0.42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | - PFS Comparison                                | Primary endpoint by computerised     |
| groups HR a          | groups HR a          | algorithm 95%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.30, 0.59 <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                 |                                      |
| CI P-value b         | CI P-value b         | Secondary endpoint - Comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | D-VRd vs VRd 3.13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                 | Overall CR or better                 |
| groups Odds ratio c  | groups Odds ratio c  | 95%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                 | P-value                              |
| CI d                 | CI d                 | Secondary Comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | groups D-VRd vs VRd 3.40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | endpoint -                                      | MRD negativity rate Odds             |
| ratio c              | ratio c              | (10 -5 ) 95%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                 | P-value                              |
| d                    | d                    | Secondary endpoint - Comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | groups D-VRd vs VRd 0.73                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                 | overall survival HR a                |
|                      |                      | 95%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.47, 1.14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | CI                                              |                                      |
|                      |                      | P-value Not disclosed a - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown). b - p-value is based on the log-rank test stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown). c - Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are ISS staging (I, II, vs. III) and cytogenetic risk (high risk vs. standard risk). | P-value Not disclosed a - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown). b - p-value is based on the log-rank test stratified with ISS staging (I, II, vs. III), and cytogenetic risk (high risk vs. standard risk or unknown). c - Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are ISS staging (I, II, vs. III) and cytogenetic risk (high risk vs. standard risk). |                                                 |                                      |

<div style=\"page-break-after: always\"></div>

## Clinical studies in special populations

Not applicable.

## Supportive study

The  GRIFFIN  study  was  a  multicentre,  randomised,  open-label,  active-controlled,  Phase  2  study, comparing D-VRd versus VRd and recruited in the US only for participants 18 to 70 years of age with NDMM who were eligible for ASCT. The first site was opened on 29 August 2016 and the last participant's last visit occurred on 8 April 2022.

The study design is depicted in Figure 8 .

Figure 8. GRIFFIN study design

<!-- image -->

ECOG  PS=Eastern  Cooperative  Oncology  Group  performance  status;  CrCl=creatinine  clearance;  IV=intravenous; PO=oral; SC=subcutaneous; G-CSF=granulocyte colony-stimulating factor; D-R=daratumumab plus lenalidomide; Q4W=every  4  weeks;  Q8W=every  8  weeks;  NGS=next-generation  sequencing;  ORR=overall  response  rate; VGPR=very  good  partial  response;  CR=complete  response;  PFS=progression-free  survival;  PFS2=PFS  on  next subsequent line of therapy; OS=overall survival.

The primary endpoint of the study was the proportion of the participants achieving a sCR by the end of post-ASCT consolidation treatment as determined by the validated computer algorithm using the 2016 IMWG criteria. Secondary endpoints included the proportion of participants who achieve PR or better, VGPR or better, CR (or sCR), per IMWG criteria, or MRD-negative status following induction treatment (prior to ASCT), ASCT (prior to start of consolidation treatment), post-ASCT consolidation (after Cycle 6), and maintenance treatment respectively.

The  prespecified  primary  analysis  occurred  after  all  randomized  patients  completed  the  post-ASCT consolidation disease evaluation or discontinued from study treatment before this time point. A second protocol-specified analysis will be performed after all randomized patients complete the maintenance phase or discontinue from study treatment before completing maintenance.

The primary hypothesis was that patients in the D-VRd group would have an improved rate of sCR by the end of post-ASCT consolidation compared with the VRd group (primary end point), tested at a 1-

<div style=\"page-break-after: always\"></div>

sided a of 0.10. All secondary analyses were evaluated using a 2-sided P value (a 0.05) and were not adjusted for multiplicity.

Two hundred twenty-three participants were enrolled/randomized in the GRIFFIN study (16 participants in the safety run-in, 104 participants randomized to the D-VRd group, and 103 participants to the VRd group;).

Among the 207 randomized participants, 201 participants  received  treatment  (D-VRd:  100  [96.2%] participants; VRd: 101 [98.1%] participants;). The median duration of follow-up was 49.6 months for 2 treatment groups combined (D-VRd: 49.8; VRd:49.4 months).

The majority of participants were male (57.0%) and white (78.2%). A total of 15.5% of the participants were black or African American. The median age was 60 years (range: 29 to 70 years) and the median weight was 82.0 kg (range: 37.4 to 158.6 kg). Approximately, half of the participants (103 [50.7%]) had an ECOG score of 1 at baseline.

Both randomization stratification factors, ISS stage and baseline CrCl, were balanced between treatment groups (ISS stage II to III: D-VRd: 54 [51.9%] participants versus VRd: 53 [51.5%] participants, and CrCl 30 to 50 mL/min: 9 [8.7%] participants in each treatment group).

In both the D-VRd and VRd treatment groups, the majority of participants had IgG multiple myeloma (D-VRd: 58.0%; VRd: 55.0%) and measurable disease by serum only (D-VRd: 51.0% participants; VRd: 58.3% participants). Approximately half of the participants (D-VRd: 47.1% participants; VRd: 48.5% participants) had ISS Stage I disease. High-risk cytogenetic abnormality, defined as any of the following: del(17p), t(4;14), and t(14;16), was balanced in both arms, (D-VRd: 16.3%; VRd: 14.4%).

The median duration of study treatment was 32.5 months in the D-VRd group and 27.5 months in the VRd group.

The median number of treatment cycles received was 32 cycles in the D-VRd arm and 24.5 cycles in the VRd  arm.  After  completion  of  the  per  protocol  maintenance  (24  months),  additional  lenalidomide maintenance was received by 63 (63.6%) participants in the D-VRd group for a median of 16.9 months while 42 (41.2%) of participants in the VRd group received this additional maintenance therapy for a median of 14.8 months.

## Primary Efficacy Endpoint - sCR by the end post-ASCT consolidation

At the time of primary analysis (CCO 25 January 2019) in 196 response-evaluable participants (D-VRd: 99 participants and VRd: 97 participants), the sCR rate by the end of post-ASCT consolidation phase was higher in the D-VRd group (42.4%) compared with the VRd group (32.0%; odds ratio [D-VRd versus VRd] was 1.57 with 95% CI: 0.87, 2.82; 2-sided p-value=0.1359 equivalent to 1-sided p-value=0.068) which was statistically significant at the pre-set 1-sided alpha level of 0.1.

## Progression-free Survival

At the time of the final analysis with a median follow-up of 49.6 months, 11 (10.6%) and 18 (17.5%) PFS  events  as  assessed  by  the  computerized  algorithm  occurred  in  the  D-VRd  and  VRd  groups, respectively.  The  HR  (D-VRd  versus  VRd)  was  0.45  (95% CI: 0.21,  0.95;  2-sided  nominal  pvalue=0.0324) and the median PFS was not reached in either treatment group. The estimated 48-month PFS rate was 87.2% in the D-VRd group and 70.0% in the VRd group. The majority of participants in the D-VRd and VRd groups (89.4% and 82.5% of participants) were censored for PFS, with leading reasons of study cutoff (D-VRd: 68.8%; VRd: 48.2%) and subsequent antimyeloma therapy use (DVRd: 16.1%; VRd: 30.6%).

Pre-specified  subgroup  analyses  of  PFS,  including  that  of  participants  with  high-risk  cytogenetic abnormalities, demonstrated that the HR point estimates for the treatment effect of D-VRd over VRd were generally in favour of D-VRd and consistent with the whole ITT population except participants with non-IgG myeloma.

<div style=\"page-break-after: always\"></div>

Of note, in the age ≥ 65y the HR was 0.29 (0.06, 1.48) compared with the HR of 0.45 (0.21, 0.95) in the ITT population.

## CR or Better Rate

By the end of the maintenance phase, the rate of CR or better (sCR + CR) was higher for the D-VRd group (79.8%) than the VRd group (57.3%) as assessed by ITT analysis set (nominal 2-sided p=0.0007).

## Minimal Residual Disease

The proportion of participants with both MRD-negativity (10 -5 ) and a response of CR or better by the end of maintenance phase was higher in the D-VRd group (61.5%) than in the VRd group (27.2%) (odds ratio=4.20; 95% CI: 2.34, 7.56; nominal 2-sided p-value&lt;0.0001).

The rate of MRD-negativity (10 -5 ) and a response of CR or better by the end of consolidation was higher in the D-VRd group (32.7%) vs VRd group (10.7%).

The  sustained  (≥1 -year)  MRD-negativity  rate  (10 -5 )  was  higher  in  participants  in  the  D-VRd  group (44.2%) compared with the participants in the VRd group (13.6%) (odds ratio: 5.00; 95% CI: 2.50, 9.99; nominal 2-sided p&lt;0.0001).

## Overall Survival

With a median follow-up of 49.6 months, OS data were immature. A total of 14 deaths (D-VRd: 7 [6.7%], VRd: 7 [6.8%]) were reported in the randomized treatment groups. The median OS was not reached in either treatment group. The HR (D-VRd versus VRd) was 0.90 (95% CI: 0.31, 2.56; nominal 2-sided pvalue=0.8408).

## Overall Response Rate

## By the end of induction:

- ORR (sCR + CR + VGPR + PR) was higher in the D-VRd group compared with the VRd group (93.3% versus 86.4%) (odds ratio [D-VRd versus VRd] 2.22 with 95% CI: 0.85, 5.78; nominal 2-sided p-value=0.0996) in ITT analysis set.
- VGPR or better rate (D-VRd 68.3%, VRd 53.4%, OR 1.83, 95% CI: 1.04, 3.21; nominal 2-sided pvalue=0.0332).
- CR or better rate (sCR + CR) was higher for the D-VRd group (18.3%) than the VRd group (12.6%) as assessed by ITT analysis set (nominal 2-sided p=0.2903).
- sCR  rate  (D-VRd  11.5%,  VRd  6.8%,  OR  1.77,  95%  CI:  0.66,  4.72;  nominal  2-sided  pvalue=0.2538).

## Post-ASCT:

- ORR (sCR + CR + VGPR + PR), was higher in the D-VRd group compared with the VRd group (94.2% versus 86.4%) (odds ratio [D-VRd versus VRd] 2.63 with 95% CI: 0.96, 7.20; nominal 2-sided p-value=0. 0549) in ITT analysis set.
- VGPR or better rate (D-VRd 82.7%, VRd 62.1%, OR 2.85, 95% CI:1.49, 5.44; nominal 2-sided pvalue=0.0010).
- CR or better rate (sCR + CR) was higher for the D-VRd group (26.0%) than the VRd group (18.4%) as assessed by ITT analysis set (nominal 2-sided p=0.2048).
- sCR rate (D-VRd 20.2%, VRd 13.6%, OR 1.62, 95%CI:0.76,3.43; nominal 2-sided p-value=0.2139).

<div style=\"page-break-after: always\"></div>

## End Consolidation:

- ORR (sCR + CR + VGPR + PR), was higher in the D-VRd group compared with the VRd group (94.2% versus 86.4%) (odds ratio [D-VRd versus VRd] 2.63 with 95% CI: 0.96, 7.20; nominal 2-sided p-value=0. 0549) in ITT analysis set.
- VGPR or better rate was higher in the D-VRd group compared with the VRd group (D-VRd: 86.5%, VRd: 68.9%), (odds ratio [D-VRd versus VRd] 2.84 with 95% CI: 1.41, 5.74; nominal 2-sided p-value=0. 0025).
- CR or better (sCR + CR) was higher for the D-VRd group (49.0%) than the VRd group (39.8%) as assessed by ITT analysis set (nominal 2-sided p=0.1874).
- sCR, see section on primary endpoint.

## By the end of maintenance:

- ORR (sCR + CR + VGPR + PR) was higher in the D-VRd group compared with the VRd group (95.2% versus 87.4%) (odds ratio [D-VRd versus VRd] 2.93 with 95% CI: 0.99, 8.64; nominal 2-sided p-value=0.0448) in ITT analysis set.
- VGPR or better rate was 92.3% in the D-VRd group and 73.8% in the VRd group (odds ratio [D-VRd versus VRd] 4.06 with 95% CI: 1.75, 9.43; nominal 2-sided p-value=0.0004).
- sCR rate was 64.4% and 45.6% (odds ratio [D-VRd versus VRd] 2.12 with 95% CI: 1.22, 3.71; nominal 2-sided p-value=0.0080) in the D-VRd and VRd treatment groups, respectively.

## 2.4.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

## Study MMY3014

Study MMY3014 was a phase 3, randomised, open-label, multicentre study comparing D-VRd versus VRd in participants with newly diagnosed MM who were eligible for ASCT. Participants were randomised in a 1:1 ratio, stratified by ISS Stage I, II, or III disease ( β -2 microglobulin and albumin) and cytogenetics (standard-risk  or  high-risk,  which  is  defined  by  the  presence  of  del17p,  t[4;14]  or  t[14;16]).  The treatment  phase  included  four  elements:  Induction  treatment,  ASCT,  consolidation  treatment  and maintenance treatment (D-R vs. R).

The  stratification  factors  have  prognostic  and  predictive  impact  in  this  setting  and  are  deemed appropriate. Treatment regiments were standard and are acceptable.

The study design does not allow for evaluation of the treatment effect of adding daratumumab to VRd in the induction phase or consolidation phase or to lenalidomide in the maintenance phase respectively, as the study did not include a randomisation pre-consolidation or a randomisation pre-maintenance. Rather,  the  treatment  effect  of  adding  daratumumab  to  the  VRd  backbone  and  to  lenalidomide maintenance has to be considered across all three treatment phases as a whole. Hence the proposed wording of the new indication by the MAH, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant, is supported without specifying treatment phases (induction, consolidation and maintenance).

Inclusion and exclusion criteria employed in the study adequately reflects patients for whom high-dose chemotherapy and autologous stem cell transplantation would be part of the intended treatment plan. However, it should be  noted that a screening period of 28 days before randomization to treatment excluded patients with NDMM who need acute or sub-acute anti-myeloma treatment with more than just

<div style=\"page-break-after: always\"></div>

40mg x 4 of dexamethasone to alleviate severe kidney disease, severe hypercalcemia or significant bone disease.

The exclusion of NDMM patients with an acute or sub-acute presentation at diagnosis can be considered justifiable as management of acutely ill NDMM patients in the strict framework of a clinical trial can be complicated. However, this should be kept in mind when extrapolating trial results to non-trial settings.

The primary endpoint in the study was PFS by computerised algorithm defined as time from the date of randomisation to the date of PD (assessed by 2011 IMWG criteria) or death. The key secondary endpoints were overall CR or better rate anytime during the study, overall MRD-negativity rate achieved at any time during the study, and OS. The choice of endpoints and objectives in this clinical setting is considered appropriate.

The  use  of  the  2011  IMWG  consensus  recommendations  for  multiple  myeloma  treatment  response criteria is also supported.

Sample size calculations appear appropriate and considered relevant factors such as enrolment period and expected HR for PFS. The primary endpoint and key secondary endpoints were evaluated in the ITT population. The first interim analysis was to be performed at approximately 143 PFS events, representing 50% of the total planned events. If the superiority of D-VRd over VRd was established in either of two planned interim analyses, it would serve as the primary PFS analysis. Assuming that 143 and 185 PFS events, respectively, are observed at the first and second PFS interim analyses, the two-sided alpha to be spent in the two interim analyses would be 0.0112 and 0.0126. Hierarchical testing was used to control the overall family-wise Type I error rate at 5% two-sided across primary and key secondary hypotheses, with specific alpha-spending functions for group sequential testing. The Hwang-Shih-DeCani alpha-spending function with a gamma parameter of -2.5 determined the significance levels at interim analyses. Secondary endpoints were tested sequentially only if PFS was significant. Hierarchical testing ensured strong control of the overall family-wise Type I error rate at 0.05. This approach to prevent Type I error inflation was endorsed.

709 patients were randomly assigned 1:1 to D-VRd (355 patients) or VRd (354 patients). As of the data cutoff date (01 August 2023), the median duration of follow up was 47.5 months. Of the 709 randomized participants, 351 participants in the D-VRd arm and 347 participants in the VRd arm received study treatment. Fewer participants in the D-VRd arm (91 [25.9%]) discontinued treatment compared with the  VRd  arm  (188  [54.2%]).  The  majority  of  discontinuations  occurred  during  induction  and maintenance.  The  most  common  reasons  for  discontinuation  of  all  components  of  study  treatment (&gt;10% of total in either arm) were adverse events (D -VRd: 9.1%; VRd: 22.5%) and progressive disease (D-VRd: 8.3%; VRd: 20.7%). The overall higher rate of discontinuation in the VRd arm was primarily driven by study design. The participants in the VRd arm only received treatment with lenalidomide during maintenance therapy, thus any discontinuation of lenalidomide led to discontinuation of all study drugs. In contrast, in the D-VRd arm, if participants discontinued lenalidomide during maintenance therapy, daratumumab study treatment was not discontinued.

Major protocol amendments were appropriately justified. Modifications of inclusion and exclusion criteria were of clarifying nature and are not believed to have altered the patient population that was intended for enrolment into the trial.

## GRIFFIN study

Overall study design was similar between MMY3014 and GRIFFIN. However, VRd and D-VRd cycle length varied between the studies with 4-week cycles and 3-week cycles respectively. There were also differences in the dosing regimens of all administered medicines.

The primary endpoint was sCR at the end of post-ASCT consolidation. sCR response was not evaluated on the ITT set but the on the response evaluable set.

<div style=\"page-break-after: always\"></div>

The differences in medication dosing and strength are overall considered minor and do not preclude that the GRIFFIN study can be considered as supportive to study MMY3014 with regard to efficacy claims.

## Efficacy data and additional analyses

## Study MMY3014

The demographic and clinical characteristics of the patients at baseline were generally balanced in the two groups and reflect a rather fit patient population with NDMM with low levels of comorbidity that could go up to 28 days without initiation of anti-myeloma treatment other than 4 x 40mg of dexamethasone and thus selecting a population with less aggressive debut of multiple myeloma without immediate need of treatment. The median age was 60.0 (range 31-70) years. The majority of the participants were white (92.1%) and had an ECOG performance score of 0 (63.6%) or 1 (31.3%).

The number of participants with SLiM-CRAB criteria (i.e., presence of biomarkers of malignancy)  at diagnosis was low in both treatment arms (D-VRd: 52 [14.7%]; VRd: 65 [18.5%]) but with a slight imbalance favouring the VRd arm. Stratification factors of cytogenetics and ISS stage were balanced between the two treatment arms. Median time in months from MM diagnosis to randomisation was 1.12 months in the VRd arm and 1.18 months in the D-VRD arm.

At the CCO on 01 August 2023, when the first planned interim analysis was conducted, a total of 153 PFS events (D-VRd: 50/355 (14.1%); VRd: 103/354 (29.1%)) had been observed, with a median followup of 47.51 months (D-VRd: 47.57 months; VRd: 47.38 months).

The addition of daratumumab to VRd resulted in a statistically significant improvement in the primary endpoint PFS with a HR=0.42 (95% CI: 0.30, 0.59; 2-sided p &lt;0.0001) compared to VRd alone. The pvalue crossed the prespecified stopping boundary of 0.0126 in favour of the D-VRd arm, turning the first interim  analysis  for  PFS  into  the  primary  analysis.  The  median  PFS  had  not  been  reached  in  either treatment  arm  (48-month  PFS  rate:  D-VRd:  84.3%;  VRd:  67.7%).  The  PFS  benefit  was  generally consistent across prespecified subgroups (ISS stage, cytogenetic risk, and baseline ECOG performance score), showing improvement for participants in the D-VRd arm compared with participants in the VRd arm, with the exception of the ≥ 65 years subgroup (HR=0.97 [95% CI: 0.52, 1.81]). In this subgroup, there was an imbalance in the cytogenetic high-risk category (D-VRd 25.5% vs VRD 19.5%), which may have contributed to the observed HR in this particular age subgroup. Overall, there is no basis for a restriction of the indication based on age. The final analysis for PFS (285 events) is projected to occur in 2028-2029 and the CHMP recommended that these results should be submitted when available.

The  addition  of  daratumumab  to  VRd  resulted  in  a  statistically  significant  improvement  in  the  key secondary endpoint overall CR or better rate compared with VRd alone with an absolute increase of 17.8% favouring treatment with D-VRd (D-VRd: 87.9%; VRd: 70.1%; odds ratio=3.13 with 95% CI: 2.11, 4.65; 2-sided p &lt;0.0001).

A  higher  proportion  of  patients  achieved  the  key  secondary  endpoint  of  MRD-negativity  at  the  10 -5 threshold in the D-VRd arm compared with the VRd arm (D-VRd: 75.2%; VRd: 47.5%; odds ratio=3.4; 95% CI: 2.47, 4.69; 2-sided p &lt;0.0001), with an absolute difference of 27.7% favouring treatment with D-VRd.

With an overall median follow-up of 47.51 months the OS data are still immature. With a total of 78 deaths (D-VRd: 34; VRd: 44), the median OS was not reached for either treatment arm. The analysis reveals no suspected detriment in the D-VRd arm with an estimated HR of 0.73 ((95% CI: 0.47, 1.14).

The remaining endpoints were not type 1 error controlled, but favoured D-VRd treatment over VRd treatment with regard to MRD-negativity at 10 -6  threshold, MRD-negativity (10 -5 ) post-consolidation, sustained MRDnegativity (&gt;12 months MRD negativity at the 10 -5  threshold, and time to subsequent anti-myeloma treatment.

<div style=\"page-break-after: always\"></div>

Treatment with either D-VRd or VRd led to comparable improvements in the measured PROs including increased physical function score, reduced fatigue symptom score and reduced pain symptom score.

Regarding ASCT, a higher number of patients failed stem cell mobilization in the D-VRd arm (9 vs 3) suggesting that the addition of daratumumab to VRd induction can reduce the probability for a successful stem cell harvest. Despite increased use of plerixafor for stem cell mobilization and lower amount of collected CD34 +  stem cells in the D-VRd arm, similar rates of hematopoietic reconstitution were observed among  transplanted  participants  for  both  treatment  arms  (D-VRd:  99.7%  (314/315);  VRd:  99.3% (300/302)). Median time to engraftment post-ASCT was 14.0 days for each treatment arm.

Despite the higher number of patients failing stem cell mobilization in the D-VRd arm, it should be noted that  the  frequency  of  patients  who  made  it  to  successful  engraftment  post  ASCT  based  on  the  ITT population was higher in the D-VRd arm compared to the VRd arm with 88.5% (314/355) vs 84.7% (300/354) respectively.

## GRIFFIN study

The sCR rate by the end of post-ASCT consolidation phase was higher in the D-VRd group (42.4%) compared with the VRd group (32.0%; odds ratio [D-VRd versus VRd] was 1.57 with 95% CI: 0.87, 2.82). A post-hoc analysis of sCR rate per ITT analysis was similar with the analysis performed by the response-evaluable analysis set: sCR of 40.4% in the D-VRd group and 30.1% in the VRd group (odds ratio [D-VRd versus VRd] was 1.58, 95% CI: 0.88, 2.82).

Pre-specified subgroup analyses of PFS, including that of participants with high-risk cytogenetic abnormalities, demonstrated that the HR point estimates for the treatment effect of D-VRd over VRd were generally in favour of D-VRd and consistent with the whole ITT population except participants with non-IgG myeloma.

Of note, in the age group ( ≥ 65y), the HR for PFS was 0.29 (0.06, 1.48) compared with the HR of 0.45 (0.21, 0.95) in the ITT population. So, the reduced efficacy seen in MMY3014 study in that subgroup with regard to PFS was not observed here.

Other endpoints in the study also seem to favour D-VRd compared to VRd.

In conclusion, the GRIFFIN study is considered supportive of the efficacy results observed in the main study MMY3014 and no major conflicting findings between the studies were observed.

## 2.4.3. Conclusions on the clinical efficacy

Results  from  the  interim  analysis  of  study  MMY3014  showed  a  statistically  significant  relevant improvement in PFS from the addition of daratumumab to VRd in patients with newly diagnosed multiple myeloma. This improvement is considered clinically significant and is supported by secondary endpoints such  as  statistically  significant  improvement  in  overall  CR  or  better  treatment  response  rates  and statistically significant higher proportion of patients achieving MRD negativity at the 10 -5  threshold. OS data are immature but do not show any sign of detriment in the experimental arm.

Supportive evidence of efficacy in support of D-VRd in the claimed indication comes from the GRIFFIN study.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

The most frequent adverse reactions of any grade  (≥ 20% patients)  observed  in  clinical  trials  with daratumumab (either intravenous or subcutaneous formulations) administered either as monotherapy or combination  treatment were  Infusion related reactions (IRRs), fatigue, nausea, diarrhoea, constipation, pyrexia, cough, neutropenia, thrombocytopenia, anaemia, oedema peripheral, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, sepsis, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea, atrial fibrillation and syncope.

The safety profile of the daratumumab subcutaneous formulation was similar to that of intravenous formulation with the exception of a lower rate of IRRs. In the phase III study MMY3012, neutropenia was  the  only  adverse  reaction  reported  at  ≥ 5%  higher  frequency  for  daratumumab  subcutaneous formulation compared to intravenous daratumumab (grade 3 or 4: 13% vs 8%, respectively).

## Patient exposure

The pivotal safety data in support of this application comments from the Phase 3 Study MMY3014 and a summary of the duration of treatment in that trial is presented in Table 18 .

Table 18 . Summary of Duration of Treatment, by Treatment Phase; Safety Analysis Set (Study 54767414MMY3014)

|                                        | VRd              | D-VRd            |
|----------------------------------------|------------------|------------------|
| Analysis set: safety                   | 347              | 351              |
| Treatment duration (months)            |                  |                  |
| N                                      | 347              | 351              |
| Mean (SD)                              | 34.055 (16.3802) | 39.993 (13.4519) |
| Median                                 | 42.185           | 45.733           |
| Range                                  | (0.07; 53.91)    | (0.49; 54.34)    |
| Induction treatmenta                   |                  |                  |
| N                                      | 347              | 351              |
| Mean (SD)                              | 3.914 (1.4112)   | 3.957 (1.3419)   |
| Median                                 | 3.450            | 3.450            |
| Range                                  | (0.07; 11.37)    | (0.49; 10.32)    |
| Pre-ASCTb                              |                  |                  |
| N                                      | 303              | 315              |
| Mean (SD)                              | 1.952 (0.9538)   | 2.105 (1.1110)   |
| Median                                 | 1.774            | 1.873            |
| Range                                  | (0.10; 7.36)     | (0.10; 7.85)     |
| ASCTc                                  |                  |                  |
| N                                      | 294              | 309              |
| Mean (SD)                              | 2.588 (0.7559)   | 2.562 (0.9796)   |
| Median                                 | 2.595            | 2.497            |
| Range                                  | (0.92; 6.37)     | (0.72; 11.96)    |
| Consolidation treatmentd               |                  |                  |
| N                                      | 262              | 274              |
| Mean (SD)                              | 1.626 (0.1776)   | 1.633 (0.2418)   |
| Median                                 | 1.610            | 1.610            |
| Range                                  | (0.53;2.53)      | (0.46; 2.40)     |
| Induction/Pre-ASCT/ASCT/Consolidation? |                  |                  |
| N                                      | 292              | 303              |
| Mean (SD)                              | 9.984 (1.5056)   | 9.976 (1.4511)   |
| Median                                 | 9.692            | 9.659            |
| Range                                  | (7.13; 17.35)    | (6.28; 16.13)    |
| Maintenance treatmentf                 |                  |                  |
| N                                      | 300              | 322              |
| Mean (SD)                              | 28.448 (12.1868) | 32.871 (8.7450)  |

<div style=\"page-break-after: always\"></div>

Key:  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  =  daratumumab  +  bortezomib (VELCADE) + lenalidomide + dexamethasone.

a - Duration of induction treatment: For subjects who received induction treatment, from first induction dose date to the  last  induction  dose  date.  For  subject  with  mobilization  occurred  within  the  induction  phase,  the  duration  of mobilization was not counted in.

b - Duration of Pre-ASCT: For subjects receive mobilization therapy, from the day after the last dose of induction, to the day before the start date of melphalan administration. Subjects who were not proceed to transplant were not taken into account for this calculation.

c - Duration of ASCT: For subjects who proceed to transplant, from the start date of melphalan administration, to the day before the first dose date of consolidation phase, or the day before the first date of maintenance phase treatment which was after the ASCT for subjects without the consolidation phase, whichever is earlier. Subjects who were end of treatment during ASCT phase were not taken into account for this calculation.

d - Duration of consolidation treatment: from first consolidation dose date to the last consolidation dose date.

e - Duration of induction/Pre-ASCT/ASCT/consolidation treatment: (a) For subjects received consolidation after having received ASCT, from first induction dose date to the last consolidation dose date. (b) For subjects received ASCT after 6 cycles of induction, from first induction dose date to the day before maintenance treatment start date, or the date of end-of treatment visit, whichever is earlier. Subjects who received both ASCT and consolidation, or received ASCT after 6 cycles of induction were taken into account for this calculation.

f - Duration of maintenance treatment: from first maintenance dose date to the last maintenance dose date.

Note: Induction phase includes patients who had more than 4 cycles treatment induction phase due to COVID-19 pandemic or patients who did not get transplant for other reasons.

In Study MMY3014, dose modifications consisted of cycle delays, dose delays, skipped doses, or dose reductions. Dose modifications were reported in participants, as follows:

- Cycle delays : Cycle delays were reported in a higher proportion of participants in the D-VRd arm compared with the VRd arm (D-VRd: 89.5%; VRd: 80.7%). The most common reason for cycle delays was AEs (D-VRd: 74.1%; VRd: 63.1%) and 'other' reasons (D-VRd: 68.7%; VRd: 51.3%). Overall, the majority of cycle delays occurred during maintenance (D-VRd: 91.6%; VRd: 80.0%), consistent with the longer duration of maintenance treatment at the time of CCO.

## · Dose delays :

- o Daratumumab, D-VRd, 7.1%, with 4.6% during induction
- o Bortezomib, D-VRd: 0; VRd: 1.7%
- o Dexamethasone, D-VRd: 1.4%; VRd: 1.7%

## · Skipped doses:

- o Daratumumab, D-VRd, 45.3%, with 33.3% of participants skipping an injection during induction
- o Bortezomib, D-VRd: 43.3%; VRd: 43.8%, primarily for AEs (D-VRd: 37.6%; VRd: 35.2%)
- o Lenalidomide, D-VRd: 84.3%; VRd: 76.7%, predominantly occurring during maintenance (D-VRd: 81.4%; VRd: 72.3%), and primarily for AEs (D-VRd: 74.4%; VRd: 62.8%)
- o Dexamethasone, D-VRd: 28.8%; VRd: 25.1%
- Dose  interruptions :  A  low  proportion  of  participants  had  daratumumab  injection  interruption (2.0%), and no participants aborted the injection.

## · Dose reductions :

- o Bortezomib, D-VRd: 27.6%; VRd: 26.2%, primarily for AEs (D-VRd: 27.4%; VRd: 25.9%)
- o Lenalidomide, D-VRd: 63.8%; VRd: 51.3%, predominantly occurring during maintenance (D-VRd: 55.9%; VRd: 49.3%), and primarily for AEs (D-VRd: 61.3%; VRd: 49.9%)

<div style=\"page-break-after: always\"></div>

- o Dexamethasone, D-VRd; 33.9%; VRd: 29.4%

## · Treatment discontinuations:

- o Daratumumab, 2.6%, with AEs as the most common reason (2.3%)
- o Bortezomib, D-VRd: 10.0%; VRd: 8.1%, primarily for AEs (D-VRd: 9.7%; VRd: 7.5%)
- o Lenalidomide, D-VRd: 26.5%; VRd: 19.6%, primarily for AEs (D-VRd: 22.5%; VRd: 12.4%)
- o Dexamethasone, D-VRd: 2.6%; VRd: 3.2%

Supportive safety information is provided by the GRIFFIN study (described in Section 2.4 of this report) and the PLEAIDES study, a multicentre, open-label, Phase 2 study to investigate the efficacy and safety of  daratumumab SC in combination with 4 standard multiple  myeloma treatment regimens: VRd in participants with NDMM who were transplant eligible; VMP in participants with NDMM who were ineligible for transplant; and Rd and Kd in participants with relapsed or refractory multiple myeloma. Participants in the D-VRd cohort (67 patients) received D-VRd treatment in 21-day cycles for a maximum of 4 cycles. Treatment consisted of daratumumab SC 1800 mg weekly for Cycles 1 to 3 and on Day 1 of Cycle 4; bortezomib SC 1.3 mg/m2 on Days 1, 4, 8 and 11 of each cycle; lenalidomide PO at 25 mg on Days 1 to 14 of each cycle; and dexamethasone PO or IV 20 mg on Days 1, 2, 8, 9, 15 and 16 of each cycle.

In the GRIFFIN study, in the D-VRd and VRd groups, the median duration of study treatment was 32.5 and 27.5 months, respectively, as per study design with fixed duration of maintenance for 24 months only then SOC lenalidomide maintenance per investigator discretion. The median number of treatment cycles received was 32 cycles in the D-VRd arm and 24.5 cycles in the VRd arm. After completion of the per  protocol  maintenance  (24  months),  additional  lenalidomide  maintenance  was  received  by  63 participants (63.6%) in the D-VRd group for a median of 16.9 months while 42 participants (41.2%) in the VRd group received this additional maintenance therapy for a median of 14.8 months.

In the PLEIADES study, participants in the D-VRd cohort received a median of 4 cycles of treatment as per study design for induction only, over a median duration of 2.6 months.

## Adverse events

An overview of the treatment emergent adverse events (TEAEs) reported Study MMY3014 is summarised in Table 19 .

Table 19. Overview of Treatment-emergent Adverse Events; Safety Analysis Set (Study MMY3014)

|                                          | VRd         | D-VRd       |
|------------------------------------------|-------------|-------------|
| Analysis set: safety                     | 347         | 351         |
| Any TEAE                                 | 344 (99.1%) | 349 (99.4%) |
| At least one related a                   | 332 (95.7%) | 347 (98.9%) |
| Maximum toxicity grade                   |             |             |
| Grade 1                                  | 4 (1.2%)    | 2 (0.6%)    |
| Grade 2                                  | 42 (12.1%)  | 24 (6.8%)   |
| Grade 3                                  | 199 (57.3%) | 193 (55.0%) |
| Grade 4                                  | 83 (23.9%)  | 117 (33.3%) |
| Grade 5                                  | 16 (4.6%)   | 13 (3.7%)   |
| Any serious TEAE                         | 171 (49.3%) | 200 (57.0%) |
| At least one related a                   | 65 (18.7%)  | 103 (29.3%) |
| TEAE leading to discontinuation of study |             |             |
| treatment b                              | 74 (21.3%)  | 31 (8.8%)   |
| COVID-19                                 | 1 (0.3%)    | 1 (0.3%)    |

<div style=\"page-break-after: always\"></div>

|                                                 | VRd        | D-VRd       |
|-------------------------------------------------|------------|-------------|
| TEAE leading to discontinuation of              |            |             |
| daratumumab c                                   | 0          | 34 (9.7%)   |
| At least one related to daratumumab             | 0          | 13 (3.7%)   |
| TEAE leading to discontinuation of bortezomib c | 41 (11.8%) | 43 (12.3%)  |
| At least one related to bortezomib              | 27 (7.8%)  | 36 (10.3%)  |
| TEAE leading to discontinuation of              |            |             |
| lenalidomide c                                  | 81 (23.3%) | 95 (27.1%)  |
| At least one related to lenalidomide            | 52 (15.0%) | 64 (18.2%)  |
| TEAE leading to discontinuation of              |            |             |
| dexamethasone c                                 | 22 (6.3%)  | 17 (4.8%)   |
| At least one related to dexamethasone           | 9 (2.6%)   | 10 (2.8%)   |
| TEAE with outcome of death                      | 16 (4.6%)  | 13 (3.7%)   |
| At least one related a                          | 4 (1.2%)   | 3 (0.9%)    |
| Death due to COVID-19                           | 1 (0.3%)   | 4 (1.1%)    |
| TEAE of COVID-19                                | 87 (25.1%) | 133 (37.9%) |
| Serious TEAE of COVID-19                        | 10 (2.9%)  | 23 (6.6%)   |

Key:  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  =  daratumumab  +  bortezomib (VELCADE) + lenalidomide + dexamethasone.

Key: TEAE = treatment-emergent adverse event.

- a TEAEs  related  to  at  least  1  of  the  4  study  treatments:  daratumumab,  bortezomib,  lenalidomide  and dexamethasone.
- b Includes  those  subjects  indicated  as  having  discontinued treatment due  to  an  adverse  event on  the end  of treatment CRF page.
- c Includes those subjects indicated as having discontinued specific study treatment due to an adverse event on the adverse event CRF page.

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events. Percentages are calculated with the number of subjects in each group as denominator.

All participants in the D-VRd and VRd treatment groups experienced at least one TEAE in the GRIFFIN study. A total of 46.5% and 52.0% of participants in the D-VRd and VRd treatment groups, respectively, experienced at least one SAE. TEAEs leading to study treatment discontinuation were reported in 29.3% of participants in the D-VRd treatment group and 29.4% of participants in the VRd treatment group. Death due to a TEAE was reported in 1 (1.0%) participant each in the D VRd and VRd treatment groups.

TEAEs were overall evenly distributed in the GRIFFIN study except grade 3 and 4 events that occurred with a slightly higher rate in the D-VRd arm compared with the VRd arm (84.8% vs. 79.4%).

In the PLEIADES study, all participants in the D-VRd cohort were reported as having a TEAE. Grade 3 or 4 TEAEs occurred in 58.2% of participants in the D-VRd cohort. Treatment-emergent SAEs were reported in 28.4% of participants in the D VRd cohort and 1 (1.5%) participant had a Grade 5 TEAE leading to death. TEAEs leading to study treatment discontinuation were reported in 1 (1.5%) participant in the D VRd cohort.

Grade 3 and 4 TEAEs and treatment-emergent SAEs was less common in the PLEAIDES trial compared with study MMY3014 and the GRIFFIN study. This is believed to be due to the fact that the PLEIADES study only covered induction treatment.

The most commonly reported TEAEs (≥10% in either treatment arm) and Grade 3 or 4 TEAEs ( (≥ 5% in either treatment arm are presented in Table 20 and Table 21 respectively.

<div style=\"page-break-after: always\"></div>

Table 20 . Treatment-emergent Adverse Events by System Organ Class and Preferred Term (at Least 10% in Either VRd or D-VRd); Safety Analysis Set (Study MMY3014)

|                                                              | VRd                   | D-VRd                 |
|--------------------------------------------------------------|-----------------------|-----------------------|
| Analysis set: safety                                         | 347                   | 351                   |
| Total number of subjects with TEAE                           | 344 (99.1%)           | 349 (99.4%)           |
| MedDRA System Organ Class / Preferred Term                   |                       |                       |
| Infections and infestations                                  | 266 (76.7%)           | 305 (86.9%)           |
| COVID-19                                                     | 83 (23.9%)            | 123 (35.0%)           |
| Upper respiratory tract infection                            | 87 (25.1%)            | 111 (31.6%)           |
| Bronchitis                                                   | 39 (11.2%)            | 68 (19.4%)            |
| Pneumonia                                                    | 38 (11.0%)            | 64 (18.2%)            |
| Nasopharyngitis                                              | 39 (11.2%)            | 58 (16.5%)            |
| Blood and lymphatic system disorders                         | 254 (73.2%)           | 292 (83.2%)           |
| Neutropenia                                                  | 204 (58.8%)           | 243 (69.2%)           |
| Thrombocytopenia                                             | 119 (34.3%)           | 170 (48.4%)           |
| Anaemia                                                      | 72 (20.7%)            | 78 (22.2%)            |
| Febrile neutropenia                                          | 38 (11.0%)            | 34 (9.7%)             |
| Gastrointestinal disorders                                   | 268 (77.2%)           | 287 (81.8%)           |
| Diarrhoea                                                    | 188 (54.2%)           | 214 (61.0%)           |
| Constipation                                                 | 118 (34.0%)           | 119 (33.9%)           |
| Nausea                                                       | 58 (16.7%)            | 71 (20.2%)            |
| Vomiting                                                     | 28 (8.1%)             | 38 (10.8%)            |
| Abdominal pain                                               | 37 (10.7%)            | 31 (8.8%)             |
| General disorders and administration site conditions         | 255 (73.5%)           | 265 (75.5%)           |
| Pyrexia                                                      | 109 (31.4%)           | 111 (31.6%)           |
| Asthenia                                                     | 89 (25.6%)            | 94 (26.8%)            |
| Fatigue                                                      | 92 (26.5%)            | 84 (23.9%)            |
| Oedema peripheral                                            | 74 (21.3%)            | 72 (20.5%)            |
| Influenza like illness                                       | 33 (9.5%)             | 39 (11.1%)            |
| Nervous system disorders                                     | 253 (72.9%)           | 262 (74.6%)           |
| Peripheral sensory neuropathy                                | 179 (51.6%)           | 188 (53.6%)           |
| Paraesthesia                                                 | 42 (12.1%)            | 46 (13.1%)            |
| Headache                                                     | 37 (10.7%)            | 31 (8.8%)             |
| Musculoskeletal and connective tissue disorders              | 197 (56.8%)           | 215 (61.3%)           |
| Back pain                                                    | 66 (19.0%)            | 80 (22.8%)            |
| Muscle spasms                                                | 56 (16.1%)            | 67 (19.1%)            |
| Arthralgia                                                   | 69 (19.9%)            | 62 (17.7%)            |
| Pain in extremity                                            | 38 (11.0%)            | 40 (11.4%)            |
| Skin and subcutaneous tissue disorders                       | 179 (51.6%)           | 189 (53.8%)           |
| Rash                                                         | 94 (27.1%)            | 82 (23.4%)            |
| Respiratory, thoracic and mediastinal disorders              | 132 (38.0%)           | 171 (48.7%)           |
| Cough                                                        | 51 (14.7%)            | 85 (24.2%)            |
| Dyspnoea                                                     | 24 (6.9%)             | 37 (10.5%)            |
| Metabolism and nutrition disorders                           | 119 (34.3%)           | 141 (40.2%)           |
| Psychiatric disorders                                        | 106 (30.5%)           | 132 (37.6%)           |
| Insomnia                                                     | 61 (17.6%)            | 95 (27.1%)            |
| Investigations                                               | 104 (30.0%)           | 111 (31.6%)           |
| disorders                                                    |                       | 100 (28.5%)           |
| Vascular                                                     | 87 (25.1%)            |                       |
| Eye disorders Injury, poisoning and procedural complications | 63 (18.2%) 58 (16.7%) | 70 (19.9%) 69 (19.7%) |
| Cardiac disorders                                            | 35 (10.1%)            | 60 (17.1%)            |
| and urinary                                                  | 41                    | 57                    |
| Renal disorders                                              | (11.8%)               | (16.2%)               |

<div style=\"page-break-after: always\"></div>

|                                                                     | VRd       | D-VRd      |
|---------------------------------------------------------------------|-----------|------------|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 33 (9.5%) | 47 (13.4%) |
| Hepatobiliary disorders                                             | 34 (9.8%) | 39 (11.1%) |
| Ear and labyrinth disorders                                         | 29 (8.4%) | 37 (10.5%) |

Key: VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

Key: TEAE = treatment-emergent adverse event.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. Percentages are calculated with the number of subjects in each group as denominator.

Note: Adverse events are coded using MedDRA version 26.0.

Table 21. Treatment-emergent Grade 3 or 4 Adverse Events by System Organ Class and Preferred Term (at Least 5% in Either VRd or D-VRd); Safety Analysis Set (Study MMY3014)

|                                                                     | VRd         | D-VRd       |
|---------------------------------------------------------------------|-------------|-------------|
| Analysis set: safety                                                | 347         | 351         |
| Total number of subjects with Grade 3 or 4 TEAE                     | 297 (85.6%) | 321 (91.5%) |
| MedDRA System Organ Class / Preferred Term                          |             |             |
| Blood and lymphatic system disorders                                | 213 (61.4%) | 261 (74.4%) |
| Neutropenia                                                         | 177 (51.0%) | 218 (62.1%) |
| Thrombocytopenia                                                    | 60 (17.3%)  | 102 (29.1%) |
| Febrile neutropenia                                                 | 35 (10.1%)  | 33 (9.4%)   |
| Anaemia                                                             | 22 (6.3%)   | 21 (6.0%)   |
| Infections and infestations                                         | 95 (27.4%)  | 124 (35.3%) |
| Pneumonia                                                           | 21 (6.1%)   | 37 (10.5%)  |
| Gastrointestinal disorders                                          | 68 (19.6%)  | 82 (23.4%)  |
| Diarrhoea                                                           | 27 (7.8%)   | 37 (10.5%)  |
| Stomatitis                                                          | 20 (5.8%)   | 21 (6.0%)   |
| Nervous system disorders                                            | 35 (10.1%)  | 46 (13.1%)  |
| General disorders and administration site conditions                | 41 (11.8%)  | 41 (11.7%)  |
| Fatigue                                                             | 18 (5.2%)   | 10 (2.8%)   |
| Investigations                                                      | 32 (9.2%)   | 30 (8.5%)   |
| Alanine aminotransferase increased                                  | 18 (5.2%)   | 18 (5.1%)   |
| Respiratory, thoracic and mediastinal disorders                     | 20 (5.8%)   | 27 (7.7%)   |
| Metabolism and nutrition disorders                                  | 32 (9.2%)   | 26 (7.4%)   |
| Skin and subcutaneous tissue disorders                              | 27 (7.8%)   | 25 (7.1%)   |
| Vascular disorders                                                  | 19 (5.5%)   | 24 (6.8%)   |
| Cardiac disorders                                                   | 9 (2.6%)    | 23 (6.6%)   |
| Hepatobiliary disorders                                             | 11 (3.2%)   | 21 (6.0%)   |
| Psychiatric disorders                                               | 19 (5.5%)   | 21 (6.0%)   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 13 (3.7%)   | 18 (5.1%)   |
| Musculoskeletal and connective tissue disorders                     | 19 (5.5%)   | 14 (4.0%)   |

Key:  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  =  daratumumab  +  bortezomib (VELCADE) + lenalidomide + dexamethasone.

Key: TEAE = treatment-emergent adverse event.

Note:  Subjects  are  counted  only  once  for  any  given  event,  regardless  of  the  number  of  times  they  actually experienced the event. Percentages are calculated with the number of subjects in each group as denominator.

Note: Adverse events are coded using MedDRA version 26.0.

In the GRIFFIN study, the most frequently reported TEAEs in either treatment group were fatigue (D-

VRd: 71.7%; VRd: 61.8%), upper respiratory tract infection (D-VRd: 67.7%; VRd: 50%), diarrhoea (D VRd: 66.7%; VRd: 54.9%) and neutropenia (D-VRd: 63.6%; VRd: 40.2%).

<div style=\"page-break-after: always\"></div>

TEAEs reported in at least 20% of participants that occurred at ≥10.0% higher frequency in the D VRd treatment group compared with the VRd treatment group were pyrexia, chills, upper respiratory tract infection, diarrhoea, constipation, abdominal pain, paraesthesia, muscle spasms, neutropenia, leukopenia, cough, decreased appetite, and insomnia.

The only TEAE reported in at least 20% of participants that occurred at a ≥10.0% higher frequency in the VRd treatment group compared with the D-VRd treatment group was peripheral neuropathy. A difference of the same magnitude was not observed in the MMY3014 study were rates of peripheral neuropathy were comparable with 51.6% in the VRd arm in 53.6% in the D-VRd arm.

The incidence of Grade 3 or 4 TEAEs was higher in the D-VRd treatment group (85.9%) compared with the VRd treatment group (79.4%). The most frequently reported Grade 3 or 4 TEAEs (≥10.0% in either treatment group) were cytopenia TEAEs.

The most frequently reported daratumumabrelated TEAEs (≥20%) in the D -VRd treatment group were neutropenia (47.5%), fatigue (38.4%), thrombocytopenia (29.3%), diarrhoea (28.3%), upper respiratory tract infection (27.3%), nausea (26.3%), anaemia (25.3%), leukopenia (23.2%), pyrexia (22.2%), and lymphopenia (21.2%).

In the PLEIADES study, the most frequently reported TEAEs (≥20%) were peripheral sensory neuropathy (41.8%), thrombocytopenia (38.8%), constipation (38.8%), neutropenia (37.3%), pyrexia (35.8%), fatigue (28.4%), and diarrhoea (23.9%).

## Adverse drug reactions

The  MAH  evaluated  safety  data  using  the  definition  of  ADR  from  the  International  Council  for Harmonisation guideline entitled, E6: Good Clinical Practice, Consolidated Guideline.

ADRs in Study MMY3014 were evaluated according to the following criteria:

- All TEAEs reported in ≥10% of participants and occurred at a higher incidence (≥5% difference) in the D-VRd arm as compared with the VRd arm were considered to have met the ADR threshold. The comparison of incidence of TEAEs between treatment arms was completed after rounding incidence to the nearest whole numbers for all events (i.e., 4.9% is rounded to 5%).
- All  laboratory  parameters  in  Study  MMY3014  were  reviewed.  No  laboratory  parameters  had  an incidence of Grade 3 or 4 values ≥10% except for h aematology parameters.
- Thrombocytopenia, Neutropenia, Lymphopenia, Leukopenia, and Anaemia were listed in a separate haematology  laboratory  table  based  on  haematology  laboratory  parameters  regardless  of  the incidence and difference between arms.
- SAEs that occurred at a higher incidence (≥2% difference) in the D -VRd treatment arm as compared with the VRd treatment arm were considered ADRs. The comparison of incidence was completed after rounding incidence to whole numbers for all events.
- TEAEs  were  evaluated  in  the  context  of  a  potential  plausible  biological  or  pharmacological association with daratumumab or as medically significant events with a high probability that they could be associated with daratumumab, regardless of frequency.

Based on this analysis, no new ADRs were identified from Study MMY3014. The frequency of the known ADRs associated with daratumumab use were updated with data from the MMY3014 and the PLEIADES study which were combined with other daratumumab monotherapy and combination studies to obtain ADR frequencies from a pooled safety data (Table 22).

Table 22. Adverse Reactions in Multiple Myeloma and AL Amyloidosis Participants Treated With Daratumumab IV or Daratumumab SC (pooled data from MMY3014 and the PLEIADES studies )

<div style=\"page-break-after: always\"></div>

|                                                  | Any Grades   | Any Grades   | Grade 3-4   |
|--------------------------------------------------|--------------|--------------|-------------|
| Infections and infestations                      |              |              |             |
| Upper respiratory tract                          |              |              |             |
| infection a                                      | Very Common  | 39%          | 2%          |
| COVID-19 a,g                                     | Very Common  | 38%          | 7%          |
| Pneumonia a                                      | Very Common  | 18%          | 11%         |
| Bronchitis a                                     | Very Common  | 14%          | 1%          |
| Urinary tract infection                          | Common       | 7%           | 1%          |
| Influenza                                        | Common       | 4%           | 1% #        |
| Sepsis a                                         | Common       | 4%           | 4%          |
| Cytomegalovirus infection a                      | Uncommon     | <1%          | <1% #       |
| Hepatitis B reactivation a                       | Uncommon     | <1%          | <1%         |
| Blood and lymphatic system                       |              |              |             |
| disorders                                        |              |              |             |
| Neutropenia a                                    | Very Common  | 43%          | 37%         |
| Thrombocytopenia a                               | Very Common  | 31%          | 18%         |
| Anaemia a                                        | Very Common  | 27%          | 11%         |
| Lymphopenia a                                    | Very Common  | 13%          | 10%         |
| Leukopenia a                                     | Very Common  | 11%          | 6%          |
| Immune system disorders                          |              |              |             |
| Anaphylactic reaction b Hypogammaglobulinaemia a | Rare Common  | 3%           | <1% #       |
| Metabolism and nutrition                         |              |              |             |
| disorders                                        |              |              |             |
| Decreased appetite                               | Very Common  | 10%          | <1%         |
| Hyperglycaemia                                   | Common       | 6%           | 3%          |
| Hypocalcaemia                                    | Common       | 6%           | 1%          |
| Dehydration                                      | Common       | 2%           | 1% #        |
| Psychiatric disorders                            |              |              |             |
| Insomnia                                         | Very Common  | 16%          | 1% #        |
| Nervous system disorders                         |              |              |             |
| Peripheral sensory neuropathy                    | Very Common  | 29%          | 3%          |
| Headache                                         | Very Common  | 10%          | <1% #       |
| Dizziness                                        | Common       | 9%           | <1% #       |
| Paraesthesia                                     | Common       | 9%           | <1%         |
| Syncope                                          | Common       | 3%           | 2% #        |
| Cardiac disorders                                |              |              |             |
| Atrial fibrillation                              | Common       | 3%           | 1%          |
| Vascular disorders Hypertension a                | Common       | 9%           | 4%          |
| Respiratory, thoracic and                        |              |              |             |
| mediastinal disorders                            |              |              |             |
| Cough a                                          | Very Common  | 22%          | <1% #       |
| Dyspnoea a                                       | Very Common  | 18%          | 2%          |
| Pulmonary oedema a                               | Common       | 1%           | <1%         |
| Gastrointestinal disorders                       |              |              |             |
| Diarrhoea                                        | Very Common  | 32%          | 4%          |
| Constipation                                     | Very Common  | 28%          | 1%          |
| Nausea                                           | Very Common  | 22%          | 1% #        |
| Vomiting                                         | Very Common  | 13%          | 1% #        |
| Pancreatitis a                                   | Common       | 1%           | <1%         |
| Skin and subcutaneous tissue                     |              |              |             |
| disorders                                        |              |              |             |
| Rash                                             | Very Common  | 12%          | 1% #        |
| Pruritus                                         | Common       | 6%           | <1% #       |
| Musculoskeletal and                              |              |              |             |
| connective tissue disorders                      |              |              |             |

<div style=\"page-break-after: always\"></div>

|                                                      | Any Grades   | Any Grades   | Grade 3-4   |
|------------------------------------------------------|--------------|--------------|-------------|
| Back pain                                            | Very Common  | 17%          | 2%          |
| Arthralgia                                           | Very Common  | 13%          | 1%          |
| Muscle spasms                                        | Very Common  | 12%          | <1% #       |
| Musculoskeletal chest pain                           | Common       | 6%           | <1% #       |
| General disorders and administration site conditions |              |              |             |
| Fatigue                                              | Very Common  | 23%          | 3%          |
| Oedema peripheral a                                  | Very Common  | 23%          | 1%          |
| Pyrexia                                              | Very Common  | 22%          | 1%          |
| Asthenia                                             | Very Common  | 19%          | 2%          |
| Chills                                               | Common       | 8%           | <1% #       |
| Injection site reactions d,f                         | Common       | 7%           | 0           |
| Injury, poisoning and procedural complications       |              |              |             |
| Infusion related reactions c Daratumumab IV e        | Very Common  | 39%          | 5%          |
| Daratumumab SC f                                     | Common       | 8%           | 1%          |

#  No Grade 4.

a Indicates a grouping of terms.

b Based on postmarketing adverse reactions.

c Infusion related reactions includes terms determined by investigators as related to infusion/injection of daratumumab.

d Injection site reactions includes terms determined by investigators as related to injection of daratumumab.

e Frequency based on daratumumab IV studies only (N=2324).

f Frequency based on daratumumab SC studies only (N=1183).

g Frequency based on MMY3014 study only (N=351) due to the onset of the pandemic during the study.

Note: Based on 3507 multiple myeloma and AL amyloidosis patients treated with daratumumab IV or daratumumab SC (daratumumab + rHuPH20).

Note: Studies included are AMY3001, MMY1001, MMY1002, MMY1004, MMY1008, MMY2002, MMY2040, MMY3003, MMY3004, MMY3006, MMY3007, MMY3008, MMY3012, MMY3013, MMY3014, GEN501, GEN503

## Serious adverse event/deaths

Serious Adverse Events and Serious Adverse Events reported in participants with at least a 2% greater frequency in D-VRd than VRd in Study MMY3014 are summarised in Table 23 and Table 24 respectively.

Table 23. Treatment-emergent Serious Adverse Events by System Organ Class and Preferred Term (at Least 2% in Either VRd or D-VRd); Safety Analysis Set (Study MMY3014)

|                                                 | VRd         | D-VRd       |
|-------------------------------------------------|-------------|-------------|
| Analysis set: safety                            | 347         | 351         |
| Total number of subjects with serious TEAE      | 171 (49.3%) | 200 (57.0%) |
| MedDRA System Organ Class / Preferred Term      |             |             |
| Infections and infestations                     | 95 (27.4%)  | 123 (35.0%) |
| Pneumonia                                       | 21 (6.1%)   | 40 (11.4%)  |
| COVID-19                                        | 6 (1.7%)    | 13 (3.7%)   |
| COVID-19 pneumonia                              | 5 (1.4%)    | 11 (3.1%)   |
| Lower respiratory tract infection               | 3 (0.9%)    | 9 (2.6%)    |
| Sepsis                                          | 9 (2.6%)    | 7 (2.0%)    |
| Upper respiratory tract infection               | 8 (2.3%)    | 7 (2.0%)    |
| Blood and lymphatic system disorders            | 18 (5.2%)   | 24 (6.8%)   |
| Febrile neutropenia                             | 16 (4.6%)   | 16 (4.6%)   |
| Gastrointestinal disorders                      | 23 (6.6%)   | 23 (6.6%)   |
| Diarrhoea                                       | 9 (2.6%)    | 7 (2.0%)    |
| Respiratory, thoracic and mediastinal disorders | 12 (3.5%)   | 23 (6.6%)   |
| Pulmonary embolism                              | 5 (1.4%)    | 9 (2.6%)    |

<div style=\"page-break-after: always\"></div>

|                                                                     | VRd       | D-VRd     |
|---------------------------------------------------------------------|-----------|-----------|
| Cardiac disorders                                                   | 12 (3.5%) | 21 (6.0%) |
| Atrial fibrillation                                                 | 2 (0.6%)  | 9 (2.6%)  |
| Nervous system disorders                                            | 13 (3.7%) | 19 (5.4%) |
| General disorders and administration site conditions                | 21 (6.1%) | 17 (4.8%) |
| Pyrexia                                                             | 16 (4.6%) | 13 (3.7%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 13 (3.7%) | 15 (4.3%) |
| Injury, poisoning and procedural complications                      | 12 (3.5%) | 13 (3.7%) |
| Vascular disorders                                                  | 10 (2.9%) | 13 (3.7%) |
| Hepatobiliary disorders                                             | 4 (1.2%)  | 12 (3.4%) |
| Musculoskeletal and connective tissue disorders                     | 7 (2.0%)  | 10 (2.8%) |
| Metabolism and nutrition disorders                                  | 10 (2.9%) | 8 (2.3%)  |

Key: VRd = bortezomib (VELCADE) + lenalidomide + dexamethasone; D-VRd = daratumumab + bortezomib (VELCADE) + lenalidomide + dexamethasone.

Key: TEAE = treatment-emergent adverse event.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. Percentages are calculated with the number of subjects in each group as denominator. Note: Adverse events are coded using MedDRA version 26.0.

Table 24. Serious Adverse Events Reported in Participants With at Least a 2% Greater Frequency in DVRd than VRd (Study MMY3014)

|                                         | VRd        | VRd      | VRd      | VRd     | D-VRd      | D-VRd    | D-VRd    | D-VRd   |
|-----------------------------------------|------------|----------|----------|---------|------------|----------|----------|---------|
|                                         | Any Grade  | Grade 3  | Grade 4  | Grade 5 | Any Grade  | Grade 3  | Grade 4  | Grade 5 |
| Analysis set: safety                    | 347        |          |          |         | 351        |          |          |         |
| Infections and infestations Pneumonia a | 27         | 20       | 2        | 2       | 57         | 45       | 3        |         |
| COVID-19 b                              | (10.0%) 10 | (7.5%)   | (0.6%)   | (0.6%)  | (20.3%) 23 | (16.2%)  | (0.9%)   | 0       |
|                                         | (3.7%)     | 0        | 0        | 0       | (8.2%)     | 0        | 0        | 0       |
| Cardiac disorders Atrial fibrillation   | 2 (0.7%)   | 1 (0.4%) | 1 (0.3%) | 0       | 9 (3.2%)   | 6 (2.2%) | 1 (0.3%) | 0       |

Key:  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  =  daratumumab  +  bortezomib (VELCADE) + lenalidomide + dexamethasone

- a Pneumonia  includes  atypical  pneumonia,  bronchopneumonia,  bronchopulmonary  aspergillosis,  idiopathic interstitial pneumonia, lobar pneumonia, lower respiratory tract infection, lung infection, pneumocystis jirovecii infection, pneumocystis jirovecii pneumonia, pneumonia, pneumonia aspiration, pneumonia bacterial, pneumonia  haemophilus,  pneumonia  influenzal,  pneumonia  klebsiella,  pneumonia  legionella,  pneumonia parainfluenzae viral, pneumonia pneumococcal, pneumonia pseudomonal, pneumonia respiratory syncytial viral, pneumonia staphylococcal, pneumonia streptococcal, pneumonia viral, and pulmonary mycosis.

b COVID-19 includes COVID-19, and COVID-19 pneumonia.

Note: Denominator is based on the number of randomized subjects in the safety analysis set. A 2% difference is determined by first rounding to the nearest whole number (the convention used for ADR determination). Adverse events are reported using MedDRA version 26.0

The incidence of treatment-emergent SAEs was lower in the D-VRd treatment group (46.5%) compared with the VRd treatment group (52.0%) in the GRIFFIN study. The most common (≥5%) treatment emergent SAEs in the D-VRd and VRd treatment groups, respectively, were Pneumonia (15.2%; 13.7%) and Pyrexia (11.1%; 9.8%).

<div style=\"page-break-after: always\"></div>

Treatment-emergent SAEs were reported in 28.4% of participants in the D VRd cohort of the PLEIADES study. The only treatmentemergent SAE reported by ≥5% of participants was Pyrexia in the D VRd cohort (6.0%).

## Deaths

At  the  time  of  the  CCO  (01 August 2023),  a  total  of  34 (9.7%)  participants  in  the  D-VRd  arm  and 43 (12.4%) participants in the VRd  arm of the safety analysis set in Study  MMY3014 had died. An additional participant in the VRd arm died prior to receiving study treatment and therefore was not included in the safety analysis set but was included in the ITT analysis set used for OS analysis. The primary  causes  of  death  were  either  disease  progression  (D-VRd:  4.6%;  VRd:  5.5%)  or  AEs (D-VRd: 4.3%;  VRd: 5.5%).  The  latter  included  5  deaths  due  to  COVID-19  AEs  (D-VRd: 4 [1.1%]; VRd: 1 [0.3%]). In addition, there were 2 deaths due to COVID-19 in the VRd arm classified under Other causes, because these events occurred outside of the TEAE reporting period. Of the 34 total deaths due to AEs, 29 were due to TEAEs and 5 were due to serious events not classified as TEAEs as they occurred outside of the TEAE reporting period.

The proportion of participants who died within 30 days of the last dose of study treatment was lower in the D-VRd arm compared with the VRd arm (D-VRd: 2.6%; VRd: 4.0%). Early deaths (occurring within 60 days of the first treatment) were reported for 1 (0.3%) participant in the D-VRd arm and 4 (1.2%) participants in the VRd arm. The primary causes of all 5 early deaths were AEs.

TEAEs with an outcome of death were similar in both treatment arms (D-VRd: 3.7%; VRd: 4.6%). TEAEs with an outcome of death reported for ≥2 participants were COVID 19, COVID -19 pneumonia, and Sepsis (2 [0.6%] each) in the D-VRd arm, and Sepsis and Septic shock (3 [0.9%] each), and Cardiac arrest and Myocardial infarction (2 [0.6%] each) in the VRd arm.

In  the  GRIFFIN  study,  a  total  of  14  (7%)  randomised  participants  died  (D-VRd:  7  [7.1%];  VRd:  7 [6.9%]).  In  the  D-VRd  treatment  group,  5  (5.1%)  participants  died  due  to  PD  after  treatment discontinuation, 1 (1%) participant died due to a TEAE of Pneumonia (bronchopneumonia), and 1 (1%) participant died outside the TEAE reporting period. In the VRd treatment group, 4 (3.9%) participants died due to PD after treatment discontinuation, 1 (1%) participant had a TEAE of death of unknown cause, and 2 (2.0%) participants died outside the TEAE reporting period.

One (1.5%) participant in the D-VRd cohort of the PLEIADES study died due to a TEAE of Respiratory failure considered unrelated to treatment.

## Laboratory findings

Haematological abnormalities were reported for most participants in Study MMY3014, consistent with the incidence of TEAEs in the SOC of Blood and Lymphatic Disorders. Grade 3 and 4 haematology values (i.e., low WBC, low platelets, low neutrophils, low lymphocytes, and low haemoglobin) were reported at higher rates in the D-VRd arm compared with the VRd arm.

The most common Grade 3 or 4 hematologic abnormalities for both treatment arms were low neutrophils and low lymphocytes. There were no Grade 4 low haemoglobin values reported in either treatment arm.

Overall, the chemistry values were consistent between treatment arms. There were no Grade 3 or 4 chemistry laboratory abnormalities reported at a frequency &gt;10% in either treatment arm.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Adverse events analysis by age group is summarised in Table 25.

Table 25. Summary of adverse events by age group (Study MMY3014)

| MedDRA Terms                                                  | Age <50 number (%) N = 53   | Age 50 - <65 number (%) N = 205   | Age 65+ number (%) N= 93   |
|---------------------------------------------------------------|-----------------------------|-----------------------------------|----------------------------|
| Total AEs                                                     | 52 (98.1%)                  | 204 (99.5%)                       | 93 (100.0%)                |
| Serious AEs - Total                                           | 23 (43.4%)                  | 112 (54.6%)                       | 65 (69.9%)                 |
| Fatal                                                         | 0                           | 8 (3.9%)                          | 5 (5.4%)                   |
| Hospitalization/prolong existing hospitalization              | 20 (37.7%)                  | 109 (53.2%)                       | 59 (63.4%)                 |
| Life-threatening                                              | 1 (1.9%)                    | 16 (7.8%)                         | 12 (12.9%)                 |
| Disability/incapacity                                         | 0                           | 0                                 | 1(1.1%)                    |
| Other (medically significant)                                 | 3 (5.7%)                    | 18 (8.8%)                         | 12 (12.9%)                 |
| AEs leading to drop-out a                                     | 2 (3.8%)                    | 17 (8.3%)                         | 12 (12.9%)                 |
| Psychiatric disorders                                         | 19 (35.8%)                  | 78 (38.0%)                        | 35 (37.6%)                 |
| Nervous system disorders                                      | 32 (60.4%)                  | 151 (73.7%)                       | 79 (84.9%)                 |
| Accidents and injuries b                                      | 9 (17.0%)                   | 36 (17.6%)                        | 19 (20.4%)                 |
| Cardiac disorders                                             | 5 (9.4%)                    | 37 (18.0%)                        | 18 (19.4%)                 |
| Vascular disorders                                            | 7 (13.2%)                   | 55 (26.8%)                        | 38 (40.9%)                 |
| Cerebrovascular disorders c                                   | 0                           | 6 (2.9%)                          | 3 (3.2%)                   |
| Infections and infestations                                   | 43 (81.1%)                  | 180 (87.8%)                       | 82 (88.2%)                 |
| Anticholinergic syndrome d                                    | 0                           | 0                                 | 0                          |
| Quality of life decreased e                                   | 0                           | 0                                 | 0                          |
| Sum of postural hypotension, falls, black outs,               | 6 (11.3%)                   | 39 (19.0%)                        | 29 (31.2%)                 |
| syncope, dizziness, ataxia, fractures Orthostatic hypotension | 0                           | 2 (1.0%)                          | 5 (5.4%)                   |
| Falls                                                         | 1 (1.9%)                    | 4 (2.0%)                          | 3 (3.2%)                   |
| Loss of consciousness/Syncope                                 | 2 (3.8%)                    | 4 (2.0%)                          | 7 (7.5%)                   |
| Dizziness f                                                   | 0                           | 17 (8.3%)                         | 11 (11.8%)                 |
| Ataxia g                                                      | 0                           | 0                                 | 1 (1.1%)                   |
| Fractures                                                     | 4 (7.5%)                    | 23 (11.2%)                        | 9 (9.7%)                   |
| <other AE appearing more frequently in older                  |                             |                                   |                            |
| patients> h                                                   |                             |                                   |                            |
| Bronchitis                                                    | 8 (15.1%)                   | 38 (18.5%)                        | 22 (23.7%)                 |
| Neutropenia                                                   | 31 (58.5%)                  | 149 (72.7%)                       | 63 (67.7%)                 |
| Thrombocytopenia                                              | 19 (35.8%)                  | 99 (48.3%)                        | 52 (55.9%)                 |
| Anaemia                                                       | 7 (13.2%)                   | 50 (24.4%)                        | 21 (22.6%)                 |
| Diarrhoea                                                     | 27 (50.9%)                  | 134 (65.4%)                       | 53 (57.0%)                 |
| Constipation                                                  | 11 (20.8%)                  | 64 (31.2%)                        | 44 (47.3%)                 |
| Nausea                                                        | 8 (15.1%)                   | 39 (19.0%)                        | 24 (25.8%)                 |
| Vomiting                                                      | 2 (3.8%)                    | 21 (10.2%)                        | 15 (16.1%)                 |
| Abdominal pain                                                | 2 (3.8%)                    | 16 (7.8%)                         | 13 (14.0%)                 |
| Asthenia                                                      | 10 (18.9%)                  | 61 (29.8%)                        | 23 (24.7%)                 |
| Oedema peripheral                                             | 4 (7.5%)                    | 37 (18.0%)                        | 31 (33.3%)                 |
| Peripheral sensory neuropathy                                 | 23 (43.4%)                  | 111 (54.1%)                       | 54 (58.1%)                 |
| Paraesthesia                                                  | 4 (7.5%)                    | 29 (14.1%)                        | 13 (14.0%)                 |
| Dizziness                                                     | 0                           | 17 (8.3%)                         | 10 (10.8%)                 |
| Back pain                                                     | 7 (13.2%)                   | 45 (22.0%)                        | 28 (30.1%)                 |
| Muscle spasms                                                 | 6 (11.3%)                   | 41 (20.0%)                        | 20 (21.5%)                 |
| Arthralgia                                                    | 6 (11.3%)                   | 38 (18.5%)                        | 18 (19.4%)                 |
| Pain in extremity                                             | 7 (13.2%)                   | 17 (8.3%)                         | 16 (17.2%)                 |
| Rash                                                          | 12 (22.6%)                  | 44 (21.5%)                        | 26 (28.0%)                 |
| Pruritus                                                      | 3 (5.7%)                    | 13 (6.3%)                         | 10 (10.8%)                 |
| Dyspnoea                                                      | 4 (7.5%)                    | 20 (9.8%)                         | 13 (14.0%)                 |

<div style=\"page-break-after: always\"></div>

| MedDRA Terms                         | Age <50 number (%) N = 53   | Age 50 - <65 number (%) N = 205   | Age 65+ number (%) N= 93   |
|--------------------------------------|-----------------------------|-----------------------------------|----------------------------|
| Decreased appetite                   | 0                           | 20 (9.8%)                         | 10 (10.8%)                 |
| Alanine aminotransferase increased   | 14 (26.4%)                  | 26 (12.7%)                        | 17 (18.3%)                 |
| Aspartate aminotransferase increased | 8 (15.1%)                   | 10 (4.9%)                         | 10 (10.8%)                 |
| Hypertension                         | 3 (5.7%)                    | 16 (7.8%)                         | 11 (11.8%)                 |
| Cataract                             | 0                           | 6 (2.9%)                          | 10 (10.8%)                 |

Key: AE=adverse event; MedDRA=medical dictionary for regulatory activities; TEAE=treatmentemergent adverse event a  AEs leading to study treatment discontinuation

b   Accidents and injuries = SMQ Accident and Injuries narrow scope term c   Cerebrovascular disorders = SMQ central nervous system vascular disorders narrow scope terms

d  Anticholinergic syndrome = SMQ anticholinergic syndrome narrow scope terms e  Includes the PTs: impaired quality of life; quality of life decreased

f   Includes  the  PTs:  dizziness/dizziness  postural/dizziness  exertional/persistent  postural-perceptual dizziness g  Includes the PTs: ataxia/autoimmune cerebellar ataxia/cerebral ataxia/vestibular ataxia

h Defined as PTs with incidence ≥10% in age &gt;65 subgroup in D -VRd arm and ≥5% higher than either of the other age subgroups

## Sex

The overall incidence of TEAEs was comparable between male and female participants in both treatment arms in study MMY3014. The incidence of Grade 3 or 4 TEAEs was higher in females compared with males in both treatment arms (D-VRd: males, 89.5%; females, 94.4%; VRd: males, 84.7%; females, 86.9%). The incidence of SAEs was higher in males compared with females in both treatment arms (DVRd: males, 59.3%; females, 53.5%; VRd: males, 54.0%; females, 42.8%).

## Race

Interpretation of the subgroup analysis by race is limited due to the small number of enrolled participants from racial groups other than white in study MMY3014.

## Renal Function

Interpretation of the subgroup analysis by baseline renal function is limited due to the small number of participants enrolled in the &lt;60 mL/min subgroup compared with the 60 to &lt;90 mL/min and ≥90 mL/min subgroups in both treatment arms.

There was a higher incidence of SAEs in the &lt;60 mL/min subgroup compared with the other subgroups in both treatment arms (DVRd: &lt;60 mL/min, 74.2%; 60 to &lt;90 mL/min, 53.4%; ≥90 mL/min, 56.9%; VRd: &lt;60 mL/min, 55.6%; 60 to &lt;90 mL/min, 43.9%; ≥90 mL/min, 52. 5%).

## Hepatic Function

Interpretation of the subgroup analysis by baseline hepatic function is limited due to the small number of participants with impaired hepatic function enrolled in the study.

## Body Weight

The overall incidence of TEAEs was comparable across the weight subgroups for both treatment arms. Participants in the lowest body weight subgroup (≤65 kg) had a higher incidence of Neutropenia and Febrile neutropenia compared with the other subgroups in the D-VRd arm. In the VRd arm, the incidence of Neutropenia and Febrile neutropenia was higher in the &gt;65 to 85 kg and &gt;85 kg body

<div style=\"page-break-after: always\"></div>

weight subgroups, respectively, compared with the other subgroups. However, the incidences of Infections and Infestations, including overall TEAEs, Grade 3 or 4 TEAEs, and SAEs were lower.

## Safety related to drug-drug interactions and other interactions

No dedicated drug-drug interaction studies were performed for daratumumab SC.

## Discontinuation due to adverse events

## Adverse Events Leading to Discontinuation of All Study Treatment

Table 26. Treatment-emergent Adverse Events Leading to All Treatment Discontinuation by System Organ Class, Preferred Term and Grade 3 or 4; Safety Analysis Set (Study MMY3014)

|                                                                  | VRd        | VRd          | D-VRd     | D-VRd        |
|------------------------------------------------------------------|------------|--------------|-----------|--------------|
|                                                                  | Any Grade  | Grade 3 or 4 | Any Grade | Grade 3 or 4 |
| Analysis set: safety                                             | 347        |              | 351       |              |
| Total number of subjects with TEAE                               |            |              |           |              |
| leading to all treatment discontinuation a                       | 74 (21.3%) | 40 (11.5%)   | 31 (8.8%) | 29 (8.3%)    |
| MedDRA System Organ Class/ Preferred                             |            |              |           |              |
| Term Neoplasms benign, malignant and unspecified (incl cysts and |            |              |           |              |
| polyps)                                                          | 11 (3.2%)  | 10 (2.9%)    | 12 (3.4%) | 12 (3.4%)    |
| Myelodysplastic syndrome                                         | 2 (0.6%)   | 2 (0.6%)     | 4 (1.1%)  | 4 (1.1%)     |
| Acute myeloid leukaemia                                          | 2 (0.6%)   | 2 (0.6%)     | 2 (0.6%)  | 2 (0.6%)     |
| Acute lymphocytic leukaemia                                      | 2 (0.6%)   | 1 (0.3%)     | 1 (0.3%)  | 1 (0.3%)     |
| Angioimmunoblastic T-cell lymphoma                               | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Cutaneous T-cell lymphoma                                        | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Prostate cancer                                                  | 1 (0.3%)   | 1 (0.3%)     | 1 (0.3%)  | 1 (0.3%)     |
| Rectal adenocarcinoma                                            | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Squamous cell carcinoma                                          | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Adenocarcinoma of colon                                          | 1 (0.3%)   | 1 (0.3%)     | 0         | 0            |
| Breast neoplasm                                                  | 1 (0.3%)   | 1 (0.3%)     | 0         | 0            |
| Malignant melanoma                                               | 1 (0.3%)   | 1 (0.3%)     | 0         | 0            |
| Phaeochromocytoma                                                | 1 (0.3%)   | 1 (0.3%)     | 0         | 0            |
| Infections and infestations                                      | 7 (2.0%)   | 2 (0.6%)     | 8 (2.3%)  | 6 (1.7%)     |
| COVID-19 pneumonia                                               | 1 (0.3%)   | 1 (0.3%)     | 1 (0.3%)  | 1 (0.3%)     |
| Clostridium difficile colitis                                    | 0          | 0            | 1 (0.3%)  | 0            |
| Pneumonia                                                        | 4 (1.2%)   | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Pneumonia legionella                                             | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Pneumonia pneumococcal                                           | 0          | 0            | 1 (0.3%)  | 0            |
| Sepsis                                                           | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Septic shock                                                     | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| Urosepsis                                                        | 0          | 0            | 1 (0.3%)  | 1 (0.3%)     |
| COVID-19                                                         | 1 (0.3%)   | 0            | 0         | 0            |
| Infection                                                        | 1 (0.3%)   | 0            | 0         | 0            |
| Meningitis cryptococcal                                          | 1 (0.3%)   | 1 (0.3%)     | 0         | 0            |
| General disorders and                                            |            |              |           |              |
| administration site conditions                                   | 6 (1.7%)   | 1 (0.3%)     | 5 (1.4%)  | 2 (0.6%)     |
| Asthenia                                                         | 0          | 0            | 3 (0.9%)  | 0            |
| Fatigue                                                          | 3 (0.9%)   | 0            | 1 (0.3%)  | 1 (0.3%)     |
| General physical health deterioration                            | 1 (0.3%)   | 1 (0.3%)     | 1 (0.3%)  | 1 (0.3%)     |
| Generalised oedema                                               | 1 (0.3%)   | 0            | 0         | 0            |
| Malaise                                                          | 1 (0.3%)   | 0            | 0         | 0            |

<div style=\"page-break-after: always\"></div>

|                                                               | VRd        | VRd          | D-VRd             | D-VRd             |
|---------------------------------------------------------------|------------|--------------|-------------------|-------------------|
|                                                               | Any Grade  | Grade 3 or 4 | Any Grade         | Grade 3 or 4      |
| Nervous system disorders Chronic inflammatory demyelinating   | 12 (3.5%)  | 2 (0.6%)     | 5 (1.4%)          | 3 (0.9%)          |
| polyradiculoneuropathy Headache                               | 0          | 0            | 1 (0.3%)          | 1 (0.3%)          |
|                                                               | 0          | 0            | 1 (0.3%)          | 0                 |
| Hypoxic-ischaemic encephalopathy Intensive care unit acquired | 0          | 0            | 1 (0.3%)          | 0                 |
| weakness                                                      | 0 0        | 0 0          | 1 (0.3%) 1 (0.3%) | 1 (0.3%) 1 (0.3%) |
| Subarachnoid haemorrhage Cerebrovascular accident             | 1 (0.3%)   | 0            | 0                 | 0                 |
| Haemorrhage intracranial                                      | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Neuralgia                                                     | 1 (0.3%)   | 0            | 0                 | 0                 |
| Neuropathy peripheral                                         | 1 (0.3%)   | 0            | 0                 | 0                 |
| Peripheral motor neuropathy                                   | 2 (0.6%)   | 0            | 0                 | 0                 |
| Peripheral sensory neuropathy                                 | 6 (1.7%)   | 1 (0.3%)     | 0                 | 0                 |
| Blood and lymphatic system                                    |            |              |                   |                   |
| disorders                                                     | 14 (4.0%)  | 10 (2.9%)    | 2 (0.6%)          | 2 (0.6%)          |
| Thrombocytopenia                                              | 6 (1.7%)   | 4 (1.2%)     | 2 (0.6%)          | 2 (0.6%)          |
| Anaemia                                                       | 2 (0.6%)   | 1 (0.3%)     | 0                 | 0                 |
| Febrile neutropenia                                           | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Immune thrombocytopenia                                       | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Leukopenia                                                    | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Neutropenia                                                   | 9 (2.6%)   | 7 (2.0%)     | 0                 | 0                 |
| Metabolism and nutrition disorders                            | 1 (0.3%)   | 1 (0.3%)     | 2 (0.6%)          | 0                 |
| Decreased appetite                                            | 0          | 0            | 2 (0.6%)          | 0                 |
| Hypoglycaemia                                                 | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Musculoskeletal and connective                                |            |              |                   |                   |
| tissue disorders                                              | 2 (0.6%)   | 0            | 2 (0.6%)          | 2 (0.6%)          |
| Muscular weakness                                             | 0          | 0            | 1 (0.3%)          | 1 (0.3%)          |
| Soft tissue necrosis                                          | 0          | 0            | 1 (0.3%)          | 1 (0.3%)          |
| Muscle spasms                                                 | 2 (0.6%)   | 0            | 0                 | 0                 |
| Vascular disorders                                            | 2 (0.6%)   | 1 (0.3%)     | 2 (0.6%)          | 1 (0.3%)          |
| Deep vein thrombosis                                          | 1 (0.3%)   | 1 (0.3%)     | 1 (0.3%)          | 0                 |
| Vasculitis                                                    | 0          | 0            | 1 (0.3%)          | 1 (0.3%)          |
| Hot flush                                                     | 1 (0.3%)   | 0            | 0 (0.3%)          | 0                 |
| Gastrointestinal disorders Colitis                            | 9 (2.6%) 0 | 3 (0.9%) 0   | 1 1 (0.3%)        | 1 (0.3%) 1 (0.3%) |
| Diarrhoea                                                     | 8 (2.3%)   | 3 (0.9%)     | 0                 | 0                 |
| Gastrointestinal toxicity                                     | 1 (0.3%)   | 0            | 0                 | 0                 |
| Injury, poisoning and procedural                              |            |              |                   |                   |
| complications                                                 | 0          | 0            | 1 (0.3%)          | 1 (0.3%)          |
| Femur fracture                                                | 0          | 0            | 1 (0.3%)          | 1 (0.3%)          |
| Psychiatric disorders                                         | 0          | 0            | 1 (0.3%)          | 0                 |
| Depressive symptom                                            | 0          | 0            | 1 (0.3%)          | 0                 |
| Renal and urinary disorders                                   | 1 (0.3%)   | 1 (0.3%)     | 1 (0.3%)          | 1 (0.3%)          |
| Acute kidney injury                                           | 1 (0.3%)   | 1 (0.3%)     | 1 (0.3%)          | 1 (0.3%)          |
| Skin and subcutaneous tissue                                  |            |              |                   |                   |
| disorders                                                     | 4 (1.2%)   | 3 (0.9%)     | 1 (0.3%)          | 1 (0.3%)          |
| Toxic skin eruption                                           | 0          | 0            | 1 (0.3%)          | 1 (0.3%)          |
| Eczema                                                        | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Rash maculo-papular                                           | 1 (0.3%)   | 0            | 0                 | 0                 |
| Stevens-Johnson syndrome                                      | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Urticaria                                                     | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Cardiac disorders                                             | 3 (0.9%)   | 2 (0.6%)     | 0                 | 0                 |
| Cardiac amyloidosis                                           | 1 (0.3%)   | 0            | 0                 | 0                 |
| Cardiac failure                                               | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Myocardial infarction                                         | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |
| Hepatobiliary disorders                                       | 1 (0.3%)   | 1 (0.3%)     | 0                 | 0                 |

<div style=\"page-break-after: always\"></div>

|                                                 | VRd       | VRd          | D-VRd     | D-VRd        |
|-------------------------------------------------|-----------|--------------|-----------|--------------|
|                                                 | Any Grade | Grade 3 or 4 | Any Grade | Grade 3 or 4 |
| Hepatotoxicity                                  | 1 (0.3%)  | 1 (0.3%)     | 0         | 0            |
| Immune system disorders                         | 1 (0.3%)  | 0            | 0         | 0            |
| Drug hypersensitivity                           | 1 (0.3%)  | 0            | 0         | 0            |
| Investigations                                  | 1 (0.3%)  | 0            | 0         | 0            |
| Alanine aminotransferase increased              | 1 (0.3%)  | 0            | 0         | 0            |
| Respiratory, thoracic and mediastinal disorders | 4 (1.2%)  | 3 (0.9%)     | 0         | 0            |
| Interstitial lung disease                       | 1 (0.3%)  | 1 (0.3%)     | 0         | 0            |
| Lung disorder                                   | 1 (0.3%)  | 0            | 0         | 0            |
| Pneumonitis                                     | 1 (0.3%)  | 1 (0.3%)     | 0         | 0            |
| Pulmonary embolism                              | 1 (0.3%)  | 1 (0.3%)     | 0         | 0            |

Key:  VRd  =  bortezomib  (VELCADE)  +  lenalidomide  +  dexamethasone;  D-VRd  =  daratumumab  +  bortezomib (VELCADE) + lenalidomide + dexamethasone.

Key: TEAE = treatment-emergent adverse event.

- a Includes  those  subjects  indicated  as  having  discontinued treatment due  to  an  adverse  event on  the end  of treatment CRF page.

Note:  Subjects  are  counted  only  once  for  any  given  event,  regardless  of  the  number  of  times  they  actually experienced the event. Percentages are calculated with the number of subjects in each group as denominator. Note: Adverse events are coded using MedDRA version 26.0.

## Adverse Events Leading to Discontinuation of Any Component of Study Treatment

The rate of TEAEs leading to discontinuation of any component of study treatment (i.e., daratumumab, bortezomib, lenalidomide, or dexamethasone) was similar in both treatment arms (D-VRd: 33.0%; VRd: 30.0%).

The  most  common  TEAEs  leading  to  discontinuation  of  any  component  of  study  treatment  with  a frequency ≥2% in either treatment arm were:

- Peripheral sensory neuropathy (D-VRd: 7.1%; VRd: 6.9%)
- Diarrhoea (D-VRd: 4.0%; VRd: 2.6%)
- Neutropenia (D-VRd: 2.3%; VRd: 3.5%)
- Thrombocytopenia (D-VRd: 2.3%; VRd: 2.0%)
- Asthenia (D-VRd: 2.0%; VRd: 0%)

The rate of TEAEs leading to discontinuation of daratumumab was 9.7% (34/351). This included 8.5% of  participants  with  Grade  3  or  4  TEAEs.  TEAEs  resulting  in  discontinuation  of  daratumumab  which occurred in &gt;2 participants were Thrombocytopenia (3 [0.9%]) and COVID 19 pneumonia (4 [1.1%]).

The majority of TEAEs leading to discontinuation of daratumumab occurred during maintenance (25 out of 34 discontinuations).

The rate of TEAEs leading to discontinuation of bortezomib was similar in both treatment arms (D-VRd: 12.3%; VRd: 11.8%). The majority of TEAEs leading to discontinuation of bortezomib occurred during induction in both treatment arms.

The rate of TEAEs leading to discontinuation of lenalidomide was high in both treatment arms (D-VRd: 27.1%  (95/351);  VRd:  23.3%  (81/347)).  The  majority  of  TEAEs  leading  to  discontinuation  of lenalidomide occurred during maintenance in both treatment arms.

The rate of TEAEs leading to discontinuation of dexamethasone was similar in both treatment arms (D-VRd: 4.8%; VRd: 6.3%).

<div style=\"page-break-after: always\"></div>

The  incidence  of  TEAEs  leading  to  study  treatment  discontinuation  (i.e., any  component  of  study treatment) was similar between the D-VRd treatment group (29.3%) and the VRd treatment group (29.4%) in the GRIFFIN study. Most of the TEAEs that resulted in study treatment discontinuation were Grade 1 or 2. In the D-VRd treatment group , TEAEs that resulted in discontinuation of &gt;1 participant were Peripheral sensory neuropathy (11.1%), Neuralgia (4.0%), and Neuropathy peripheral, Neutropenia, and Rash (2.0% each).

The incidence of TEAEs leading to discontinuation of any component of study treatment (i.e., daratumumab SC, bortezomib, lenalidomide, dexamethasone/corticosteroids) in the D-VRd cohort in the PLEIADES study was 11.9%. The only TEAEs leading to discontinuation of any component occurring in &gt;1 participant was Peripheral sensory neuropathy (D-VRd: 6.0%). TEAEs leading to daratumumab SC treatment discontinuation occurred in 2 participants (3.0%). Of these, 1 participant (1.5%) had a Grade 3  or  4  event.  There  were  no  TEAEs  leading  to  discontinuation  of  daratumumab  SC  occurring  in &gt;1 participant.

## Post marketing experience

Post-marketing safety information is available for both daratumumab SC and daratumumab IV.

A  cumulative  review  was  performed  for  all  medically  confirmed  spontaneous  cases  (serious  and nonserious) of daratumumab received in the Global Medical Safety (GMS) database through 01 August 2023. A separate cumulative review of cases reporting SC administration was also performed.

Based  on  4,516,014,540  mg  distributed  worldwide  by  the  MAH  from  launch  to  31  July  2023,  the estimated exposure to daratumumab IV is 177,790 person-years.

Based  on  5,900,450,400  mg  distributed  worldwide  by  the  MAH  from  launch  to  31  July  2023,  the estimated exposure to daratumumab SC is 149,001 person-years.

Based on the total 10,416,464,940 mg distributed worldwide by the MAH from launch to 31 July 2023, the estimated exposure to daratumumab IV and SC is 326,791 person-years.

The  cumulative  search  of  the  GMS  database  through  01  August  2023  retrieved  a  total  of  15,531 spontaneous cases. Of these, 1,763 cases were screened as medically unconfirmed cases (1,117) and cases reporting multiple unidentifiable patients (646), therefore resulting in 13,768 spontaneous cases for further analysis. Of the 13,768 cases, for the cases reporting sex, more than half of the cases (55%, 4,695/8,542)  concerned  males  and  where  age  or  age  group  was  reported,  most  concerned  elderly patients  (60.2%;  4,863/8,084).  The  patients'  age  ranged  from  0.1 to  100  years  (mean  age  was 66 years, and the median age was 68 years).

Of the 13,768 cases, the most frequently reported MedDRA SOCs were Injury, poisoning and procedural complications  (30.5%),  General  disorders  and  administration  site  conditions  (14.2%),  Respiratory, thoracic,  and  mediastinal  disorders  (8.3%),  Investigations  (6.8%),  and  Infections  and  Infestations (6.3%).  The  most  common  PTs  were  Off  label  use  (8.6%),  Infusion  related  reaction  (8.1%),  and Intentional product use issue (3.3%). Of the 13,768 cases, 1,918 (13.9%) reported daratumumab SC administration.  Injury,  poisoning  and  procedural  complications  (24.8%),  General  disorders  and administration site conditions (17.3%), and Investigations (7.2%) were the most common SOCs. Off label use (7.2%), Intentional product use issue (4.2%), and Infusion related reaction (3.1%) were the most common PTs.

Of the 13,768 cases, 7,018 were serious. Among these serious cases, the most frequently reported serious PTs (≥ 2% of the reported events) were Plasma cell myeloma (7.4%), Infusion related reaction (7.3%),  Death  (3.2%),  Disease  progression  and  Neutropenia  (3.1%  each),  Pneumonia  (2.6%), Thrombocytopenia (2.4%), and Dyspnoea (2.1%). Of the 7,018 serious cases, 768 (10.9%) reported daratumumab SC administration.  The  most  frequently  reported  serious  PTs  (≥  2%  of  the  reported events) involving SC administration of daratumumab were Neutropenia and Plasma cell myeloma (5.1% each), Thrombocytopenia (3.0%), Infusion related reaction (2.8%), and Pneumonia (2.6%).

<div style=\"page-break-after: always\"></div>

A  total  of  1,047  cases  reported  1,326  events  with  a  fatal  outcome.  Among  these  cases,  the  most frequently reported fatal PTs (≥2% of the reported events) were Death (28.7%), Plasma cell myeloma (9.4%), Disease progression (6.9%), Pneumonia (3.5%), Sepsis (3.5%), COVID-19 (2.9%), and Septic shock  (2.3%).  Of  the  1,047  cases  reporting  fatal  events,  63  (6.0%)  reported  daratumumab  SC administration. Among these 63 cases, the most frequently reported fatal PTs (≥2% of the reported events) were Death (26.5%), Plasma cell myeloma (9.6%), Septic shock (7.2%), Cardio-respiratory arrest and Infusion related reaction (3.6% each), and Cardiac failure, COVID-19, COVID-19 pneumonia, Primary amyloidosis, and Sepsis (2.4% each).

## 2.5.1. Discussion on clinical safety

The safety profile of daratumumab in combination with bortezomib, lenalidomide and dexamethasone in patients with NDMM eligible for ASCT is based on the results from the open-label, randomised, phase 3 study MMY3014. Supportive data from the phase 2 study GRIFFIN who received the same backbone treatment with a slightly different treatment schedule and intravenous administration of daratumumab have also been included. Additionally, safety data from the PLEIADES study where daratumumab was added to four cycles of VRd induction treatment have also been provided.

The adverse event profile of daratumumab in combination with VRd was consistent with the already known safety profile of daratumumab from previous clinical studies. No new ADRs were identified from the submitted data, however, the frequencies of a number of known ADRs, including that for COVID-19 have been updated.

The PT of pulmonary embolism occurred at a higher incidence in the D-VRd arm as compared with the VRd arm (2.6% vs. 1.4%). However, it is acknowledged that multiple myeloma in itself conveys an increased risk of VTEs and that VTEs are a well-established risk with lenalidomide treatment. Additional risk factors for VTEs in patients with multiple myeloma are immobilisation related to bone involvement, kidney injury, diabetes due to glucocorticoid use, and acute infection due to immunosuppression. COVID19 also increases the risk of pulmonary embolism and this also occurred with a higher frequency in the D-VRd arm. Due to these confounding factors the CHMP considered that pulmonary embolism should not be considered a new ADR for daratumumab.

The most clinically important adverse events (all grades, preferred terms) that occurred more frequently reported in the D-VRd arm compared to the VRd arm in study MMY3014 were neutropenia (69.2% vs 58.8%), thrombocytopenia (48.4% vs. 34.3%), diarrhoea (61.0% vs 54.2%), Insomnia (27.1% vs. 17.6%)

and  pneumonia  (18.2%  vs  11.0%).  The  addition  of  daratumumab  to  the  VRd  backbone  and  to lenalidomide  maintenance  led  to  increased  rates  of  airway  infections  and  symptoms,  neutropenia, thrombocytopenia, diarrhoea and insomnia.

Focusing on maximum toxicity grade, the overall incidence of Grade 3 or 4 TEAEs was higher in the DVRd arm compared with the VRd arm (91.5% vs. 85.6%) with largest differences between arms observed for neutropenia (62.1% vs. 51.0%) and thrombocytopenia (29.1% vs. 17.3%). No Grade 3 or 4 TEAEs occurred at a ≥5% higher frequency in the VRd arm compared with the D -VRd arm.

The incidence of treatment-emergent SAEs was higher in the D-VRd arm compared with the VRd arm (D-VRd: 57.0%; VRd: 49.3%), driven by a higher incidence of SAEs during maintenance in the D-VRd arm (D-VRd: 38.8%; VRd: 26.0%). The incidence of SAEs was similar in both treatment arms during induction and consolidation. The most common treatmentemergent SAEs at a ≥2% higher frequency in the D-VRd arm compared with the VRd arm were, Pneumonia (D-VRd: 11.4%; VRd: 6.1%), COVID-19 (D-VRd: 3.7%; VRd: 1.7%), and Atrial fibrillation (D-VRd: 2.6%; VRd: 0.6%). No treatment-emergent SAEs occurred at a ≥2% higher frequency in the VRd arm compared with the D -VRd arm.

A total of 34 participants (9.7%) in the D-VRd arm and 43 participants (12.4%) in the VRd arm had died at the time of the CCO (01 August 2023). The primary causes of death were either AEs (D-VRd: 4.3%;

<div style=\"page-break-after: always\"></div>

VRd: 5.5%) or disease progression (D-VRd: 4.6%; VRd: 5.5%). Of note, deaths within 60 days of first study treatment were reported for 1 (0.3%) participant in the D-VRd arm and 4 (1.2%) participants in the VRd arm. The primary causes of all 5 early deaths were AEs. This suggests that adding daratumumab to VRd does not increase the risk of early death in the induction phase.

The rate of TEAEs leading to discontinuation of all study treatment was lower in the D-VRd arm compared with the VRd arm (D-VRd: 8.8%; VRd: 21.3%). This difference was driven by the higher incidence of TEAEs leading to discontinuation of study treatment (predominantly lenalidomide) during maintenance in the VRd arm (D-VRd: 7.1%; VRd: 19.0%). The participants in the VRd arm only received treatment with  lenalidomide  during  maintenance  therapy,  thus  any  discontinuation  of  lenalidomide  led  to discontinuation of all study drugs. In contrast, in the D-VRd arm, if participants discontinued lenalidomide during maintenance therapy, daratumumab study treatment was not discontinued.

The rate of TEAEs leading to discontinuation of daratumumab was 9.7% (34/351). This included 8.5% of  participants  with  Grade 3  or 4  TEAEs.  TEAEs  resulting  in  discontinuation  of  daratumumab  which occurred in &gt;2 participants were Thrombocytopenia (3 [0.9%]) and COVID -19 pneumonia (4 [1.1%]). The majority of TEAEs leading to discontinuation of daratumumab occurred during maintenance (25 out of 34 discontinuations).

The lack of drug-drug interaction studies for daratumumab was considered acceptable. As an IgG1 қ monoclonal antibody, the biotransformation of daratumumab is expected to be similar to endogenous IgG (i.e., degraded into small peptides and amino acids via catabolic pathways) and subject to similar elimination  pathways  (Tabrizi  2006;  Mascelli  2007).  Renal  excretion  and  hepatic  enzyme-mediated metabolism of intact daratumumab are therefore unlikely to represent major elimination routes. Due to the high affinity to a unique epitope on cluster of differentiation 38, daratumumab is also not anticipated to alter the activity of drug-metabolizing enzymes.  Since there is no overlapping pathway of elimination, no interactions are expected between daratumumab and small molecule drugs including bortezomib, lenalidomide and dexamethasone.

No new safety signals were identified from the cumulative review of post-marketing cases, both overall and separately for daratumumab SC. The cumulative review of the post-marketing spontaneous cases revealed that based on the most common events, SAEs, and fatal events, the post-marketing experience of daratumumab SC is generally consistent with the overall post-marketing experience. The post-marketing experience was consistent with the known safety profile of daratumumab or clinical experience of the population under treatment.

## 2.5.2. Conclusions on clinical safety

Safety findings from the pivotal study MMY3014 in support of this application and the supportive GRIFFIN and PLEIADES studies are consistent with the known safety profile of daratumumab as characterised previously from other clinical studies.

No new ADRs were identified but the frequency of some of these ADRs has been updated based on the totality of the data.  Even though the addition of daratumumab to VRd resulted in slightly more grade 3 and 4 TEAEs and SAEs, this did not lead to more treatment related deaths.

Overall, submitted safety information supports the use of daratumumab in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 10.1 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 10.1 with the following content:

## Safety concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                                                            |
|------------------------------|---------------------------------------------------------------------------------------|
| Important identified risks   | Interference for blood typing (minor antigen) (positive indirect Coombs' test)        |
|                              | Hepatitis B virus reactivation                                                        |
| Important potential risks    | None                                                                                  |
| Missing information          | Use in patients with AL amyloidosis who have pre-existing serious cardiac involvement |

## Pharmacovigilance plan

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                           | Summary of Objectives                                                                                                                                                                                                                                        | Safety Concerns Addressed                                                              | Milestones                                                    | Due Dates                                                     |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                          | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                | Category 3 - Required additional pharmacovigilance activities                          | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| A multicenter prospective study of daratumumab- based therapy in patients with newly diagnosed AL amyloidosis. Ongoing | Primary objective is to further characterize cardiac adverse events in patients with newly diagnosed AL amyloidosis treated with subcutaneous daratumumab-based therapy in terms of the incidence, severity, clinical presentation, management, and outcome. | Use in patients with AL amyloidosis who have pre- existing serious cardiac involvement | Draft Protocol: Interim report: Final report:                 | Aug 2021 2 nd Quarter 2024 1 st Quarter 2026                  |

## Risk minimisation measures

## Summary Table of Risk Minimisation Activities

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                        | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Interference for blood typing (minor antigen) (positive indirect Coombs' test)        | Routine risk minimization measures: • SmPC Section 4.4, which advises that patients should be typed and screened, and phenotyping or genotyping be considered prior to starting daratumumab treatment; • SmPC Sections 4.4, which advises HCPs to notify blood transfusion centers of this interference with indirect antiglobulin tests in the event of a planned transfusion; • SmPC Section 4.4, which recommend that if an emergency transfusion is required, non-cross-matched ABO/RhD compatible RBCs can be given per local blood bank practices; • SmPC Section 4.5, which recommend mitigating daratumumab interference by treating reagent RBCs with DTT to disrupt daratumumab binding or other locally validated methods, and that Kell negative units should be supplied after ruling out or identifying alloantibodies using DTT treated RBCs; • PL Section 2, which instructs patients to inform the person doing the blood test to match blood type that they are receiving treatment with daratumumab. Additional risk minimization measures: • Distribution of educational materials and Patient Alert Cards to HCPs and blood banks as described in the PL, in Annex II, D. |
| Hepatitis B virus reactivation                                                        | Routine risk minimization measures: • SmPC Section 4.8 and PL Section 4; • SmPC Section 4.4 and PL Section 2, which advise HBV screening before initiation of treatment with daratumumab and to monitor for clinical and laboratory signs of HBV reactivation during and for at least 6 months following the end of daratumumab treatment for patients with evidence of positive HBV serology; • SmPC Section 4.4, which advises to manage patients according to current clinical guidelines, and to consider consulting a hepatitis disease expert as clinically indicated; • SmPC Section 4.4, which advises to suspend treatment with daratumumab and to institute appropriate treatment in patients who develop reactivation of HBV while on daratumumab. Resumption of daratumumab treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV; • PL Section 2, which includes a warning to patients with history or current HBV infection; Additional risk minimization measures: • Distribution of a DHPC to HCPs who prescribe daratumumab was issued in the EU member states in June 2019.               |
| Use in patients with AL amyloidosis who have pre-existing serious cardiac involvement | Routine risk minimization measures: • SmPC Section 5.1. Additional risk minimization measures: • None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

Key: AL amyloidosis = light chain amyloidosis; DHPC = Direct Healthcare Professional Communication; DTT = dithiothreitol; HBC = hepatitis B virus; HCP = healthcare professional; PL = package leaflet; RBC = red blood cell; SmPC = Summary of Product Characteristics.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 the SmPC have been updated. The Package Leaflet has been updated accordingly.

In addition, the list of local representatives in the PL has been revised to amend contact details for the representative in Ireland.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable as the currently proposed indication extension, minimal changes have been introduced to the package leaflet and the proposed changes reflect language and a format that is consistent with that in the currently approved leaflet.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The MAH submitted a variation application to extend the indication of Darzalex 1800 mg solution for subcutaneous  injection  to  include  daratumumab  in  combination  with  bortezomib,  lenalidomide  and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

The proposed addition to the existing indication is only for the subcutaneous use of daratumumab.

## 3.1.2. Available therapies and unmet medical need

High-dose chemotherapy with melphalan followed by ASCT is the standard approach for eligible patients. Bortezomib, lenalidomide, and dexamethasone (VRd), along other triplet regimens such as bortezomib, thalidomide, and dexamethasone (VTd) and bortezomib, cyclophosphamide, and dexamethasone (VCd), are amongst the preferred induction regimens recommended by NCCN and ESMO treatment guidelines for the primary therapy of patients with NDMM who are candidates for transplantation.

After  transplant,  some patients are given a further short intense period of treatment to deepen the response obtained with induction therapy, commonly referred to as consolidation therapy. Maintenance therapy is generally administered for a long duration and aims to improve PFS with minimal toxicity and without  impacting  quality  of  life.  Lenalidomide  was  approved  in  the  US  and  Europe  in  2017  as monotherapy for maintenance therapy and is currently considered the standard of care.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

Study MMY3014 (PERSEUS) was a phase 3, randomised, open-label, multicentre study comparing DVRd versus VRd in participants with newly diagnosed MM who were eligible for ASCT. The treatment phase included four elements: Induction treatment, ASCT, consolidation treatment, and maintenance treatment (DR vs. R).

The primary endpoint was PFS defined as time from the date of randomization to the date of PD (assessed by 2011 IMWG criteria) or death. The key secondary endpoints were overall CR or better rate anytime during the study, overall MRD-negativity rate (10 -5 ) achieved at any time during the study, and OS. Participants were randomised in a 1:1 ratio, stratified by ISS Stage I, II, or III disease ( β -2 microglobulin and albumin) and cytogenetics (standard-risk or high-risk, which is defined by the presence of del17p, t[4;14] or t[14;16]).

## 3.2. Favourable effects

At the CCO of 01 August 2023, when the first planned interim analysis was conducted, a total of 153 PFS events (D-VRd: 50/355 (14.1%); VRd: 103/354 (29.1%)) had been observed, with a median followup of 47.51 months (D-VRd: 47.57 months; VRd: 47.38 months). The addition of daratumumab to VRd resulted in a statistically significant improvement in the primary endpoint PFS with a HR=0.42 (95% CI: 0.30, 0.59; 2-sided p &lt;0.0001) compared to VRd alone.

The result for the primary endpoint was supported by the key secondary endpoints, overall CR or better rate  and  MRD-negativity  at  a  10 -5   threshold.  Both  endpoints  favoured  D-VRd  treatment  over  VRd treatment. With a total of 78 deaths (D-VRd: 34; VRd: 44), the median OS was not reached for either treatment arm.

## 3.3. Uncertainties and limitations about favourable effects

The PFS benefit was generally consistent across prespecified subgroups (ISS stage, cytogenetic risk, and baseline ECOG performance score), with the exception of the ≥65 years subgroup. However,  there was an imbalance in the cytogenetic high-risk category (D-VRd 25.5% vs VRD 19.5%) in this subgroup, which may have contributed to the observed HR.

OS data are immature. In addition, it is unlikely that the trial will be able to demonstrate that the PFS benefit shown will translate into OS superiority, since it is likely that many patients randomised to the VRd arm will receive daratumumab in subsequent treatment lines, confounding OS.

The study design does not allow for evaluation of the treatment effect of adding daratumumab to VRd in the induction phase or consolidation phase or to lenalidomide in the maintenance phase respectively, as re-randomisation pre-consolidation or re-randomisation pre-maintenance were not considered. The treatment effect of adding daratumumab to the VRd backbone and to lenalidomide maintenance has to be considered across all treatment phases as a whole.

## 3.4. Unfavourable effects

The most clinically important adverse events (all grades, preferred terms) more frequently reported in the D-VRd arm compared to the VRd arm in study MMY3014 were neutropenia (69.2% vs 58.8%), thrombocytopenia (48.4% vs. 34.3%), diarrhoea (61.0% vs 54.2%), insomnia (27.1% vs. 17.6%) and pneumonia (18.2% vs 11.0%) consistent with the previous available data.

Focusing on maximum toxicity grade, the overall incidence of Grade 3 or 4 TEAEs was higher in the DVRd arm compared with the VRd arm (91.5% vs. 85.6%) with largest differences between arms observed for neutropenia (62.1% vs. 51.0%) and thrombocytopenia (29.1% vs. 17.3%).

<div style=\"page-break-after: always\"></div>

A total of 34 participants (9.7%) in the D-VRd arm and 43 participants (12.4%) in the VRd arm had died at the time of the CCO (01 August 2023). The primary causes of death were either AEs (D-VRd: 4.3%; VRd: 5.5%) or disease progression (D-VRd: 4.6%; VRd: 5.5%). Of note, deaths within 60 days of first study treatment were reported for 1 (0.3%) participant in the D-VRd arm and 4 (1.2%) participants in the VRd arm. The primary causes of all 5 early deaths were AEs.

## 3.5. Uncertainties and limitations about unfavourable effects

The median age of the included patients in the pivotal trial was 60 years, which is well below the average age of patients diagnosed with multiple myeloma (approximately 70 years). A screening period of 28 days before randomisation to treatment excluded patients with NDMM who needed acute or sub-acute anti-myeloma treatment with more than just 40mg x 4 of dexamethasone to alleviate kidney disease, severe  hypercalcemia  or  significant  bone  disease.  Given  these  selection  criteria  selecting  for  a  fit, younger  patient  population  with  low  symptom  burden  from  multiple  myeloma  and  low  levels  of comorbidity, it is likely that AE rates and complications to treatment will be higher outside clinical trial settings than what was observed in study MMY3014.

## 3.6. Effects Table

Table 27 . Effects Table for Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the treatment of NDMM in patients eligible for ASCT (data cut-off: 01 August 2023)

| Effect               | Short description                                                                                        | Unit                 | D-VRd n = 355   | VRd n =354   | Uncertainties / Strength of evidence                                                                                                  | References   |
|----------------------|----------------------------------------------------------------------------------------------------------|----------------------|-----------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Favourable Effects   | Favourable Effects                                                                                       |                      |                 |              |                                                                                                                                       |              |
| PFS                  | Time from randomisati on to first disease progression (according to the IMWG response criteria) or death | N %                  | 50 14.1%        | 103 29.1%    | SoE: PFS: HR 0.42 (95% CI: 0.30, 0.59) CR or better rate: OR 3.13, (95% CI: 2.11, 4.65) MRD negativity 10 -5: OR: 3.40 (95% CI: 2.47, | MMY3014      |
| Unfavourable Effects | Unfavourable Effects                                                                                     | Unfavourable Effects | D-VRd n = 351   | VRd n = 347  |                                                                                                                                       |              |
| Grade 5 AEs          | AEs leading to death                                                                                     | %                    | 4.3             | 5.5          |                                                                                                                                       | MMY3014      |
| Neutropenia          | All Grade 3-4                                                                                            | % %                  | 69.2 62.1       | 58.8 51.0    |                                                                                                                                       | MMY3014      |
| Diarrhoea            | All Grade 3-4                                                                                            | % %                  | 61.0 10.5       | 54.2 7.8     |                                                                                                                                       | MMY3014      |
| Thrombocytopenia     | All Grade 3-4                                                                                            | % %                  | 48.4 29.1       | 34.3 17.3    |                                                                                                                                       | MMY3014      |
| Insomnia             | All Grade 3-4                                                                                            | % %                  | 27.1 2.3        | 17.6 1.7     |                                                                                                                                       | MMY3014      |
| Pneumonia            | All Grade 3-4                                                                                            | % %                  | 18.2 10.5       | 11.0 6.1     |                                                                                                                                       | MMY3014      |

<div style=\"page-break-after: always\"></div>

Abbreviations: D= daratumumab; VRd= bortezomib, lenalidomide and dexamethasone; PFS = Progression free survival; IMWG= International Myeloma Working Group; HR = Hazard ratio; CI = Confidence Interval, CR: Complete response; MRD: Minimal residual disease

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Results  from  the  interim  analysis  of  study  MMY3014  showed  a  statistically  significant  relevant improvement in PFS from the addition of daratumumab to VRd induction and consolidation treatment and from daratumumab added to lenalidomide maintenance treatment in patients with newly diagnosed multiple myeloma. This improvement is considered clinically significant and is supported by secondary endpoints such as statistically significant improvement in overall CR or better treatment response rates and statistically significant higher proportion of patients achieving MRD negativity at the 10 -5  threshold. OS data are immature but do not show any sign of detriment in the experimental arm.

The safety profile is in general as expected in the context of the patient population, the backbone therapy and the known safety profile of daratumumab SC. Overall there are no new safety findings or new adverse drug reactions, although daratumumab may increase the risk for neutropenia, thrombocytopenia,  pneumonia,  diarrhoea  and  insomnia  induced  by  backbone  therapy.  The  overall incidence of Grade 3 or 4 AEs was higher in the D-VRd arm compared with the VRd arm with largest differences between arms observed for neutropenia and thrombocytopenia. The incidence of SAEs was higher in the D-VRd arm but were driven by a higher incidence of SAEs during the maintenance phase in the D-VRd arm. Deaths due to AEs were comparable between study arms.

## 3.7.2. Balance of benefits and risks

The combination of D-VRd has demonstrated to confer clinically relevant benefit in the treatment of adult patients  with  newly  diagnosed  multiple  myeloma.  This  is  considered  to  outweigh  the  toxicity  of  the combination, which is in line with the known safety profile of daratumumab and which can be managed adequately with the routine and additional risk minimisation measures that are already in place for this product.

## 3.8. Conclusions

The overall benefit-risk of Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends, by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include Darzalex as a subcutaneous injection in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma, who are eligible for autologous stem cell transplant, based on the primary analysis results from the pivotal study 54767414 / MMY3014 (PERSEUS), a randomised, open-label, activecontrolled, multicentre phase 3 study.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Darzalex is not similar to Talvey, Carvykti, Abecma, Farydak, Blenrep, Ninlaro and Kyprolis within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Darzalex-EMEA/H/C/004077/II/72.